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Abstract
The differentiation o f F9 embryonal carcinoma (EC) cells into parietal endoderm 
(PE)-like cells provides a tractable model for studying molecular events during early 
and inaccessible stages o f murine development. It has been previously shown that PE 
formation is accompanied by a ~10-fold decrease in RNA polymerase (pol) III 
transcription. This down-regulation was attributed to a reduction in the activity o f the 
basal pol III factor TFIIIB; however, the mechanism involved was not established. 
The work presented here was aimed at elucidating the precise changes that lead to a 
decrease in pol III transcriptional activity during F9 differentiation.
The protein levels o f all three components o f the TFIIIB complex, B rfl, Bdpl and 
TBP, were found to deerease. In the case o f Brfl and B dpl, this decrease did not 
reflect a change in their stability, as proteasome inliibition did not have an effect on 
protein abundance. On the other hand, a specific down-regulation o f the mRNAs 
encoding Brfl and Bdpl was observed. Temporal analysis o f F9 differentiation, 
however, revealed that the decline in TFIIIB levels follows that in pol III 
transcription in the same extracts. Furthermore, over-expression o f Brfl did not 
result in an increase in pol III transcription in PE cells. These data point to TFIIIB 
playing a secondary role in the down-regulation of pol III during differentiation. 
TFIIIB activity, and consequently pol III transcription, can be regulated by a number 
o f proteins. For example, c-Myc activates pol III transcription, while the 
retinoblastoma protein (pRb) is a repressor. Time course analysis revealed that c- 
Myc down-regulation and pRb up-regulation closely follows the decline in pol III 
transcription during differentiation. Furthermore, recombinant c-Myc efficiently 
restored transcription in PE extracts. These two proteins, therefore, provide likely
II
candidates for the primary regulatory mechanism of pol III transcription in response 
to differentiation, through their effect on TFIIIB.
Ill
Table of contents
A bstract.......................................................................................................................................II
Table o f contents..................................................................................................................... IV
List o f figures......................................................................................................................... VII
List o f tables............................................................................................................................. IX
A bbreviations........................................................................................................................... IX
D eclaration............................................................................................................................... XI
Acknowledgements............................................................................................................... XII
D edication..............................................................................................................................XIII
CHAPTER 1..............          1
INTRODUCTION..................................................................................................................I
1.1 RNA POLYMERASE III................................................................................... 1
1.1 A  Eukaryotic RNA polymerases .................................................................. 1
1.1.2 Class III genes .................................................................................................4
1.1.3 Promoter structure o f  class III genes ........................................................10
1.1.3.1 Type 1 prom oters................................................................................ 11
1.1.3.2 Type 2 prom oters.................................................................................12
1.1.3.3 Type 3 prom oters.................................................................................14
1.1.3.4 Mixed prom oters..................................................................................16
1.1.4 Transcription factors required fo r  po l III transcription ..................... 17
1.1.4.1 TFIIIB ................................................................................................ 18
1.1.4.2 T F IIIC ................................................................................................... 25
1.1.4.3 Additional general factors  ........    27
1.1.4.4 Gene-specific factors...........................................................................27
1.1.5 Assembly o f  the pre-initiation complex ................................................... 30
1.1.6 Regulation o f  pol III transcription ...........................................................32
1.1.6.1 Activities that reduce pol III transcription.....................................32
1.1.6.2 Activities that stimulate pol III transcription................................. 38
1.1.7 Physiological regulation o f  pol III transcription................................. 43
1.1.7.1 Cell cycle.................. .'..........................................................................43
1.1.7.2 Differentiation...................................................................................... 45
1.1.8 Deregulation o f  pol III transcription by transformation.....................46
1.1.9 Concluding rem arks..................................................................................... 49
1.2 The F9 cell system .............................................................................................51
1.2.1 Early mouse embryogenesis........................................................................51
1.2.2 Teratomas........................................................................................................52
IV
1.2.3 The F9 cell line..............................................................................................53
1.2.3.1 Induction of differentiation............................................................... 53
1.2.3.2 Differentiation-induced changes........................................................56
1.2.4 Virus infection ............................................................................................... 66
1.3 The Ubiquitin -  Proteasome System............................................................ 68
1.3.1 Introduction ......................................................................................   68
1.3.2 Ubiquitin-mediated degradation............................................................... 69
1.3.2.1 U biquitin ............................................................................................... 69
1.3.2.2 Conjugating enzym es..........................................................................70
1.3.2.3 The proteasom e.................................................................................. 75
1.3.3 Degradation signals ................................................................................... 77
1.3.5 Cellular targets o f  the ubiquitin-proteasome pa thw ay ......................... 79
1.3.6 Proteasome inhibitors................................................................................. 80
1.4 Objectives........................................................................................................... 82
CHAPTER 2................................             83
Materials and M ethods.......................................................................................................83
2.1 Cell culture.........................................................................................................83
2.2 Optimisation of transfection using (3-galactosidase assays...................... 84
2.3 Stable transfection.............................................................................................85
2.4 Preparation o f whole-cell extracts................................................................. 86
2.5 Measuring protein concentration....................................................................88
2.6 Separation o f proteins by polyacrylamide gel electrophoresis................88
2.7 Western blotting..........................  89
2.8 A ntibodies.......................................................................................................... 90
2.9 Preparation o f total cellular R N A ..................................................................90
2.10 Measuring RNA concentration......................................................................92
2.11 Northern blot analysis o f total cellular R N A .............................................. 92
2.12 Preparation o f cDN A s   ..............................................................................95
2.13 Reverse transcriptase -  Polymerase chain reaction (RT-PCR)................95
2.14 Transformation o f competent cells................................................................ 97
2.15 Preparation o f plasmid DNA...........................................................................98
2.16 RNA pol III in vitro transcription assay........................................................99
2.17 Electrophoretic mobility shift assay (EM SA)............................................101
2.18 In vitro proteasome assay.............................................................................. 103
CHAPTER 3..........                104
The protein levels o f the TFIIIB complex decrease following differentiation.... 104
3.1 Introduction.................................................................................................... 104
3.2 Results...............................................................................................................105
3.2.1 Differentiation o f  F9 embryonal carcinoma cells ................................ 105
3.2.2 RNA polymerase III transcription decreases during F9 cell
differentiation.............................................................................................. 109
3.2.3 Down-regulation o f  TFIIIB components following differentiation .113
3.2.4 Time course o f  TFIIIB down-regulation................................................ 115
3.3 D iscussion........................................................................................................ 118
V
3.3.1 Differentiation o f  F9 ce lls .........................................................................118
3.3.2 Regulation o f  pol III transcription in differentiated F9 cells 120
3.3.3 Timing o f  TFIIIB down-regulation...........................................................121
CHAPTER 4 .........................................       123
Brfl and Bdpl are not degraded by the proteasome.................................................. 123
4.1 Introduction...................................................................................................... 123
4.2 R esults............................................................................................................... 126
4.2.1 Proteasome inhibition in F9 EC and PE ce lls .....................................126
4.2.2 In vitro proteasome a ssay ......................................................................... 128
4.2.3 Proteasome inhibition does not affect the levels o f  B rfl and Bdpl,
nor po l III transcription ............................................................................ 130
4.2.4 RT-PCR analysis o f  TFIIIB components.................................................133
4.2.5 Time course analysis o f  TFIIIB mRNAs.................................................. 135
4.2.6 mRNA levels o f  the TFIIIB complex are affected by proteasome
inhibition ...................................................................................................... 137
4.3 D iscussion.........................................................................................................139
4.3.1 Proteasome inhibition in F9 EC and PE ce lls .......................................139
4.3.2 B rfl and B dpl protein levels and pol III transcription in MG132-
treated PE ce lls ...........................................................................................140
4.3.3 Co-regulation o f  TFIIIB components.......................................................141
4.3.4 RT-PCR analysis o f  MG132-treated cells ...............................................142
CHAPTER 5.............................               144
Over-expression o f Brfl does not rescue pol III transcription................................. 144
5.1 Introduction...................................................................................................... 144
5.2 Results............................................................................................................... 145
5.2.1 HA-hBrfl is overexpressed in stably transfected cells........................ 145
5.2.2 Over expression o f  B rfl does not affect the proliferation rate o f  F9
EC ce lls ............................................................................................... i...... 150
5.2.3 Levels o f  HA-hBrfl are not affected by differentiation or MG 132
treatm ent...................................................................................................... 150
5.2.4 Effect o f  HA-hBrfl overexpression on pol III transcription  156
5.2.5 Recombinant hBdpl does not restore po l III transcription following
differentiation .............................................................................................. 158
5.3 D iscussion.........................................................................................................160
5.3.1 Establishment o f  an H A-hBrfl overexpressing cell l in e ................... 160
5.3.2 Proliferation rate o f  F9 EC cells overexpressing H A -hB rfl 162
5.3.3 HA-hBrfl levels in response to differentiation and proteasome
inhibition ...................................................................................................... 163
5.3.4 RNA polymerase III transcription in HA-hBrfl clones .......................164
CHAPTER 6.....            167
Regulation o f other pol III regulators during differentiation....................................167
VI
6.1 Introduction......................................................................................................167
6.2 Results................................ ..... .......................................................................173
6.2.1 The pocket proteins, pRb, p i  07 and p i  30, are differentially regulated
during F9 cell differentiation ................................................................... 173
6.2.2 Protein levels o f  the tumour suppressor p53 do not change when F9 
EC cells differentiate into P E ................................................................... 175
6.2.3 Levels o f  the catalytic subunits o f  casein kinase 2 (CK2) are reduced 
in PE c e lls ..................................................................................................179
6.2.4 Active, but not total ERK, is down-regulated in PE c e lls ................... 179
6.2.5 Members o f  the myc/max/mad network are down-regulated in PE
ce lls ............................................................................................................... 182
6.2.6 Recombinant c-Myc can partially restore pol III transcription in PE  
extracts..........................................................................................................185
6.2.7 The DNA-binding activity o f  c-Myc is reduced in PE c e lls ................188
6.3 D iscussion....................................................................................................... 189
6.3.1 p R b /p l0 7 /p l3 0 ............................................................................................ 189
6.3.2 p 5 3 ..................................................................................................................195
6.3.3 C K 2 ..............................................................................................................196
6.3.4 E R K ..............................................................................................................197
6.3.5 Myc/Max/Mad netw ork   ...................................................................197
6.3.6 Concluding rem arks................................................................................... 200
CHAPTER 7...........               202
D iscussion...........................................................................................................................202
CHAPTER 8.......                 216
References...........................................................................................................................216
List of figures
C h ap te r 1 In troduction
Figure 1.1 Different types o f RNA polymerase III prom oters.................................... 15
Figure 1.2 TFIIIC and TFIIIB interactions with a tRNA promoter............................28
Figure 1.3 Different pathways for recruitment o f TFIIIB and RNA polymerase III
..............................................................................................................................31
Figure 1.4 Antagonistic influences targeting T FIIIB ....................................................50
Figure 1.5 The development o f extraembryonic endoderm in the F9 embryonal
carcinoma (EC) cell system and in the mouse em bryo............................ 55
Figure 1.6 Pathways o f protein breakdown in mammalian cells.................................70
Figure 1.7 The ubiquitin conjugation pathway............................................................... 72
Figure 1.8 The 26S proteasom e......................................................................................... 77
VII
C h ap te r 3 The protein  levels of the T FIIIB  complex decrease following 
differentiation
Figure 3.1 Differentiation of F9 cells.............................................................................108
Figure 3.2 RNA polymerase III transcription is reduced in PE cells......................... 110
Figure 3.3 Time com'se o f pol III down-regulation................................................... 112
Figure 3.4 Differentiation causes a reduction in the levels o f T FIIIB ....................114
Figure 3.5 Time course o f TFIIIB decrease.................................................................117
C h ap te r 4 B rfl and B d p l are  not degraded by the proteasom e
Figure 4.1 Comparison of thr ee proteasome inhibitors................................................ 125
Figure 4.2 MG132 is functional in F9 PE cells..............................................................127
Figure 4.3 In vitro proteasome assay .............................................................................129
Figure 4.4 Effect o f proteasome inhibition on TFIIIB levels and pol III
transcriptional activity...................................................................................132
Figure 4.5 RT-PCR analysis o f EC and PE R N A ...................................................... 134
Figure 4.6 Time course analysis o f  differentiating cells using R T -PC R ...............136
Figure 4.7 Effect o f proteasome inhibition on the mRNA levels o f various genes
...................................................................................................   138
C h ap te r 5 O ver-expression of B rf l does not rescue pol I I I  transcrip tion
Figure 5.1 Screening o f  G 418-resistant c lones........................................................... 147
Figure 5.2 Total Brfl levels in HA-hBrfl c lones...................................................... 149
Figure 5.3 Proliferation curves o f HA-hBrfl and control c e lls ............................... 151
Figure 5.4 Levels o f HA-hBrfl in differentiated, stably transfected ce lls ............ 153
Figure 5.5 Stability o f HA-hBrfl in EC and PE cells................................................ 155
Figure 5.6 Effect o f Brfl over-expression on pol III transcription......................... 157
Figure 5.7 Time-course o f pol III down-regulation in HA-hBrfl c e lls ..................159
Figure 5.8 Recombinant Bdpl add-back.......................................................................161
C h ap te r 6 Regulation of o ther pol III regulators during  differentiation
Figure 6.1 The pocket proteins are differentially regulated in differentiating F9
c e lls .................................................................................................................. 174
Figure 6.2 Dephosphorylation o f pR b........................................................................... 177
Figure 6.3 p53 levels remain unchanged during differentiation.............................. 178
Figure 6.4 CK2 protein levels are reduced during differentiation........................... 180
Figure 6.5 Levels o f active ERK are reduced in F9 PE cells .................................... 181
Figure 6.6 Levels o f the Myc/Max/Mad network proteins in F9 EC and PE cel Is 184
Figure 6.7 Recombinant c-Myc restores pol III transcription in PE extracts.........186
Figure 6.8 Recombinant c-Myc can activate pol III transcription before or after
assembly of the pre-initiation com plex......................................................187
Figure 6.9 Binding to a consensus E-box sequence is reduced in PE extracts......191
Figure 6.10 Binding to a consensus E-box oligonucleotide increases in the presence 
o f recombinant c-M yc...................................................................................193
VIII
Chapter 7 Discussion
Figure 7.1 Proposed model for the down-regulation o f pol III transcription during 
differentiation o f F9 ce lls .............................................................................214
List of tables
Chapter 1 Introduction
Table 1.1 Targets o f the ubiquitin-proteasome pathway.
Chapter 2 Materials and Methods
Table 2.1 A ntibodies  ......................
Table 2.2 PCR prim ers....................
90
97
Abbreviations
ATP Adenosine triphosphate
bp Base pairs
Bdpl B double-prime 1
B rfl, Brf2 TFIIB-related factor 1, 2
BSA Bovine serum albumin
Cdk Cyclin-dependent kinase
CK2 Casein kinase 2
CMV Cytomegalovirus
CTP Cytosine triphosphate
db-cAMP Dibutyryl cyclic AMP
DEPC-H 2O Diethylpyrocarbonate water
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
DSE Distal sequence element
DTT Dithiothreitol
EC Embryonal earcinoma
EDTA Ethylene diamine tetra-acetic acid
EMSA Electrophoretic mobility shift assay
ERK Extracellular signal-regulated protein kinase
FBS Foetal bovine serum
GTP Guanine triphosphate
h Human
HAT Hi stone acetyl transferase
HDAC Hi stone deacetylase
HECT Homologous to E6-AP C-terminus
IX
Hepes N-2-hydroxyethylpiperazine-N’-2-ethane-sulphonic acid
HPRT Hypoxanthine guanine phosphoribosyl transferase
IBMX 3 -Isobuty I-1 -methylxanthine
ICM Inner cell mass
ICR Internal control region
IVT In vitro transcription
kD Kilodalton
MAPK Mitogen activated protein kinase
MEK MAP/ERK kinase
mRNA Messenger RNA
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate-buffered saline
PE Parietal endoderm
PIC Preinitiation complex
PMSF Phenylmethylsulfonyl fluoride
Pol RNA Polymerase
PSE Proximal sequence element
PTF Proximal sequence element binding transcription factor
PYS Parietal yolk sac
RING Really interesting new gene
rNTPs Ribonucleotidetriphosphates
RA Retinoic acid
rRNA Ribosomal RNA
RT-PCR Reverse transcriptase-polymerase chain reaction
SDS Sodium dodecyl sulphate
SINEs Short interspersed elements
SNAPc snRNA activating protein complex
snRNA Small nuclear RNA
SV40 Simian virus 40
TAF TBP-associated factor
TBP TATA-binding protein
TBS Tris buffered saline
TEMED N, N, N ’, N ’ -tetr amethy lethy lenediamine
TF Transcription factor
Tris Tris (hydroxymethyl) methylamine
tRNA Transfer RNA
ts Temperature sensitive
TTP Thymidine triphosphate
Tween 20 Polyoxyethylene sorbitan monolaurate
U Units
UV Ultraviolet light
UTP Uridine triphosphate
V Volts
VE Visceral endoderm
y Yeast
X
Declaration
All work presented within this thesis was performed entirely by m yself and in no 
way forms part o f any other thesis. The work was carried out during my time as a 
post-graduate student at the Division o f Biochemistry and Molecular Biology, 
Faculty o f Biomedical and Life Sciences, University of Glasgow, UK, from January 
2002, while under the supervision o f Professor Robert J. White.
Dimitris Athineos 
June 2005
XI
Acknowledgements
Firstly, I would like to thank my supervisor, Bob White, for all his help and guidance 
over the last three years, for the very thorough proofreading o f this manuscript, and 
for giving me the opportunity to do a PhD in the first place. A big thank you to 
everyone else in the lab, for guiding me along when I started, and keeping my spirits 
up near the end -  when it mattered most. I would specially like to thanlc Lynne, Zoë 
and Jen, for providing comic relief, support and an answer to any inane question I 
could come up with. Thanks girls.
Special thanks to my Cat, for believing in, and putting up with, me. Without your 
support, encouragement and ‘gentle’ prodding, I would still be writing my 
introduction. You made these last three years all the more worthwhile.
Finally, a huge thank you to my brother, Omiros, for being there whenever I needed 
him. And to my mother, for selflessly giving everything she could to me and my 
brother without a second thought. None o f this would have been possible without 
you. Thank you so much.
XII
Dedicated to my mother 
A(|)iGpo)|iEvo a tr) prtTspa pou
XIII
CHAPTER 1
INTRODUCTION
1,1 RNA POLYMERASE III
L L 1 Eukaryotic RNA polymerases
Most eukaryotic cells contain four DNA-dependent RNA polymerases. Three of 
these are nuclear, while mitochondria contain their own unique RNA polymerase 
(Sentenac, 1985). Plants are an exception, with an extra nuclear RNA polymerase, 
IV, (Onodera et a l ,  2005), in addition to the one found in chloroplasts. The nuclear 
RNA polymerases were originally identified through chromatography on DEAE 
Sephadex columns (Roeder and Rutter, 1969). They are classified according to 
various properties, including salt requirements, template preferences and differential 
sensitivity to a-amanitin, a toxin isolated from the poisonous Amanita mushrooms 
(Kedinger et a l ,  1970; Sentenac, 1985). In mammals, RNA polymerase II (pol II) 
shows the highest sensitivity to the toxin, with a 50% reduction in its activity at only 
25 ng/ml. RNA polymerase III (pol III) has an intermediate sensitivity (50% of 
activity at 20 pg/ml), while RNA polymerase I (pol I) is completely resistant 
(Schwartz et a l ,  1974). The situation in Saccharomyces cerevisiae is different, with 
pol III being highly resistant, while pol I exhibits intermediate sensitivity. As in 
mammals, yeast pol II is very sensitive to a-amanitin (Schultz and Hall, 1976). Pols I 
and II are also inhibited by actinomycin D, with pol I being the more sensitive of the 
two enzymes, while tagetitoxin (a bacterial phytotoxin produced by Pseudomonas
1
syringaé) inhibits pol III preferentially (Steinberg et al., 1990). More than any other 
property o f the RNA polymerases, the sensitivity to these toxins has been used to 
determine which genes are transcribed by which polymerase. Accordingly, pol I- 
transcribed genes are termed class I, pol Il-transcribed genes class II and pol Ill- 
transcribed genes class III.
The best characterised nuclear RNA polymerases are from S. cerevisiae, where the 
genes for all subunits have been cloned. Individual subunits are named after the 
enzyme they belong to (i.e. A for pol I, B for pol II and C for pol III) and their 
apparent size (in kDa). Pol III, with 17 subunits, appears to be the most complex of 
the nuclear RNA polymerases, compared to the 14 and 12 subunits o f pols I and II, 
respectively. O f these, 5 subunits are shared between the three polymerases (ABC27, 
ABC23, ABC 14.5, ABC 10a and ABC 10(3), while two are shared with pol I (AC40 
and AC 19). The two largest subunits of pol III (C l60 and C l28) are homologous to 
the equivalent subunits of pols I and II, while C25 and C l 1 are homologous to two 
pol I subunits. The remaining six (C82, C53, C37, C34, C31 and C l7) are unique to 
pol III. The functional core o f pol III is made up o f five subunits, C l 60, Cl 28, AC40, 
AC 19 and ABC23. Not surprisingly, these subunits are either shared between the 
polymerases, or are homologous, both to each other and to subunits from the solitary 
archaeal or bacterial RNA polymerase (Geiduschek and Kassavetis, 2001). The pol 
Ill-specific subunits appear to be important for recognition o f the TFIIIC -  TFIIIB -  
DNA preinitiation complex (see below). Recently, human pol III was purified, and 
its subunits identified by mass spectrometry (Hu et a i ,  2002). Analysis revealed that 
the human enzyme contains orthologs o f all the yeast pol III subunits.
Despite the shared and homologous subunits, pols I, II and III differ both in 
localisation and target genes. Pol I is responsible for the transcription o f a single 
gene, whose product, the 45S pre-ribosomal RNA, is later processed into the 5.8S,
18S and 28S ribosomal RNA (rRNA) molecules. Pol I has, therefore, only one 
promoter structure to recognise. Nevertheless, pol I is believed to account for as 
much as 70% of the total nuclear transcription (in HeLa cells), occurring at distinct 
areas within the nucleus, called nucleoli. Specifically, the rRNA is synthesised in the 
fibrillar centres, while ribosome assembly takes place in the surrounding granular 
area (Shaw and Olsen, 1984).
Pol II is at the other extreme, being responsible for the transcription of all protein- 
coding genes, as well as most small nuclear RNA (snRNA) genes. In order for the 
cell to efficiently control the transcription o f all these genes, pol II promoters are 
suitably diverse, both in their regulatory and core regions. Despite the large number 
o f genes, pol II transcription accounts for 20% of HeLa total nuclear transcription. 
Actively transcribing pol II seems to be spatially separated at particular locations 
within the nucleoplasm, of which around 8,000 may exist in HeLa cells (Pombo ei 
a/., 1999).
Pol III transcribes a much smaller set of genes than pol II. Its products are small, 
untranslated RNAs, including the 5S rRNA, transfer RNA (tRNA) and U6 snRNA 
(see below). Transcription o f this set o f genes by pol III provides the remaining 10% 
o f nuclear transcription in HeLa cells. Consistent with the smaller set o f target genes, 
promoters o f class III genes do not exhibit the variety seen in class II genes, being 
divided into three main types (see below). As is the case for pol II, active pol III is 
concentrated at specific sites, which are separate from the pol II sites. Around 2,000 
o f these sites are thought to exist in the nucleus of a HeLa cell, each one containing 
approximately five active polymerases (Pombo et a l,  1999).
LL 2 Class III genes
The genes transcribed by RNA polymerase III have the common characteristic of 
encoding small, untranslated RNAs that serve various essential functions in cells. For 
example, 5S rRNA and tRNA aie required for protein synthesis, while U6 snRNA 
and HI and MRP RNAs are involved in post-transcriptional processing. 
Interestingly, the adenoviral VA genes, thought to be important for diverting the 
translational machinery o f an infected cell for the virus’ own needs, are also 
transcribed by pol III. The majority o f pol III templates in mammals, however, 
belong to the short interspersed repeat (SINE) family of genes, the function o f which 
is not known.
- 5S rRNA
The 5S rRNA is the smallest o f the ribosomal RNAs, at around 120 nucleotides, and 
the only one transcribed by pol III. After its synthesis, it becomes associated with the 
large subunit of the ribosome, although its exact role is still unlcnown.
5S rRNA genes are often, but not always, situated in repeated clusters. For example, 
in S. cerevisiae, the genes for each o f the four rRNAs are located in a shared repeat, 
even though 5S rRNA is synthesised by a different polymerase than the other three 
(Nath and Bollon, 1977). It is worth noting that the expression o f the rRNA genes in 
this repeat is not interdependent, as pol III inhibition does not affect pol I 
transcription (Gudenus et a l ,  1988). In humans, there are about 200 to 300 copies of 
the 5S gene, many o f which are located in clusters o f tandem repeats, although some 
single copies could also exist (Sorensen and Frederiksen, 1991).
tRNA
tRNA molecules are 70 -  90 nucleotides in length. Their primary function is to serve 
as adaptors between messenger RNA (mRNA) and amino acids, thus converting the 
genetic information encoded in the mRNA sequence into an amino acid sequence. 
This is made possible by the fact that each tRNA is United to a particular amino acid, 
matching it to a specific codon in the message. Therefore, a tRNA that recognises the 
codon for leucine, and brings leucine to the growing polypeptide chain is termed 
tRNA^'^", etc. Eukaryotic cells contain 50 -  100 distinct tRNA species (Sharp et a l,
1985), although relative amounts o f different tRNAs vary considerably from one cell 
type to another, depending on codon usage (Garel, 1976). There are approximately 
350 tRNA genes in S. cerevisiae, most o f which are dispersed throughout the genome 
without clustering (Guthrie and Abel son, 1982). In contrast, irregular clustering 
seems to be the rule in higher eukaryotes. For example, a 46 kb region in 
chromosome 2 in Drosophila melanogaster contains 18 tRNA genes (Dingermann el 
a l,  1982). In humans, around 500 tRNA genes encode 60 -  90 tRNA isoacceptors 
(Hatlen and Attardi, 1971; IHGSC, 2001). Some of these genes are scattered 
individually throughout the genome, e.g. tRNA'^^^ (Santos and Zasioff, 1981). 
Although some small scale clustering has been previously reported, analysis of the 
draft human genome sequence revealed considerable clustering on a genome-wide 
scale. Thus, more than 25% of all tRNA genes (around 140) are found in a 4 Mb 
region (~ 0.1% of the genome) o f chromosome 6, with smaller clusters found on 
other chromosomes. In fact, more than half o f the identified tRNA genes (280 out of 
497) are located on either chromosome 1 or chromosome 6 (IFIGSC, 2001).
- U6 snRNA
Part o f the post-transcriptional processing o f pre-mRNA to mature mRNA, involving 
the removal o f introns, is carried out by the spliceosome (reviewed in Kramer, 1996). 
The spliceosomes, which are present in the nuclei of all eukaryotic cells at high 
numbers (lOVcell), are RNA-protein complexes, part o f a group o f structurally 
related snRNPs (small nuclear ribonucleoproteins). In addition to the protein 
components, spliceosomes contain five snRNA species. Four o f these are synthesised 
by pol II, while the fifth, U6, is synthesised by pol III (Kunkel et a l ,  1986). 
Trypanosomes are an exception, since U2, in addition to U6, is made by pol III 
(Fantoni et a l ,  1994). U6 is the smallest o f the five snRNAs in the spliceosome, 106 
nucleotides in length, but it is also the most conserved (Brow and Guthrie, 1988). In 
S. cerevisiae, U6 snRNA is encoded by an essential, single-copy gene (Brow and 
Guthrie, 1988). In humans, however, there appear to be more than 40 copies o f the 
gene, dispersed throughout the genome, with many more pseudogenes and related 
sequences (IHGSC, 2001).
- 7SL RNA
7SL is a 300 nucleotide-long, pol Ill-transcribed RNA that forms the scaffold o f the 
signal recognition particle. This RNP plays an important role in the co-translational 
insertion o f nascent polypeptides into the endoplasmic reticulum (Walter and Blobel, 
1982). There are three 7SL genes in humans, with more than 700 pseudogenes 
(IHGSC, 2001).
- 7SK RNA
7SK is an abundant RNA, 330 nucleotides in length, transcribed from a single copy 
gene in humans (Murphy et al., 1986). Despite its ubiquitous natuie and high degree 
o f conservation (Ullu et a i ,  1982), the role o f 7SK has remained elusive, Murphy et 
a l  (1986) showed that it can interact with eight polypeptides, forming a 12S RNP. 
Recently, two reports demonstrated that 7SK can act as a negative regulator o f pol II 
elongation, by inhibiting P-TEFb (Nguyen et a l,  2001; Yang et a l ,  2001). P-TEFb is 
a heterodimer o f Cdk9 and cyclins T1 or T2, which phosphorylates pol II at its C- 
terminal domain, leading to the formation o f more processive elongation complexes 
(Price, 2000). 7SK seems to associate with P-TEFb, blocking its kinase activity.
- HI and MRP RNAs
HI is the 369 nucleotide-long RNA component o f RNase P, an endoribonuclease that 
is involved in the post-transcriptional processing o f the 5 terminus o f tRNA 
(Bartkiewicz et a l ,  1989; Lee and Engelke, 1989). HI RNA has several blocks of 
sequence homology with MRP RNA (Gold et a l,  1989). MRP RNA is a component 
o f the RNase MRP, another endoribonuclease involved in pre-rRNA processing 
(Morrissey and Tollervey, 1995; Schmitt and Clayton, 1993). Both HI and MRP 
RNAs are transcribed from single-copy genes in humans (Baer ei a l ,  1990; Chang 
and Clayton, 1989).
“ Products of unknown function (vault, Y, B C l and BC200 RNAs)
Vaults are the largest known cytoplasmic RNPs, with a mass three times that of 
ribosomes (~ 13 MDa), but o f unknown function (reviewed in Kickhoefer et a l,  
1996; Scheffer et a l ,  2000). Although proteins contribute to most o f a vault’s mass, 
it contains multiple copies of vault RNAs (vRNAs). vRNAs from different species 
vary in length (86 -  142 nucleotides), as well as gene copy number. For example, 
there is a single gene in rats (Kickhoefer et a l ,  1993), while the human genome 
contains three distinct genes, encoding different, but very similar, vault RNAs (van 
Zon et a l ,  2001).
BCl and BC200 expression is very restricted, being confined to a specific subset of 
neurons in the central and peripheral nervous systems o f rodents (for B C l) and 
primates (for BC200) (Tiedge et a l ,  1993; Tiedge el a l,  1991). Even there, they can 
only be found in the somatic and dendritic domains of the neurons, as part o f RNPs, 
A proposed role for these RNPs is in the transport and/or translation o f dendritic 
mRNAs, although no conclusive evidence has been discovered yet (Tiedge et a l,  
1993; Tiedge et a l ,  1991). Despite the impressive similarity in expression patterns, 
suggesting a similar function, there is little sequence homology between BCl and 
BC200 RNAs (Martignetti and Brosius, 1993). In fact, BCl is thought to have 
evolved from a tRNA' '^®, while BC200 from an Alu or 7SL RNA (DeChiara and 
Brosius, 1987; Martignetti and Brosius, 1993).
Y RNAs are 69 to 112 nucleotides in length and aie found in complexes with the Ro 
autoantigen (Wolin and Steitz, 1983). Although the function o f these RNPs is not 
known, it has been suggested that they might play a role in the 5S rRNA quality 
control pathway (O'Brien and Wolin, 1994).
SINEs
The most quantitatively important class o f pol III-transcribed genes in higher 
organisms is the SINEs (short interspersed elements) (reviewed in Jelinek and 
Schmid, 1982). For example, Xenopus laevis contains 20,000 copies o f the satellite 1 
repetitive element, comprising approximately 1% of its total haploid genome (Lam 
and Carroll, 1983). The major SINE in primates is the Alu family (reviewed in 
Mighell et a l ,  1997). In the haploid human genome, there are 500,000 to I million 
copies o f Alu genes, representing 6 -  13% of total. The Alu consensus sequence is 
-280  base pairs long, and consists o f two similar', but distinct monomers, only the 
first o f which contains a functional pol III promoter. Rodents have their own 
abundant SINE families. Rat genomes contain large numbers o f  the ID element ( -  
135,000), while the most common ones found in mice belong to the B1 and B2 
families (100,000 and 80,000 respectively) (Bennett et a l,  1984; Sapienza and St- 
Jacques, 1986).
The principal SINE families appear to have evolved from class III genes o f known 
physiological role. Several SINES, e.g. B2 and ID, are thought to have arisen from 
tRNA genes (Daniels and Deininger, 1985). In contrast, the B1 and Alu families 
show sequence homology with the 7SL RNA (Ullu and Tschudi, 1984). Despite this 
fact, a clearly defined functional role has not been demonstrated for any SINE family 
(Howard and Sakamoto, 1990). Proposed functions include roles in regulating the 
expression o f adjacent genes, splicing, translation, DNA replication, cell stress 
responses, regulation o f growth and the turnover of specific mRNAs (White, 2002). 
Because SINEs are propagated by retrotransposition, in which the transcript is 
reverse transcribed into DNA and then inserted into a new genomic site, they can 
have significant impact on the structure and evolution o f the genome, even though
the transcripts themselves might be bereft o f function. The most obvious effect is the 
disruption o f sequences at the site o f integration, potentially leading to mutagenesis. 
On a larger scale, the presence o f so many homologous sequences in the genome 
could lead to recombination events.
- V iral genes
Certain vimses contain genes that are transcribed by pol III. The best characterised 
example is the adenoviral genes V A l and VA2. These ~ 160 bp genes are transcribed 
at high levels during the late stages o f viral infection (Soderlund et a i ,  1976; 
Weinmann et a i ,  1974), where they have been shown to stimulate the translation of 
viral mRNAs (Thimmappaya et a l ,  1982).
Another example is the Epstein-Barr virus (EBV). Like adenovirus, EBV contains 
two small genes, approximately 165 base pairs in length, called EBERl and EBER2, 
that are transcribed by pol III (Rosa et a l ,  1981). Although the exact mechanism is 
not yet clear, EBER RNAs have been shown to have transforming potential under 
certain circumstances (White, 2004b). This is the first example o f an oncogenic RNA 
and provides evidence for the possibility that a pol III product can transform cells.
1.1.3 Promoter structure o f class III genes
Depending on their organisation, class III gene promoters have been divided into 
three main categories, termed type 1, type 2 and type 3 (Figure 1.1). Type 1 and 2 
promoters, present in most class III genes, have the unusual characteristic o f being 
intragenic, i.e. within the transcribed region o f the gene. These discontinuous
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structures, called internal control regions (ICRs), consist o f essential sequence blocks 
separated by nonessential nucleotides. This feature sets them apart from the third 
promoter type. Type 3 promoters are devoid o f intragenic elements, relying instead 
on sequences in the 5’ flanking region, upstream of the transcription start site. In this 
respect, type 3 promoters resemble promoters o f pol I- and pol Il-transcribed genes.
1.1.3.1 Type 1 promoters
The 5S rRNA gene is the only example o f a type I pol III promoter. The best 
characterised 5S promoter is that o f Xenopus (Figure 1.1). Extensive studies have 
defined the minimum ICR between base pairs 50 and 97 downstream of the 
transcription start site (+50 to +97). This region consists o f three separate elements: 
the A-block (+50 to +64), the intermediate element (IE, +67 to +72) and the C-block 
(+80 to +97) (Bogenhagen, 1985; Pieler et a l ,  1985a; Pieler et a l ,  1985b). The 
importance o f these sequences is demonstrated by the fact that mutations in the A~ or 
C-blocks o f a major 5S gene in Xenopus oocytes abolish transcription (Keller et a l ,  
1990). Although the sequence o f the bases between these elements is not important 
for transcription, the spacing is. For example, it has been shown that alterations in the 
spacing between the A-block and the intermediate element, from -3 to +10 base 
pairs, results in reduced transcription and inability to form a stable transcription 
complex (Pieler et a l ,  1987). Studies have demonstrated that the region between the 
start site and the A-block is also important for expression o f Xenopus 5S genes, 
especially in conditions suboptimal for transcription (Keller et a l ,  1990). In optimal 
conditions, however, the minimal ICR (+50 to +97) is sufficient for accurate 
transcription (Pieler et al., 1987).
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The situation is slightly different in S. cerevisiae. In vitro transcription o f the 5S 
rRNA gene requires only two promoter elements; the C-block, located at +81 to +94, 
as well as a region from -14 to +8, called sse (Challice and Segali, 1989). 
Surprisingly, the region from +9 to +80, which includes an A-block homology, is not 
absolutely required in vitro, although it contributes to the efficiency o f transcription. 
In vivo, however, point mutations in the A-block, IE or C-block substantially reduce 
transcription (Lee et a l ,  1995). The distance between the sse and C-block is also 
very important, with changes o f more than a few base pairs resulting in a large 
reduction in 5S expression (Challice and Segali, 1989).
1.1.3.2 Type 2 promoters
This type o f promoter is utilised by the majority o f class III genes, including tRNA 
and 7SL, the viral VA and EBER genes, as well as SINE families, like Alu, B1 and 
B2. It consists of two essential and highly conserved regions of about 10 base pairs 
each, called A- and B-blocks, generally separated by 30 -  40 base pairs (Figure 1.1). 
It is worth noting that, in Xenopus, A-blocks from type 1 and type 2 promoters are 
related in sequence and interchangeable. This, however, is not the case in 
Neurospora (Ciliberto et a l ,  1983; Shi and Tyler, 1991). These two regions have 
been shown to be essential promoter elements, while other internal and flanking 
sequences can have modulatory effects on transcription. Analysis o f tRNA genes 
from various organisms, including Xenopus, Drosophila, nematode and yeast, 
revealed two highly conserved regions, corresponding to the A- and B-blocks, with 
consensus sequences TGGCNNAGTGG and GGTTCGANNCC, respectively (Galli 
et a l ,  1981). The conservation o f these sequences is such that they can also be found
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in certain bacterial and chloroplast tRNA genes (Folk et a l ,  1982; Gruissem et a l ,  
1982), Furthermore, chimeric genes with an A-block from one tRNA gene and a B- 
block from another have been shown to be active, demonstrating the functional 
compatibility o f A- and B-blocks from different genes (Galli et a l ,  1981). Part of the 
reason for this remarkable conservation might stem from the fact that the A- and B- 
blocks encode the D- and T-loops, respectively, which are required for tRNA 
function. Several studies have demonstrated the importance o f these two elements in 
tRNA transcription. For example, point mutations in these sequences can have a 
substantial effect on transcription efficiency (Newman et a l ,  1983; Reyes et al., 
1986; Traboni et a l,  1984).
As mentioned before, the flanking regions of type 2 promoters, although not 
necessary for transcription in vitro, may play a regulatory role in vivo. Indeed, the 
very limited homology observed in the flanking sequences between even related 
tRNA genes makes them good candidates for selective transcriptional control, which 
is necessary to the adaptation o f tRNA genes to different codon and amino acid 
utilisation in different cell types. This is obseiwed, for example, in members o f the 
tRNA^^"" gene family in X. laevis (Gouilloud and Clarkson, 1986). 5’ flanking 
sequences are likely to have some impact upon the transcription o f most, if not all, 
tRNA genes, with numerous examples demonstrated in yeast, Drosophila, Xenopus 
and humans. Similarly, 3’ flanking sequences have been shown to influence 
transcription efficiency (White, 2002).
The location of the A-block in type 2 promoters differs from that seen in type 1 
promoters, the former being much closer to the start site. In Xenopus tRNA genes, 
for example, it is located between +10 and +20 bp, whereas the 5S A-block is 
situated at +50 bp (Galli et a l ,  1981). The site at which initiation can occur seems to 
be primarily determined by the A-block, although the exact position is determined by
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the local sequence, influenced by the upstream flanking region (White, 2002). In 
contrast to the A-block, the position o f the B-block is quite variable, in part due to 
the presence o f short introns in some tRNA genes. In yeast, for example, where 10% 
o f tRNA genes contain introns, the separation between A- and B-blocks can be 27 to 
93 base pairs (Geiduschek and Tocchini-Valentini, 1988). Generally, distances o f 30 
to 60 base pairs appear to be optimal for transcription, although separation up to 400 
base pairs can be tolerated (Baker et a l ,  1987; Dingermann et a l ,  1983). 
Remarkably, both elements are recognised and bound by a single protein complex, 
TFIIIC (see below).
1.1.3.3 Type 3 promoters
The type 3 promoter was originally identified in mammalian U6 snRNA genes (Das 
et al., 1988; Kunkel and Pederson, 1988) and in the human 7SK gene (Murphy et al.,
1986). They have also been found in human HI and MRP RNA genes (Baer et a l ,  
1990; Topper and Clayton, 1990). This type o f promoter is strikingly different from 
types 1 and 2, in that the essential elements are upstream o f the transcription start 
site, within the 5’ flanking region (Figure 1.1). In mice and humans, for example, this 
region is necessary and sufficient for expression of U6 snRNA (Das et a l ,  1988). 
The core elements o f  type 3 promoters consist of a proximal sequence element 
(PSE), located between -70 and -50 bp and a TATA box, between -30 and -25 bp 
(Das et a l ,  1988). The PSE found in U6 promoters is almost identical to the one 
from U2 snRNA genes, which are transcribed by pol II, and the two are 
interchangeable (Lobo and Hernandez, 1989). In fact, the PSE on its own constitutes 
the core promoter for pol Il-transcribed U snRNAs. Point mutations in the TATA
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box can reduce or abolish transcription by pol III (Kunkel and Pederson, 1989). 
Curiously, class II U snRNAs do not contain TATA boxes, and its deletion from the 
U6 promoter will switch transcription from pol III to pol II (Lobo and Hernandez, 
1989). Also critical in U6 expression is the distance between PSE and the TATA 
box, with expression becoming severely compromised if the separation is altered 
(Goomer and Kunkel, 1992).
+1
Type 1 : 5S rRNA
ICR +120
1 1 c r r r r -
Type 2: tRNA
Type 3 : Hs U6 snRNA 0 —
+106
Trrr-
TATA
Mixed type : Sc U6 snRNA
+113
TATA
Figure 1.1 D ifferent types of RNA polym erase HI prom oters
The type 1 promoter o f the X. laevis 5S rRNA gene consists o f an internal control 
region (ICR), which can be subdivided into the A-block (+50 to +64), the 
intermediate element (IE, +67 to +72) and the C-block (+80 to +97). Type 2 
promoters, represented here by the X. laevis tRNA^^" promoter, consist o f an A-block 
(+8 to +19 in this case) and a B-block (+52 to +62). A typical type 3 promoter is that 
found in the human U6 snRNA gene, with a distal sequence element (DSE) far 
upstream of the start site (-215 to -240) that enhances transcription and a core 
promoter composed o f the proximal sequence element (PSE, -65 to -48) and a TATA 
box (-32 to -25). Finally, some promoters are a combination o f features from the 
three main promoter types. The example presented here is the S. cerevisiae U6 
snRNA, which contains a TATA box at a position similar to the human gene (-30 to - 
23), an A-block (+21 to +31) and a B-block outside the transcribed region (+234 to 
+244). The start site is represented by +1 and the termination site by TTTT.
15
A sequence located about 150 base pairs upstream of the PSE, called the distal 
sequence element (DSE), has been shown to enhance expression in vivo. This 
element can also be found in U1 and U2 snRNA genes (Kunkel and Pederson, 1988). 
The positioning of the transcription start site is determined by both the PSE and the 
TATA box, although neither plays a dominant role. The precise sequence, however, 
around the start site can also influence the position and level o f transeription 
(Goomer and Kunkel, 1992).
L I.3.4 Mixed promoters
Some pol III promoters contain a combination o f the typical promoter elements 
described before, and, as such, cannot be readily classified. Figui'e 1.1 shows one 
example, namely the S. cerevisiae U6 snRNA promoter. It consists o f three elements, 
one upstream and two downstream of the start site, all o f which are required for 
efficient transcription in vivo (Brow and Guthrie, 1990). The TATA box and A- 
blocks are located at similar positions as the ones in the human U6 and tRNA 
promoters, respectively, while the B-block is unusually located approximately 120 
base pairs downstream of the coding region.
Another gene that shows mixed characteristics in its promoter is the human 7SL 
gene. Although it possesses A- and B-blocks, their sequence is fairly degenerate 
(Ullu and Weiner, 1985). Significant expression requires both these internal, as well 
as external, sequences, which include an ATF-binding site and a putative TATA box 
(Bredow et a l ,  1990; Howe and Shu, 1993). The upstream sequences o f the human 
7SL gene can be efficiently substituted by those o f the 7SK gene, which has a type 3
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promoter stmcture (Kleinert et a l ,  1988). Yeast 7SL genes, on the other hand, 
conform to the typical type 2 promoter structure (Willis, 1993).
SirailaiTy, the EBV EBER2, silkworm tRNA^'^, Xenopus tRNA^^^ and rat vault RNA 
genes, while containing A- and B-blocks that are homologous to those from type 2 
promoters, also possess upstream sequence elements found in type 3 promoters 
(White, 2002).
LL 4 Transcription factors required for pol III transcription
Pol III by itself shows no specificity towards particulai* DNA sequences, and will 
initiate transcription randomly (Cozzarelli et a l ,  1983; Weil et a l ,  1979). It requires 
the assistance o f transcription factors, which recognise the appropriate subset o f 
promoters and recruit the polymerase to the start site o f the correct genes (Parker and 
Roeder, 1977).
Chromatographic separation o f HeLa cell extracts over phosphocellulose revealed 
that two fractions, called PC-B (0.1 -  0.35 M KCl) and PC-C (0.35 -  0.6M KCl) 
were required for specific transcription o f tRNA and VA genes (Segali et a l ,  1980). 
The general factors included in these fractions were designated TFIIIB and TFIIIC, 
respectively. It was subsequently demonstrated that many other class III genes, e.g. 
vault RNA, B1 and B2, required these two fractions in combination, while either 
fraction alone did not support transcription (Carey et a l ,  1986a; Kickhoefer et a l ,  
1993; Singh et a l ,  1985). Transcription o f 5S was shown to require, in addition to 
PC-B and PC-C, a third phosphocellulose fraction, PC-A (Engelke et a l ,  1980; 
Segali et a l ,  1980). This gene specific-factor was called TFIIIA.
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Since these initial experiments, it has been made clear that the crude 
phosphocellulose fractions contain many factors that are involved in pol III 
transcription. The terms TFIIIA, TFIIIB and TFIIIC will from now on be used to 
indicate the protein complexes that constitute the basal transcription factors for class 
III genes. Additional factors that regulate this basal transcription machineiy will be 
described in a later chapter.
1.1.4.1 TFIIIB
Although TFIIIB was purified from yeast in 1986 (Klekamp and Weil, 1986), it was 
not until a few years later that its importance in pol III transcription became truly 
apparent. Kassavetis et al. (1990) demonstrated that, once recmited to the promoter 
o f a tRNA or 5S gene, TFIIIB would remain there, even under conditions that 
stripped away the initial recruiting factors or prohibited the formation of new 
complexes. Furthermore, TFIIIB could then support several rounds o f accurately 
initiated transcription. This led to the suggestion that, at least in yeast, TFIIIB was 
sufficient to recruit pol III to the appropriate gene and direct several rounds of 
transcription, and that the function o f the other factors, TFIIIC and/or TFIIIA, were 
to recruit TFIIIB to the promoter (Kassavetis et a i ,  1990). The TFIIIB complex is 
composed of thi'ee polypeptides: TBP, Brfl/Brf2 and Bdpl.
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TBP
It was initially believed that the TATA-binding protein (TBP) was only involved in 
the transcription o f class II genes with TATA boxes in their promoters. The 
suspicion that this might not be the case came from the observation that the class III 
gene encoding U6 snRNA contained a TATA box, while the other U snRNAs, 
transcribed by pol II, did not. It was then shown that, not only was this TATA box 
responsible for selecting pol III over pol II in yeast and human U6 snRNA genes 
(Lobo and Hernandez, 1989; Mattaj et a l ,  1988), but also that transcription from the 
U6 promoter required TBP (Lobo et a l ,  1991; Margottin et a l ,  1991; Simmen et a l ,  
1991). TBP is also required by TATA-less class III genes. This was demonstrated by 
in vitro competition experiments, where TATA box sequences from class II 
promoters specifically competed for a human factor required by various TATA-less 
class III genes, including 5S, tRNA and VA (White et a l ,  1992a; White et a l ,  
1992b). Furthermore, recombinant TBP restored the transcription o f TATA-less class 
III genes in systems where TBP was depleted by fractionation or inactivated by heat 
treatment (White et a l ,  1992a; White et a l ,  1992b). It is now known that TBP is 
utilised by all three polymerases (Hernandez, 1993; Rigby, 1993). Its universal role 
has been demonstrated in yeast, where mutations in TBP affect transcription by all 
three polymerases (Cormack and Struhl, 1992; Schultz et a l ,  1992).
TBP genes have been cloned from a wide variety o f organisms, including humans, 
mice, frogs, flies, plants and yeast (Hernandez, 1993). Most organisms have only one 
TBP gene, although the genome o f some plant species, like Arabidopsis, contain two 
genes that encode highly similar proteins (Gasch et a l ,  1990). All TBP genes encode 
a small polypeptide, 27 -  38 kDa in size. It consists of an N-terminal region that is
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variable in both size and sequence, and a very highly conserved C-terminus 
(Hernandez, 1993). The function o f the N-terminal region is still being debated, with 
conflicting reports concerning its significance. It has been suggested that it can 
modulate the activity o f the conserved C-terminal domain (Kuddus and Sclimidt, 
1993; Lescure et a l ,  1994; Mittal and Hernandez, 1997). The C-terminal region 
contains two direct imperfect repeats (~ 40% identity) o f 66 -  67 residues, flanking a 
short, basic region. Binding o f TBP to a TATA box occurs through contact o f these 
repeats with the minor groove o f the DNA (Starr and Hawley, 1991; Yamamoto et 
a l ,  1992), inducing substantial bending o f the DNA (Horikoshi et a l ,  1992). X-ray 
crystallographic analysis o f one o f  the Arabidopsis TBP polypeptides revealed that 
the C-terminal domain folds into a highly symmetrical structure, resembling a saddle 
(Nikolov et a l ,  1992). The concave underside, lined by p-sheets, is wide enough to 
accommodate DNA, whereas the convex topside, made up o f a-helices, is accessible 
for interactions with other factors (Nikolov et a l , 1992).
Proteins that form complexes with TBP are called TBP-associated factors (TAFs). 
Fractionation o f HeLa extracts has revealed that several different TBP -  TAF 
complexes exist in cells, each one seiwing a different polymerase. In the case o f pol I, 
the TBP-containing complex, SL-1 (also called TIF-IB), contains three TAFs (Comai 
et a l ,  1992), while TFIID, supporting transcription by pol II, contains around 10 
TAFs (Pugh and Tjian, 1992). As mentioned before, the pol Ill-specific factor, 
TFIIIB, is composed o f TBP and two TAFs, Brfl (or Brf2) and Bdpl.
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- Characterisation of S. cerevisiae TFIIIB
S. cerevisiae TFIIIB can be separated, by cation exchange chromatography, into two 
activities, called B’ and B” , both o f which are required for transcription o f tRNA in 
the presence o f purified TFIIIC and pol III (Kassavetis et a l ,  1991). 
Photocrosslinking experiments revealed the presence o f two polypeptides in the 
TFIIIB fraction, 70 and 90 kDa, recmited to the tRNA promoter by interaction with 
TFIIIC (Bartholomew et a l ,  1990; Bartholomew et a l ,  1991). Significant progress in 
the characterisation o f S. cerevisiae TFIIIB was made when three groups, 
independently, cloned the gene encoding the 70 kDa subunit, now referred to as Brfl 
(TFIIB-related factor i  -  for a description o f a universal nomenclature of TFIIIB 
components see (Willis, 2002). It was cloned both as a suppressor o f a mutation in 
the A-block o f a tRNA gene (Lopez-De-Leon et a l ,  1992) and as a suppressor 
whieh, at high copy number, rescues certain temperature-sensitive mutations in TBP 
(Buratowski and Zhou, 1992; Colbert and Hahn, 1992). The latter data suggested that 
Brfl can interact with TBP, and that TBP might be a part o f the TFIIIB activity. This 
was shown to be the case for both yeast and mammalian TFIIIB activities by 
biochemical methods (Chiang et a l ,  1993; Huet and Sentenac, 1992; Kassavetis et 
a l ,  1992; Lobo et a l ,  1992; Taggart et a l ,  1992; White and Jackson, 1992).
The BRFl gene is essential for growth, and its importance for pol III transcription 
was demonstrated by several experiments. Disruption of the gene resulted in a rapid 
decrease in the in vivo transcription o f tRNA, but not o f class I and II genes 
(Buratowski and Zhou, 1992; Lopez-De-Leon et a l ,  1992). Similarly, while extracts 
from BRFl  mutants were defective for transcription by pol III (but wild-type for pol 
I and pol II), addition of recombinant ScBrfl {S. cerevisiae B rfl) could reconstitute
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the transcription o f 5S and tRNA genes (Colbert and Hahn, 1992). Addition of 
recombinant ScBrfl to wild-type extracts resulted in stimulation o f pol III 
transcription, suggesting that Brfl is normally a limiting factor in vivo (Colbert and 
Hahn, 1992; Lopez-De-Leon et a l ,  1992). The cloning of the gene encoding the B ” 
subunit, now referred to as Bdpl (B-double prime 1), completed the characterisation 
o f  & cerevisiae TFIIIB (Ishiguro et al., 2002).
- Characterisation of human TFIIIB
Identification o f the components o f TFIIIB in mammals proved to be more 
complicated. Whereas all pol III promoters in S. cerevisiae require the same TFIIIB 
complex (Joazeiro et a l ,  1994), the initial characterisation o f mammalian TFIIIB 
showed that type 1 and 2 promoters use different components in the TFIIIB fraction 
than type 3. Transcription from type 1 and 2 'promoters requires a complex consisting 
o f TBP, Bdpl and a homologue o f yeast B rfl, HsBrfl {Homo sapiens B rfl) (Mital et 
a l ,  1996; Wang and Roeder, 1995). On the other hand, type 3 promoters were shown 
to utilise, in addition to TBP and B dpl, a protein related to Brfl in its N-teiminus, 
but not its C-terminal region (Mital et a l ,  1996; Schramm et a l ,  2000; Teichmann et 
a l ,  2000; Wang and Roeder, 1995), now referred to as Brf2 (Willis, 2002). S. 
cerevisiae Brfl has, therefore, at least two homologues in human cells, HsBrfl and 
HsBrfZ. From now on, this specialised complex will be referred to as BrfZ-TFIIIB.
In addition to Brf2, mammalian cells also contain alternatively spliced variants o f 
B rfl (McCulloch et a l ,  2000). One o f these, Brfl_v2 has been implicated in human 
U6 transcription, even though the full-length protein, B rfl, is not involved 
(McCulloch et a l ,  2000).
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Using a combination o f database searches for sequences similar to the SANT domain 
o f yeast Bdpl (see below) and library screening, Schramm et a i  (2000) isolated and 
cloned Bdpl from human cells. As is the case with B rfl, a number o f human Bdpl 
splice variants have been identified (Kelter et a l ,  2000; Schramm et a l ,  2000). 
Which o f these alternatively spliced forms o f Bdp 1 is involved in pol III transcription 
is still unclear (Schramm and Hernandez, 2002).
- Structural characteristics of Brfl/Brf2 and Bdpl
Human and S. cerevisiae B rfl, as well as HsBrfZ, contain two distinct domains in the 
N-terminal half o f the polypeptide, both o f which are conserved between Brfl (and 
Brf2) and TFIIB (Buratowski and Zhou, 1992; Colbert and Hahn, 1992; Lopez-De- 
Leon et a l ,  1992). One consists o f a zinc-binding domain at the extreme N-terminus, 
while the ‘core domain’, occupying most o f the remaining N-terminal half, is made 
up o f two, 76 residues-long imperfect repeats. Although the C-terminal half, which is 
absent in TFIIB, is significantly less conserved, it contains, in yeast, three well- 
conserved regions, designated homology regions H I, H2 and H3 (Khoo et a l ,  1994). 
H2 and H3 are also conserved in HsBrfl (Andrau et a l ,  1999; Mital et a l ,  1996). 
Mutagenesis experiments have shown that Brfl contains two distinct TBP-binding 
domains, which interact with opposite faces o f the TBP-DNA complex. As a result, 
Brfl is able to bind stably to TBP in the absence of DNA, unlike TFIIB (Kassavetis 
et a l ,  1991; Wang and Roeder, 1995). The C-terminal H2 region comprises the high- 
affmity TBP-binding surface o f B rf l, interacting primarily with the convex surface 
and side of the first TBP pseudo-repeat (Colbert et a l ,  1998; Kassavetis et al., 
1998b). The second TBP-binding site is thought to lie in the core domain in the N-
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tenuinal half. The importance o f the TBP-binding site in the C-terminus is 
demonstrated by the fact that the N-terminal half of Brfl does not bind stably to a 
TBP-DNA complex (Kassavetis et a i , 1998b). HsBrfZ, which lacks an H2 domain at 
its C-terminus, is able to bind the TBP-DNA complex through the N-terminal direct 
repeat region, although the interaction is weak (Cabart and Murphy, 2001; Schramm 
et a l ,  2000).
Yeast Bdpl contains a domain related to a Myb repeat, found in the SWI-SNF and 
ADA complexes, the transcriptional co-repressor N-Cor and yeast TFIIIB B dpl, and 
thus referred to as the SANT domain (Aasland et a l ,  1996). This domain is 
absolutely required for TFIIIC-dependent (but not TFIIIC-independent) pol III 
transcription (Kumar et a l ,  1997). A region just upstream o f the SANT domain is 
required for transcription from linear, but not supercoiled, templates (Kassavetis et 
a l ,  1998a). Although human Bdpl is much larger than its yeast counterpart, the two 
proteins share three regions o f homology: the SANT domain, which is 43% identical, 
and the regions immediately upstream and downstream of it, with 21% and 17% 
identity, respectively (Schramm et a l ,  2000). The larger size o f human Bdpl comes 
from its C-terminal extension, which contains 19 imperfect repeats o f 26 -  28 amino 
acids, which include potential phosphorylation sites. ScBdpl has been shown to 
contact ScBrfl and TBP, as well as the DNA itself (Colbert et a l ,  1998; Shah et a l ,
1999). This binding to DNA has been postulated to contribute to the stability o f the 
TFIIIB-DNA complex (Grove et a l ,  1999).
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1.1.4.2 TFIIIC
Like TFIIIB, TFIIIC was first purified from yeast, where it is also referred to as the t  
factor. S. cerevisiae TFIIIC consists of six subunits, t138, t131, t98, t91 , t60  and 
t55, all o f which have been cloned and shown to be essential for cell viability 
(Bartholomew e( a l ,  1990; Braun et a l ,  1992; Swanson et a l ,  1991). Limited 
protease treatment revealed that S. cerevisiae TFIIIC consists o f two domains, xa 
and XB, separated by a flexible linker (Marzouki et a l ,  1986). These data are 
supported by direct visualisation o f TFIIIC -  tDNA complexes using scanning 
transmission electron microscopy (STEM), where TFIIIC appears as either two 
tightly packed or clearly separated globular domains, depending on the separation o f 
the A" and B-blocks (Schultz et a l ,  1989). Although the xg domain binds strongly to 
the B-block and appears to be the major determinant for binding, xa, which binds 
weakly to the A-block, is also required for transcription (Figure 1.2).
In humans, the TFIIIC fraction was originally resolved into two activities, TFIIIC 1 
and TFIIIC2 (Dean and Berk, 1987; Yoshinaga et a l ,  1987). Although both seem to 
be required for 5S, tRNA and V Al gene transcription, TFIIIC 1 was found to be 
sufficient for the transcription o f the 7SK and U6 genes (both o f which have type 3 
promoters) (Oettel et a l ,  1997; Yoon et a l ,  1995; Yoshinaga et a l ,  1987). The 
situation became more complicated with the description o f two other TFIIIC 1 
activities, TFIIIC 1-like and TFIIIC 1’, with different chromatographic but similar 
functional properties (Oettel et al., 1997; Wang and Roeder, 1996). A recent report, 
however, suggests that HsBdpl is an essential component o f the TFIIIC 1 activities, 
with different HsBdpl alternatively spliced variants being components o f the 
TFIIIC 1 and TFIIIC 1-like activities (Weser et a l ,  2004).
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The TFHIC2 fraction was found to contain an activity that corresponds, at least in 
part, with yeast TFIIIC and resides in a complex of five polypeptides o f 220, 110, 
102, 90 and 63 kDa (Kovelman and Roeder, 1992; Yoshinaga et a l ,  1989). This 
complex is called TFIIIC2 or TFIIIC2a, and is the complex that is actively involved 
in pol III transcription. The TFIIIC2 fraction also contains an inactive complex, 
designated TFIIIC2b (Kovelman and Roeder, 1992). TFIIIC2b, which represents 
approximately 10 -  20% of total TFIIIC in growing HeLa cells, lacks the TFIIICl 10 
subunit, but seems to contain a 77 kDa subunit that is absent from TFIIIC2a 
(Kovelman and Roeder, 1992; Yoshinaga et a l ,  1989). From now on, TFIIIC2a will 
be referred to as TFIIIC (factor, as opposed to activity).
All five subunits have been cloned. TFIIIC220, TFIIICl 10 and TFIIIC90 show no 
significant homology to any o f the yeast subunits, whereas TFIIIC63 and TFIIIC 102 
display weak homology to t95 (22%) and t131 (31%), respectively (Hsieh et a l ,  
1999c). TFIIIC220 is functionally similar to the yeast xl38, as it is responsible for 
recognising the B-block o f the promoter (L’Etoile et a l ,  1994; Lagna et a l ,  1994), 
although the two proteins share no sequence homology. Similarly, TFIIIC90 seems 
to be functionally equivalent to the x60 subunit o f yeast TFIIIC, as they interact with 
the same set o f proteins (Hsieh et a l ,  1999b). TFIIIC90, however, has an added 
intrinsic HAT (histone acetyltransferase) activity, for both free and nucleosomal H3 
(Hsieh et a l ,  1999b). TFIIICl 10 also has an intrinsic HAT activity, and can acetyiate 
free and nucleosomal histones H3 and H4, as well as nucleosomal histone FI2B 
(Kundu et a l ,  1999).
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1.1.4.3 Additional general factors
An additional general factor, TFIIIE, has been described in yeast (D ied et a l ,  1993). 
It appears to be required for the efficient transcription o f 5S rRNA and tRNA genes 
using partially purified factors, and can stimulate transcription o f tRNA and U6 
genes in a reconstituted system using recombinant TFIIIB and highly purified TFIIIC 
and pol III (D ied et a l ,  1993; Ruth et a l ,  1996). Nevertheless, a defined role for 
TFIIIE in pol III transcription has not yet been identified. Possibilities that have been 
suggested include stimulation of TFIIIB recruitment, stabilisation o f the transcription 
complex and catalysis of the conformational rearrangements in TFIIIB (Ruth et a l ,  
1996).
An activity required for transcription o f tRNA and 5S genes has also been identified 
in silkworm, termed TFIIID (Ottonello et a l ,  1987). A similar TFIIID activity has 
not been demonstrated in other systems, and it has been suggested that silkworm 
TFIIIC and TFIIID represent a subdivision o f the components associated with TFIIIC 
in other organisms (Sprague, 1992; Young et a l ,  1991).
1.1.4.4 Gene-specific factors
- TFIIIA
Transcription of the 58 rRNA gene requires, in addition to the general factors TFIIIB 
and TFIIIC, the presence of a gene-specific factor, TFIIIA (Engelke et al., 1980). 
TFIIIA was the first eukaryotic transcription factor to be purified and also the first to 
have its gene cloned (Engelke et al., 1980; Ginsberg et al., 1984). Surprisingly, it was
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not first purified from yeast, like TFIIIB and TFIIIC, but rather frorr early X. laevis 
oocytes, due to its considerable abundance, as a complex with 5S rRNA (Engelke et 
al., 1980). It has since been purified from human cells (Moorefield and Roeder, 
1994), S. cerevisiae (Wang and Weil, 1989) and silkworm (Smith et al., 1995).
'B
Figure 1.2 TFIIIC and TFIIIB interactions with a tRNA promoter
The position o f the various S. cerevisiae TFIIIB and TFIIIC subunits on a SUP4 
tRNA gene, as determined by cross-linking and protein-protein association 
experiments. The start site (+1), end o f the gene (+108) and A- and B-blocks are 
indicated.
X. laevis TFIIIA is 344 amino acids long and, apart from 90 N-terminal and 10 C- 
terminal residues, is composed o f nine tandem 27-amino acid repeats, which form 
zinc fingers (Miller et al., 1985). These are essential for the DNA-binding activity of 
TFIIIA (Hanas et al., 1983), and are a common feature in DNA-binding proteins. 
Using another zinc-finger protein, it was demonstrated that the a-helix contained in 
each finger makes contacts with the major groove o f the DNA (Pavletich and Pabo,
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1991). The DNA-binding domain o f TFIIIA can be separated into three regions. Zinc 
fingers 1 - 3  bind to the C-block o f the 5S promoter and are thought to contribute 
most o f the binding energy o f TFIIIA. Fingers 7 - 9  make contacts with the A-block, 
while finger 5 recognises the IE. The other two zinc fingers, 4 and 6, provide the 
appropriate spacing between the three regions (Clemens et al., 1992; Hayes and 
Clemens, 1992; Liao et al., 1992). Although TFIIIA proteins from other organisms 
also contain nine zinc fingers (e.g. Archambault et al., 1992; Moorefield and Roeder,
1994), it seems to have evolved quite rapidly, with considerable divergence observed 
even among frog species. For example, the X. laevis protein shows only 84% identity 
to the X. borealis TFIIIA and 63% to Rana catesbeiana (Gaskins and Hanas, 1990). 
This may be explained, in part, by the fact that the only essential function o f TFIIIA 
in S. cerevisiae is in 5S rRNA transcription (Camier et al., 1995).
In Xenopus, at least, TFIIIA has additional functions in both the storage and transport 
o f 5S rRNA (Tafuri and Wolffe, 1993). Binding o f TFIIIA to 5S leads to the 
formation o f the 7S RNP, which can then be exported from the nucleus (Guddat et 
al., 1990). This can lead to depletion o f TFIIIA from the nucleus, providing a 
negative feedback loop for regulating the production o f 5S rRNA.
- SNAPc
Transcription from the type 3 promoters o f U6 snRNA and 7SK does not require 
TFIIIA or TFIIIC, since they are devoid o f the internal promoter elements that the 
two factors recognise (Schramm and Hernandez, 2002). The gene-external PSE of 
type 3 promoters is instead recognised by another transcription factor, independently 
identified as SNAPc or PTF (Murphy et al., 1992; Sadowski et al., 1993; Yoon et al.,
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1995). SNAPc/PTF is comprised of five subunits of 190, 50, 45, 43 and 19 kDa 
(Schramm and Hernandez, 2002). The two largest, SNAP 190 and SNAP50 are 
responsible for contacts with the DNA, whereas the remaining subunits cannot bind 
DNA independently (Henry et al., 1995; Yoon et al., 1995).
The importance of SNAPc for U6 and 7SK transcription is demonstrated by the fact 
that depletion of endogenous SNAPc specifically represses transcription from the U6 
and 7SK promoters, whereas it does not affect VAl transcription (Sadowski et al., 
1996; Yoon and Roeder, 1996). Interestingly, U1 and U2 transcription was also 
inhibited, and addition o f highly purified SNAPc restored transcription of all four 
genes, suggesting that the same factor, SNAPc, is involved in pol II and pol III 
transcription of U snRNAs.
1.1.5 Assembly o f  the preAnitiation complex
Efficient and accurate transcription requires the assembly o f transcription factors at 
the relevant gene promoter, in an ordered and stepwise manner, which will allow the 
recruitment o f the polymerase and its placement over the correct start site. The 
pathway o f transcription complex assembly for RNA polymerase III is summarised 
in Figure 1.3.
In type 2 promoters, TFIIIC recognises and binds the A- and B-blocks o f the 
promoter (Lassar et al., 1983). This interaction allows the recruitment o f TFIIIB and 
pol III (Bicker et al., 1985; Setzer and Brown, 1985). Transcription from type 1 
promoters requires prior binding o f TFIIIA, which recognises all three elements of 
the ICR (Engelke et al., 1980; Sakonju et al., 1981). This TFIIIA-DNA complex 
allows binding o f TFIIIC (Lassar et al., 1983). TFIIIA can be, therefore, viewed as a
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specificity factor, which changes the promoter-recognition properties o f TFIIIC and 
targets it to the 5S promoter. Following binding o f TFIIIC, the recruitment pathway 
is similar to that in type 2 promoters. In type 3 promoters, SNAPc binds to the PSE,
Type 1 Type 2
Type 3
Brf2-TFmBSNAPc
Figure 1.3 Different pathways for recruitment of TFIIIB and RNA 
polymerase III
Pre-initiation complexes assembled on the three promoter types. In type 1 promoters, 
TFIIIA recognises and binds the ICR, allowing the recruitment o f  TFIIIC. This is 
followed by recruitment o f TFIIIB and then pol III. The A- and B-blocks o f type 2 
promoters are recognised by TFIIIC, which then recruits TFIIIB and then pol III. In 
type 3 promoters, SNAPc and the Brf2-TFIIIB complex bind the PSE and TATA 
box, respectively. This is followed by the recruitment o f pol III.
while the TATA box is recognised by the TBP component o f tue BrfZ-TFIIIB 
complex (Schramm et al., 2000; Teichmann et al., 2000; Yoon et al., 1995). Binding 
o f SNAPc and Brf2-TFIIIB to the promoter leads to the recruitment o f pol III (Chong
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et ai., 2001), presumably through protein-protein interactions, although this has not 
yet been demonstrated.
Once assembled, class III transcription complexes are extremely stable, and their 
components remain associated after initiation, supporting multiple rounds o f 
transcription (Bogenhagen et al., 1982; Lassar et a l ,  1983). Subsequent rounds 
proceed 5- to 10-fold more rapidly than the initial round o f transcription (Dieci and 
Sentenac, 1996).
L L 6 Regulation o f pol III transcription
The previous chapters described the components o f the basal pol III transcription 
machinery, and how they all come together to allow expression o f class III genes. In 
order for the cell to modulate the output o f pol III to suit its requirements at any 
given time, as well as in response to various stimuli, a host o f additional factors is 
employed. Some o f these will be described below.
1.1.6.1 Activities that reduce pol III transcription
-D r l
Drl is a 19 kDa phosphoprotein that was isolated from HeLa cells due to its ability to 
repress pol II transcription (Inostroza et a i ,  1992). Although it can function 
independently, a 28 kDa co-repressor called DRAPl can bind to D rl and enhance its 
ability to inhibit transcription (Mennelstein et a l ,  1996). In the case o f pol II, this is
32
accomplished by binding to TBP and disrupting its interaction with TFIIB and/or 
TFIIA (Inostroza et a l ,  1992; Yeung et a l ,  1994).
D rl can also inhibit transcription by pol III, both in vitro and in vivo. Highly purified 
or recombinant D rl can repress the expression o f class III genes when added to crude 
extracts or fractionated factors (White et a l ,  1994), while its overexpression in yeast 
has been shown to repress tRNA transcription (Kim et a l ,  1997). This repression can 
be relieved either by raising the levels o f TBP or by adding TFIIIB, but not TFIIIC, 
fractions (White et a l ,  1994). Similarly to the pol II system, D rl binding to TBP 
prevents its interaction with B rfl, by competing for overlapping binding sites (White 
et a l ,  1994). Interestingly, D rl does not affect pol I transcription, either in vitro or in 
vivo (Kim et a l ,  1997; White et a l ,  1994). It has, therefore, the potential to tip the 
balance o f transcription in the favour o f pol I, when, for example, rRNA production 
is lagging behind that o f 5S rRNA.
- pRb/pl07/pl30
pRb is a 105 kDa nuclear phosphoprotein, encoded by the retinoblastoma 
susceptibility gene RB. The RE gene was isolated because o f its association with 
retinoblastoma, a childhood retinal malignancy, although it has also been found 
mutated in other human tumours (Friend et a l ,  1986; Whyte, 1995). RB was one of 
the first tumour suppressor genes to be identified, and has been extensively studied. 
It plays an important role both in cell growth (increase in cell size) and proliferation 
(increase in cell number), as the ability of cells to undergo growth- or proliferation- 
arrest is severely compromised if  pRb is inactivated (Weinberg, 1995; Whyte, 1995).
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One o f the most studied fimctions o f pRb is its involvement in the regulation o f the 
cell cycle (Zheng and Lee, 2001), especially the Gl-to-S phase transition. In the 
absence o f mitogenic stimuli, pRb is critical for arresting the cell cycle at the 
restriction (R) point, two-thirds through the G1 phase. Under favourable conditions, 
however, pRb is inactivated through hyperphosphorylation by cyclin D- and cyclin 
E-dependent kinases, allowing the cells to pass the R point, committing to DNA 
synthesis and division (Zheng and Lee, 2001). pRb has also been implicated with cell 
cycle regulation beyond the G1 phase, regulation of genome integrity and 
differentiation (Zheng and Lee, 2001).
pRb can be functionally divided into three regions: the N- and C-termini, between 
amino acids 1 -  378 and 768 -  869 (of the human protein), respectively, and the 
pocket domain (Welch and Wang, 1993; Welch and Wang, 1995). The pocket 
domain can be further divided into the A and B subdomains, separated by an 
inessential spacer. The structural integrity of the pocket domain is required for 
interaction with most o f pRb targets, and is frequently found mutated in cancers 
(Chen et a l ,  1995; Weinberg, 1995).
While pRb has been shown to repress pol Il-transcribed genes, either through 
interactions with E2F (Stevaux and Dyson, 2002) or by recruiting histone 
deacetylases (HDACs) to promoters (Brehm and Kouzarides, 1999), it does so in a 
limited way: the overall level o f pol II transcription is not affected in primary 
fibroblasts from RB'/' mice, compared to equivalent cells from wild-type mice 
(White et a l ,  1996). In the same system, however, pol III transcriptional activity is 
enhanced 5-fold (Larminie et a l ,  1997; White et a l ,  1996). Furthermore, 
overexpression of pRb in transfected cells, as well as addition o f recombinant pRb to 
a reconstituted system with partially purified factors, resulted in the repression of 
various class III genes, including 5S rRNA, tRNA and U6 snRNA (White et a l ,
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1996). Thus, pRb was shown to be a general repressor o f pol III transcription, a 
function requiring the A/B pocket domain, as well as its C-terminal region (White et 
a l ,  1996).
pRb-mediated repression o f class III genes is accomplished via distinct mechanisms, 
owing to the different transcription factor requirements between type 1/2 and type 3 
promoters. Binding o f pRb to TFIIIB has been shown to dismpt its interaction to 
TFIIIC, and thus block its recruitment to type 1 and 2 promoters (Chu et a l ,  1997; 
Larminie et a l ,  1997; Sutcliffe et a l ,  2000). Type 3 promoters, on the other hand, 
exemplified by U6 snRJNfA, do not require TFIIIC for the recruitment o f TFIIIB, and 
indeed use a different TFIIIB complex, i.e. Brf2-TFIIIB. In this case, pRb has been 
shown to be recruited to the promoter itself, though protein-protein interactions with 
SNAPc and Brf2-TFIIIB (Hirsch et a l ,  2004). The molecular mechanisms that 
underlie this repression, however, are still not clear.
pRb can also inhibit pol I transcription, by binding the upstream binding factor 
(UBF) and preventing it from recruiting SL-1 and the stimulatory co-factor GBP 
(Hannan et a l ,  2000; Pelletier et a l ,  2000). General repression of both pol I and pol 
III transcription by pRb provides the cell with a single mechanism that can efficiently 
block the expression o f many genes involved in protein synthesis, thus affecting cell 
growth. Separately, through its E2F-related regulation of many cell cycle-related 
genes, pRb can also influence cell proliferation.
pRb has two relatives, p i 07 and p i 30, with which it shares 30 -  35% amino acid 
identity. This homology mostly lies in the A/B pocket region, hence the name 
‘pocket proteins’ that is often used for the three proteins collectively, p i 07 and p i30 
are more closely related to each other, however, than to pRb, with ~ 50% amino acid 
identity and highly conserved regions extending throughout the protein. This 
includes the spacer sequence between the A/B subdomains o f the pocket region
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(Mulligan and Jacks, 1998). In contrast to pRb, the spacer is essential to the funetion 
o f p i 07 and p i 30, as it contains the binding site for cyclin A/Cdk2 and cyclin 
E/Cdk2 complexes (Mulligan and Jacks, 1998).
Although there is some functional overlap between the pocket proteins, there are also 
some elear differences (reviewed in Classon and Dyson, 2001). For example, like 
pRb, p i07 and p i30 can each inhibit cell growth and proliferation if  overexpressed 
in tumour cells, an effect associated with cell cycle arrest at the G1 phase. On the 
other hand, no human tumours have been shown to contain mutations in the p i 07 
gene, while only a few contain mutations o f the p i  30 gene, suggesting that they 
might not share the tumour suppressing function of pRb. Similar to pRb, p i 07 and 
p i 30 can repress pol III transcription, at least from type 1 and 2 promoters (Sutcliffe 
et a l ,  1999). Overexpression o f p i 07 and p i 30 in transfected cells, and recombinant 
proteins in vitro, can repress the expression o f 5S rRNA and V A l, while pol III 
transcription is enhanced in p i 07 7' p i 30'/' primary fibroblasts. This repression is 
achieved in a manner similar to pRb, i.e. by binding to TFIIIB and preventing its 
association with, and therefore its recruitment by, TFIIIC (Sutcliffe et a l ,  1999).
p53
p53 is another tumour suppressor, activation of which, in response to several stimuli, 
can lead to cell growth and proliferation arrest and apoptosis (Vogelstein et a l ,  
2000). p53, unlike pRb, is not an essential cell cycle regulator, as has been revealed 
by studies o n p53'/' mice, which develop normally (Donehower et a l ,  1992). These 
mice, however, display a strong predisposition to cancer, with 74% of them
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developing tumours within 6 months o f birth. This demonstrates that p53 provides an 
important checkpoint against tumourigenesis.
Although many biochemical functions have been ascribed to p53, the best 
characterised is its ability to bind to specific sequences in DNA and activate the 
expression o f adjacent genes (el-Deiry, 1998). DNA binding is mediated by the 
central core domain (residues 100 -  300), while the acidic N-terminal dqmain 
(residues 1 - 4 3 )  mediates transcriptional activation thi'ough interactions with TBP 
and several TAFs in TFIÏD (Farmer et a l ,  1996). p53 can also repress certain class II 
genes without p53-binding sites, by recruiting HDACs (Murphy et a l ,  1999), e.g. c- 
(Kley et a l ,  1992) and cyclin A (Yamamoto et a l ,  1994). 
p53 can also repress pol III transcription (Cairns and White, 1998; Chesnokov et a l ,
1996). The best demonstration o f this came from p5 3 T  primary fibroblasts, where 
tRNA and 58 rRNA expression is significantly elevated, compared to cells from 
wild-type mice (Cairns and White, 1998). p53-mediated pol III repression is not an 
indirect response to cell cycle changes, as certain mutations in p53 that block its 
transcriptional repression frmction do not affect its ability to arrest cells at G1 (Stein 
et a l ,  2002a; Stein et a l ,  2002b). Furthermore, repression o f the transcription of 
various pol III templates can be demonstrated in vitro, using recombinant p53 
(Cairns and White, 1998; Chesnokov el a l ,  1996; Stein et a l ,  2002b).
Although class III genes do not contain p53-binding sites, the DNA-binding domain 
o f p53 is critical for the repression o f pol III transcription, with regions both in the N- 
and C-termini contributing to this function (Stein et a l ,  2002b). Instead, repression is 
achieved by protein-protein interactions with TFIIIB (Cairns and White, 1998). It is 
now understood that p53, through binding to the TBP component o f TFIIIB, prevents 
the interactions between TFIIIC and TFIIIB that lead to recruitment o f the latter to 
most class III promoters (Crighton et a l ,  2003). Indeed, p53 induction leads to
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reduced recruitment of TFIIIB to tRNA promoters in vivo (Crighton et a l ,  2003). For 
type 3 promoters, where TFIIIC is not required for pre-initiation complex assembly, 
the ability o f p53 to prevent the association of TFIIIB with pol III might come into 
play, although the exact molecular mechanism is still not clear.
As is the case with pRb, p53 can also inhibit pol I transcription (Zhai and Comai,
2000). Since the major products o f pol I and pol III transcription, rRNA and tRNA, 
are essential for the translational capacity of the cells, their repression by p53 might 
contribute to its growth-an’esting function.
1.1.6.2 Activities that stimulate pol III transcription
- Oct-1 and Staf
In addition to the PSE, type 3 promoters have an upstream regulatory element called 
DSE (Schramm and Hernandez, 2002). The DSE contains octamer motifs that are 
recognised by Oct-1, a member o f the POU domain family o f transcription factors 
(Rosenfeid, 1991). Oct-1, and the related factor Oct-2, can stimulate transcription 
from type 3 promoters by stabilising the binding o f SNAPc to the PSE (Mittal et a l , 
1996; Murphy et al., 1992).
Staf is another factor that can enhance transcription from class III genes with a type 3 
promoter. It is a 65 kDa polypeptide, containing seven tandemly repeated zinc 
fingers (Schuster et a l ,  1995), through which it has been shown to bind to the DSE 
element of several vertebrate U snRNA genes (Schaub et a l ,  1997). The majority of 
DSEs (~ 70%) contain an Oct-1 binding site within the Staf site, suggesting that the 
two proteins may act cooperatively to activate transcription (Myslinski et a l ,  1993; 
Schaub et a l ,  1997).
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CK2
CK2, formerly known as casein kinase 2, is a highly-conserved serine/threonine 
kinase, distributed ubiquitously in eukaryotes (reviewed in Litchfield, 2003). It is 
typically found in tetrameric complexes, consisting o f two catalytic (a  and/or a ’) and 
two regulatory p subunits. Within the cell, CK2 has been detected in the nucleus and 
the cytoplasm, as well as associated with specific structures and organelles, including 
the plasma membrane, endoplasmic reticulum and ribosomes. Unsurprisingly, CK2 
has been shown to paiticipate in the phosphorylation and regulation o f a broad array 
o f cellular targets, and thus is implicated in a large number o f cellular processes 
(Litchfield, 2003). For example, candidate cellular CK2 substrates include proto­
oncogene products, like c-Myc and c-Jun, the tumour suppressors p53 and BRCAl 
and transcriptional regulators, such as Max (Litchfield, 2003).
The involvement o f CK2 in the regulation o f pol III transcription was first 
demonstrated in S. cerevisiae, using a strain carrying a temperature-sensitive 
mutation in the a ’ catalytic subunit o f CK2 (Hockman and Schultz, 1996). Using 
these cells, it was shown that, at the non-permissive temperature, pol III transcription 
was down-regulated. It was later shown that CK2 activates pol III transcription by 
phosphoiylating the TBP component o f TFIIIB, enhancing its recruitment to the 
promoters o f class III genes (Ghavidel et al., 1999; Ghavidel and Schultz, 1997; 
Ghavidel and Schultz, 2001).
The situation seems to be quite similar in mammalian cells, where CK2 has been 
shown to have a potent effect on pol III transcription (Johnston et a l ,  2002). CK2 
binds and phosphorylates TFIIIB, facilitating its recruitment by TFIIIC. In human
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cells, however, the CK2 target for phosphorylation appears to be B rf l, as opposed to 
TBP, although all three components of TFIIIB, B rfl, Bdpl and TBP, can be 
phosphorylated in vitro (Johnston et a l ,  2002). In the case o f type 3 promoters, 
which do not require B rfl, Hu et a l  (2003) showed, using a well defined U6 
transcription system, that CK2 phosphorylation of the Brf2-TFIIIB complex was 
inhibitoiy. On the other hand, treatment o f the highly purified pol III complex 
resulted in activation of transcription, suggesting that, at least in this system, CK2 
can have both positive and negative regulatory effects. Further work suggests that the 
CK2 target in Brf2-TFIIIB is B dpl, and that its phosphorylation -  and inactivation -  
occurs in a cell cycle-specific manner (Hu et a l , 2004). It is worth noting that CK2 
has been shown to also stimulate rRNA synthesis by pol I, both in mammals and 
yeast (Belenguer et a l ,  1989; Ghavidel and Schultz, 2001; Voit et a l ,  1992). This 
provides the cell with yet another opportunity to coordinate the output of pols I and 
III, perhaps helping to ensure that the supply o f rRNA and tRNA is appropriate for 
the physiological status o f the cell.
ER K
Mitogen-activated protein kinase (MAPK) pathways aie signalling systems that 
translate various extracellular stimuli, e.g. growth factors, to appropriate intracellular 
responses, culminating in the alteration o f expression of a particular set o f genes. 
They exist in all eukaryotes, and control fundamental processes, sueh as growth and 
proliferation, differentiation, smwival and apoptosis. The basie arrangement consists 
o f a G-protein upstream of a core module of three kinases: a MAPK kinase kinase 
(MAPKKK or MAP3K), that phosphorylates and activates a MAPK kinase
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(MAPKK or MAP2K), which in turn activates MAPK. One o f these modules, the 
ERK (extracellular-signal regulated kinase) pathway, is involved in growth control in 
all its facets, including cell proliferation, transformation, differentiation and 
apoptosis and is employed by a wide variety of growth and differentiation factors 
(reviewed in Kolch, 2000; Robinson and Cobb, 1997). It features Ras as the G- 
protein, Raf as MAP3K, MEK (MAPK/ERK kinase) as MAP2K and ERK as MAPK. 
Amongst the many growth-promoting activities o f the ERK pathway is its ability to 
link growth factor signalling to ribosome biogenesis in mammalian cells (Whitmarsh 
and Davis, 2000).
ERK has been shown to phosphorylate, and thus activate, UBF, increasing the 
synthesis o f rRNA by pol I (Stefanovsky et a l ,  2001). In order for this to be 
physiologically relevant, 5S rRNA synthesis must increase concomitantly. This has 
indeed proven to be the case, as serum induction o f quiescent fibroblasts leads to an 
ERK-dependent activation o f pol III transcription (Felton-Edkins et a l ,  2003a). 
Importantly, the effects were shown to be independent o f pRb or the cell cycle. 
Instead, ERK was shown to bind and phosphorylate B rfl, both in vitro and in vivo. 
This phosphorylation seems to promote binding o f TFIIIB to TFIIIC and pol III, 
enhancing its recruitment to most pol III promoters.
c-Myc
c~myc belongs to a small family o f proto-oncogenes, the other members o f which are 
N- and L~myc, and has been shown to be involved in the regulation o f the cell cycle, 
cell growth and apoptosis, among others (Grandori et a l ,  2000). c-Myc is a 
transcription factor containing a basic helix-loop-helix-leucine zipper (bHLFI-LZ)
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domain at its C-terminus, which mediates DNA binding and dimérisation, and a 
transcription activation domain at its N-terminus. Heterodimerisation o f c-Myc with 
Max, which also contains a bHLH-LZ domain, allows it to recognise and bind the 
hexameric DNA sequence CACGTG (belonging to the larger class o f sequences 
known as E-boxes, CANNTG), resulting in the activation o f transcription from 
promoters that carry such an element (Murre et al., 1989). This transcription 
activation function is mediated, at least in part, by the recruitment o f a hi stone 
acetyltransferase (McMahon et a l ,  2000). c-Myc has also been shown to repress 
transcription o f certain target genes (Li et a l ,  1994).
c-Myc is thought to promote cell cycle progression by activating the genes encoding 
cyclin D2 and Cdk4, while repressing p21^’*’^ a Cdk inhibitor (Bouchard et a l ,  2001 ; 
Coller et a l ,  2000; Hermeking et a l ,  2000). In conjunction with the indirect 
activation o f another Cdk inhibitor, p2?'^''^\ by cyclin D2, the net effect o f c-Myc 
would be the prolonged activation o f cyclin E/Cdk2 and inhibition (phosphorylation) 
o f pRb by Cdk2 and Cdk4 (Coller et a l ,  2000). In addition to its proliferative role, c- 
Myc seems to be crucially involved in cell growth regulation. In some cell types, 
these two functions can be separated, with grovrth being induced in the absence o f 
increased proliferation (e.g. Beier et a l ,  2000; e.g. Schuhmacher et a l ,  1999). On the 
other hand, loss o f c-Myc results in reduced protein synthesis and growth (Johnston 
et a l ,  1999; Mateyak et a l ,  1997). Growth-related genes that are directly induced by 
c-Myc include several ribosomal proteins, translation factors, nucleolar proteins and 
rRNA-processing factors (Coller et a l ,  2000; Guo et a l ,  2000; Rosenwald, 1996; 
Schlosser et a l ,  2003).
c-Myc has been shown to activate pol I transcription, both indirectly, by inducing 
UBF, a pol I-specific transcription factor (Poortinga et a l ,  2004) and directly, by 
binding to SL-1 and promoting its recruitment to promoters (Grandori et a l ,  2005).
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c-M yc’s repertoire has been recently expanded to include pol III, as it was shown to 
potently activate tRNA and 5S rRNA transcription (Gomez-Roman et a i ,  2003). 
Surprisingly, c-Myc was found at the promoter of these genes, even if they do not 
contain E-boxes. It was observed, instead, that interactions between TFIIIB and the 
N-terminal transactivation domain o f c-Myc were responsible for its reemitment 
(Gomez-Roman et al., 2003).
L 1,7 Physiological regulation o f pol III transcription
Previously, the role o f  individual proteins in the regulation o f pol III transcription 
was described. In living cells, however, these factors do not act independently, but 
are part o f networks that modulate cell behaviour in response to particular stimuli. 
The impact o f two of these processes, cell cycle and differentiation, on pol III 
activity will be described further.
1.1.7.1 Cell cycle
In cycling cells, the transcriptional activity o f pol III varies during the different 
stages o f the cell cycle. It is low during early G l, increasing gradually as cells enter 
S phase. Pol III activity remains high, about 2- to 3-fold compared to G l, throughout 
S and G2, decreasing again as cells enter mitosis (see below) (White el a l ,  1995a). 
TFIIIB activity was shown to follow the same pattern, suggesting that it is an 
important target for the cell cycle regulation of pol 111 transcription. TFIIIC binding 
activity, on the other hand, was unaffected throughout the cell cycle (White et a l .
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1995a). Detailed time course analysis has revealed that the significant rise in TFIIIB 
and pol III activity during late G l coincides with pRb inactivation through 
phosphorylation by cyclin D- and E-dependent kinases, near the restriction (R) point 
(Johnson et a l ,  1974; Mauck and Green, 1974). The involvement o f pRb is also 
supported by the fact that pRb binding to TFIIIB is substantially diminished after the 
cells have passed the R point (Scott et a l ,  2001). pRb remains inactive through the 
rest o f the cell cycle, until after mitosis, when its dephosphorylation renders it 
capable once again to bind TFIIIB at early G l (Mittnacht, 1998).
Pol III activity is also reduced when cells exit the cell cycle, presumably reflecting a 
reduced requirement for protein synthesis (Johnson et a l , 1974; Mauck and Green, 
1974). In this quiescent state, GO, TFIIIB activity was shown to be reduced, and in 
fact limiting for pol III transcription, whereas TFIIIC activity, which is sometimes 
limiting in cycling cells, was unaffected (Scott et a l ,  2001). Similarly to cycling 
cells, pRb appears to be involved in the repression of TFIIIB in GO, where it is 
present in its hypophosphorylated, active fonm (Grana et a l,  1998). pRb was indeed 
shown to bind to TFIIIB in growth-aiaested cells, an interaction that diminished 
following mitogenic stimulation -  and thus entry into the cell cycle. Furthermore, 
R B T  cells exhibited a reduced ability to down-regulate pol III transcription following 
exit from the cell cycle (Scott et a l ,  2001). The fact that some decrease in pol III 
transcription is still observed in these cells suggests that other mechanisms might 
also be involved, p i07 and p i 30, related pRb and both able to repress pol III 
transcription tlirough binding to TFIIIB (Sutcliffe el a l ,  1999), are attractive 
candidates. Between these two, however, p i 30 is more likely to be relevant, since it 
is highly expressed in quiescent cells and in an active form (Smith et a l , 1996).
In mitosis, all nuclear transcription is repressed (reviewed in Gottesfeld and Forbes,
1997). Repression o f pol III transcription has been shown to be a result of
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phosphorylation and inactivation o f TFIIIB. In Xenopus, this seems to involve cdc2 
and one or more additional kinases (Gottesfeld et a l ,  1994; Leresche et a l ,  1996). 
HeLa cells, although possessing a more complicated cell cycle than early Xenopus 
embryos, appear to employ a similar mechanism. Thus, TFIIIB was found to be 
specifically inactivated during mitosis, attributed to the inactivation o f one or more 
o f its TAF components (White et a l ,  1995b). Further work demonstrated that the 
Brfl subunit o f TFIIIB is specifically phosphorylated during mitosis, leading to a 
reduction in TFIIIB and pol III occupancy o f 5S rRNA and tRNA genes (Fairley et 
a l ,  2003). Interestingly, Bdpl and pol III are preferentially released from promoters, 
with Brfl and TBP showing only a slight (~ 20%) reduction. TFIIIC occupancy 
remains undiminished during mitosis (Fairley et a l,  2003). Accordingly, addition o f 
recombinant Brfl or B dpl, but not TBP, relieves mitotic repression o f pol III 
transcription (Fairley et a l,  2003; White et a l ,  1995b).
1.1.7.2 Differentiation
In situ hybridisation experiments in early mouse embryos revealed an interesting 
pattern o f expression o f the B2 gene (Vasseur et a l,  1985; for a brief description of 
the first stages of mouse embryogenesis, see Chapter 1.2). B2 transcripts were 
present in oocytes and increased in abundance following fertilisation. By day 4, B2 
expression could be detected in the imier cell mass (ICM), but was down-regulated in 
the trophectoderm. At 7.5 days post-coitum, B2 RNA was present in the embryonic 
ectoderm and mesoderm, but was undetectable in the embryonic and extraembryonic 
endoderm. These experiments, therefore, revealed that pol HI transcription was 
tightly linked to the developmental stages o f the early mouse embryo.
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A murine cell line, F9, has been widely used to study early mouse embryogenesis, 
because it can be induced to mimic particular differentiation events (described in 
detail in Chapter 1.2). Using this system, it has been shown that differentiation 
results in a decrease in the abundance o f class III transcripts, as a consequence o f 
reduced pol III activity. For example, B2, VAl and tRNA synthesis is reduced 
(White et a l ,  1989). Importantly, it was shown that differentiated cells exhibit 
reduced TFIIIB, but not TFIIIC, activity (White et a l ,  1989). This observation was 
supported in a later report, using more purified fractions (Alzuhem and White, 
1998). It was also shown that the protein levels of at least two components o f TFIIIB, 
Brfl and TBP, decreased following differentiation, whereas two TFIIIC subunits 
were unaffected (Alzuhem and White, 1998). Since, however, Brfl is not required 
for transcription from type 3 promoters, some additional mechanism should be 
involved.
Part o f that answer may lie in the observation that the third component o f TFIIIB, 
B dpl, is also down-regulated following differentiation (Weser el a l ,  2004). 
Interestingly, this group identified Bdpl as an essential component o f the previously 
uncharacterised TFIIIC 1 activity (-ies), which they had earlier suggested was 
limiting in F9 PE cells (Meissner et a l ,  2002).
1A,8 Deregulation o f pol III transcription b y  transformation
A wide variety of transformed cell types have been shown to express abnormally 
high levels o f pol III products, including lines transformed by DNA or RNA tumour 
viruses and chemical carcinogens (e.g. Carey et al., 1986b; Gottesfeld et al., 1996; 
Ki'amerov et al., 1990; Larminie et al., 1999; Scott et al., 1983). Elevated pol III
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activity has also been observed in tumours in situ, compared to adjacent healthy 
cells, thus validating the observations made in cell lines (Chen et al., 1997a; Chen et 
al., 1997b; Winter et al., 2000). Increased pol III activity, therefore, seems to 
correlate well with the transformed state. Less understood, in many cases, is the 
mechanism by which pol III deregulation occurs. Some possible mechanisms will be 
discussed below.
pRb is an important cell cycle regulator. The most common way that cancer cells use 
to overcome its restraining effect is tlnough its constitutive hyperphosphorylation. 
This is achieved either by activating the cyclin-dependent kinases responsible for 
phosphorylating pRb and/or by inactivating the inliibitors o f these kinases. For 
example, 30 -  40% of primary breast tumours overexpress cyclin D1 (Bates and 
Peters, 1995), while many glioblastomas and some gliomas have amplifications of 
the cdk4 gene (Weinberg, 1995). Furthermore, pancreatic, oesophageal and bladder 
carcinomas frequently contain deletions or mutations in the gene for p i 6, a cyclin D- 
dependent kinase inhibitor (Rocco and Sidransky, 2001; Shen*, 2001). The overall 
effect o f these changes is the constitutive hyperphosphorylation o f pRb, rendering it 
unable to bind its targets, one of which is TFIIIB (Scott et al., 2001). Accordingly, 
pol III transcription can be activated by overexpression o f cyclin D or Cdk4, or by 
depletion of p i 6 (Scott et al., 2001).
Many tumours carry mutations in pRb itself. The majority (98%) o f pRb mutations 
found in tumours include the extended pocket domain (residues 393 -  892) (Harbour, 
1998). This region has been shown to be necessary and sufficient for the interaction 
between pRb and TFIIIB, and mutations within it can prevent pRb from repressing 
pol III transcription (Felton-Edkins et al., 2003b; Larminie et al., 1997).
Another important regulator o f pol III transcription is p53, mutations o f which in 
tumours have been well documented (Hoilstein et al., 1994; Hollstein et al., 1991).
47
Most o f these map to its central domain, which is essential for TFIIIB repression 
(Stein et al., 2002b). Pol III transcription, therefore, may be derepressed in cancers 
with such mutations. In some tumours, p53 function can also be lost due to viral or 
cellular oncogenes. For example, Hdm2, the human homologue o f Mdm2 (an E3 
ligase that targets p53 for degradation), is overexpressed in certain cancer types, 
including osteosarcomas and soft-tissue tumours (Momand et al., 1998). Stein,et al. 
(2002b) demonstrated that Hdm2 can stimulate pol III transcription by relieving 
TFIIIB from p5 3-mediated repression.
In addition to the factors that repress pol III transcription, several proteins or 
pathways lead to its activation. Thus, CK2, c-Myc and the ERK MAPK cascade all 
result in the up-regulation o f pol III transcription. Elevated activity o f all of these 
factors has been demonstrated in human cancers. The most striking example is ERK. 
20% of all human tumours, including 90% of pancreatic cancers, have abnormal 
activity o f Ras, the upstream kinase o f the ERK pathway. ERK itself is induced in 
approximately 30% of tumours (Downward, 2003). Up-regulation o f these activating 
factors presents another potential mechanism for deregulating pol III transcription in 
transformed and tumour cell types.
The most obvious way for tumours to increase pol III transcription, although not as 
common, is by increasing the levels o f the pol Ill-specific transcription factors. This 
has been shown to be the case with both TFIIIC and TFIIIB. Studies have shown that 
TFIIIC is overexpressed in SV40- and polyomavirus-transfoimed cell lines (Felton- 
Edkins and White, 2002; Larminie et al., 1999; White et al., 1990), as well as in 
ovarian carcinomas (Winter et al., 2000). In cell culture models, SV40 and 
polyomavirus stimulates the expression o f the Bdpl subunit o f TFIIIB, while 
hepatitis B virus causes induction o f TBP (Felton-Edkins and White, 2002; Wang et
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al., 1997). Importantly, the Brfl subunit o f TFIIIB is sometimes overexpressed in 
breast and cervical carcinomas (Daly et al., 2005).
LL 9 Concluding remarks
TFIIIB is an essential, pol Ill-specific transcription factor, whose role is to recruit the 
polymerase to the appropriate promoters. Although its own recruitment is dependent 
on other factors, namely TFIIIC or SNAPc, under particular conditions in yeast, 
TFIIIB by itself is sufficient to recruit pol III and to initiate accurate transcription. 
The central role o f TFIIIB is underlined by the fact that all but a few regulators that 
exert an influence on pol III transcription act thiough this multi subunit complex 
(Figure 1.4). In addition to the regulators mentioned previously, several viral proteins 
also affect pol III transcription through TFIIIB, directly or indirectly (White, 2004a). 
Thus, TFIIIB stands at the crossroads o f many regulatory pathways, and its activity 
determines to a large extent the levels o f pol III transcription.
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Figure 1.4 Antagonistic influences targeting TFIIIB
Repressors (green) and enhancers (yellow) o f TFIIIB activity. The pocket proteins 
and p53 directly repress TFIIIB. This restraint is removed by the adenoviral E l A 
product, the large T antigens o f SV40 and polyomavirus, the E6 and E7 products of 
high-risk human papillomaviruses, as well as the cellular oncogene Mdm2 and the 
cyclin D- and E-dependent kinases. p l6  helps to restore repression o f TFIIIB, by 
inhibiting pRb phosphorylation by the Cdks. On the other hand, TFIIIB is directly 
activated by the kinases ERK and CK2 and the cellular oncogene c-Myc. Another 
oncogene, Ras, can indirectly stimulate TFIIIB function both by activating ERK and 
cyclin D production.
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1.2 The F9 cell system
1.2.1 Early mouse embryogenesis
Following fertilisation, the mouse egg, encapsulated in a transparent cell coat called 
the zona pellucida, starts dividing. Within 2 days, it reaches an 8-cell stage called 
the morula. Further divisions lead to the first differentiation event in mouse 
embryogenesis, the formation o f the blastocyst at day 4. This is comprised o f an 
outer, spherical layer o f cells, the trophectoderm, and a cluster of cells inside it,
i
located at one of the poles, called the inner cell mass (ICM). The trophectoderm will 
eventually form the placenta, while the ICM will give the whole o f the embryo 
proper, through further growth and differentiation events. The first stages of this 
process include the formation o f the primitive endoderm, a layer o f cells on the 
periphery o f the ICM (~ day 4 Za), which will then give rise to visceral and parietal 
endoderm by days 5 to 6 (Grover and Adamson, 1986 and references therein). Part of 
the regulation that will determine cell type is governed by interactions with 
neighbouring cells. For example, if  presumptive visceral endoderm cells come into 
contact with trophectoderm-derived, extraembryonic ectoderm, they will differentiate 
into parietal endoderm (Hogan and Tilly, 1981). The fate o f  the cells is also 
temporally controlled, as visceral endoderm cells from the 6^ '^  day o f gestation can 
give rise to both visceral and parietal endoderm, whereas cells from the day can 
only generate visceral endoderm (Gardner, 1982).
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1.2.2 Teratomas
Clearly, the regulation o f differentiation during early mouse embryogenesis is very 
complicated. Studying these mechanisms is made more difficult by the small amount 
o f material one can work with and the heterogeneity o f the starting populations. Both 
o f these problems were overcome with the observation that the stem cells of 
teratomas, embryonal cai'cinoma (EC) cells, are very similar to the ICM o f the 
blastocyst-stage mouse embryo. In addition, EC cells have the ability to differentiate 
into cell types similar to those that result from ICM differentiation (thoroughly 
discussed in Silver et a l ,  1983). Teratomas are tumours that nearly always occur in 
the gonads, composed of a disorganised mass o f cells at various stages of maturation 
(Stevens and Hummel, 1957). They can form spontaneously, but can also be 
experimentally induced by a number o f methods, including grafting pre- and 
postimplantation embryos to an extrauterine site, such as the testis (Stevens, 1970) or 
kidney (Damjanov et a l ,  1971). When all the EC cells in a teratoma become 
differentiated, the tumours are benign. If, however, the tumours consist o f a mixture 
o f EC and differentiated cells or undifferentiated EC cells entirely, they are 
malignant and often referred to as teratocarcinomas. Single EC cells from teratomas 
have been shown to take part in normal embryo development when injected into 
blastocysts (Brinster, 1974; Mintz and Illmensee, 1975; Papaioannou et a l,  1975), 
suggesting that they still retain their ability to differentiate into various cell types. 
Although EC cells from teratocarcinomas can be cultured in vitro, it was observed 
that, because o f their pluripotency, the differentiation was chaotic and unpredictable, 
making it difficult to study. For example, some cell lines give rise to numerous 
differentiated derivatives when cultured as dense monolayers (Nicolas et a l ,  1976).
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However, selection and adaptation o f EC cells to tissue culture has lead to the 
establishment o f several lines with a more limited differentiation potential 
(summarised in Silver et a l ,  1983). The cell line that has been most widely used for 
in vitro studies o f differentiation is the F9 cell line.
1.2.3 The F9 cell line
The F9 cells were derived from the transplantable, experimentally induced OTT6050 
teratocarcinoma (Bemstine et al., 1973), established by implanting a six-day-old 
embryo in the testis o f a strain 129 mouse (Stevens, 1970). One o f the advantages o f 
this cell line is that the karyotype has remained fairly stable over the years (Alonso et 
a l,  1991). They have been used as a model to study a variety o f mechanisms, such as 
the involvement of retinoic acid in gene expression and differentiation and the 
changes that occur when the ICM differentiates into the two types o f extraembryonic 
endoderm, visceral and parietal, in the mouse embryo. However, because EC cells 
lose their tumourigenicity when they differentiate (Strickland and Sawey, 1980), they 
have also been used as a reverse model for transformation, especially in regard to 
proto-oncogenes.
1.2.3.1 Induction of differentiation
F9 EC cells show very little spontaneous differentiation, both in vivo and in vitro 
(Sherman and Miller, 1978). However, treatment with a variety o f agents results in 
their differentiation into endoderm-like cells, depending on the culture conditions
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and inducing agent. Treatment of monolayer or suspension cultures o f EC cells with 
retinoic acid (RA) and dibutyryl cyclic AMP (db-cAMP -  a more stable analogue of 
cyclic AMP) results in their differentiation into parietal endoderm-like (PE) cells 
(Grover and Adamson, 1986; Strickland and Mahdavi, 1978; Strickland et a l ,  1980). 
The effects o f db-cAMP on EC cells can be potentiated by the cyclic 
phosphodiesterase inhibitor IBMX, which further increases the half-life^ and 
therefore the levels, o f cAMP in the cells, or by other cAMP-elevating chemicals. 
Differentiation o f F9 EC cells to PE has also been achieved using N ’-N’- 
dimethylacetamide and 5-bromodeoxyuridine (Moore et a l ,  1986), the fluorescent 
dye Hoechst 33342 (Steuer et a l,  1990), as well as certain ginsenosides together with 
db-cAMP (Lee et a l ,  1996b). On the other hand, treatment o f small aggregates (30 -  
50) of EC cells in suspension with RA results in the foimation o f visceral endoderm- 
like cells (Hogan et a l ,  1981). It has been shown, however, that differentiation o f F9 
cells to visceral or parietal endoderm involves an initially common biochemical 
pathway and that the two differentiation pathways are reversible for the first day 
(Grover and Adamson, 1986). These data support the hypothesis (Strickland, 1981) 
that RA converts EC cells to primitive endoderm-like cells, which, depending on 
external influences, form either visceral or parietal endoderm. Therefore, 
differentiation o f the F9 cell line closely parallels events in early embiyogenesis, 
where the ICM foims parietal and visceral endoderm, via an intermediate primitive 
endoderm stage (Figure 1.5). It has been suggested that, since differentiation o f F9 
cells normally leads to endoderm-like cells, this is a line o f primitive endoderm cells, 
rather than true EC cells. However, there have been reports of F9 cells differentiating 
into derivatives o f all thi'ee genn layers -  ectoderm, mesoderm and endoderm -  
depending on culture eonditions (Kellermann et al., 1987; Koopman and Cotton,
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1986; Koopman and Cotton, 1987), suggesting that F9 EC cells are indeed 
pluripotent.
F9 EC 
(ICM)
R A Primitive Endodenn- 
like cells
(Primitive Endoderm)
Visceral Endoderm-like cells
(Visceral Endoderm)
Parietal Eiidodeiin-like cells 
(Parietal Endodemi)
Figure 1.5 The development of extraembryonic endoderm in the F9 
embryonal carcinoma (EC) cell system and in the mouse embryo
Treatment o f monolayer cultm'es o f F9 EC cells with retinoic acid (RA) leads to the 
formation o f primitive endoderm-like cells. I f  allowed to aggregate, these cells will 
form visceral endoderm. On the other hand, if  the intracellular cAMP is elevated, 
they form parietal endodeim (PE). In red are the corresponding stages in the mouse 
embryo, which the F9 cells mimic during their differentiation. The inner cell mass 
(ICM) gives rise to the primitive endoderm, which will then form the visceral and 
parietal endoderm.
It is worth noting that EC cells become committed to differentiate within hours o f 
addition o f the inducing reagents. Dong et a l  (1990) showed that treatment with RA 
for 3 hours is enough to induce differentiation to visceral endoderm. Similarly, an 8- 
hour treatment with RA and db-cAMP is enough to commit cells to the PE 
differentiation pathway (Levine et a l ,  1984).
Since I have exclusively used PE cells for my experiments, the remainder o f this 
chapter will focus on the events following induction o f differentiation o f EC cells 
along this pathway alone.
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1.2,3.2 Differentiation-induced changes
Differentiation o f F9 cells is accompanied by a large number o f changes, both 
moiphologic and biochemical. EC cells normally grow as tightly packed colonies. 
Treatment with low doses (0.1 pM) o f retinoic acid causes them, within 24 hours, to 
move apart from one another and the colonies to become less compact. Follbwing 
that, the cells assume a flat morphology, with perinuclear granules (Strickland and 
Mahdavi, 1978). In the presence o f both RA and db-cAMP, the cells become more 
rounded and often develop neural-like processes that can extend many cell diameters 
(^ u f f  and Fewell, 1980; Strickland et a l ,  1980).
Another dramatic change that takes place following induction o f differentiation 
towards parietal endoderm concerns the rate o f proliferation. F9 EC cells have a high 
proliferation rate, with a doubling time o f ~ 12 hours in the exponentially growing 
phase. The cell cycle is characterised by a very short G l phase (less than 0.5 hours) 
and an S phase o f about 10 hours, both of which can also be seen in the 
preimplantation mouse embiyo (Rosenstraus et a l ,  1982). Induction o f 
differentiation by RA alone causes a lengthening o f the G l phase to approximately 
2.5 hours and o f the S phase to 12.5 hours. In both cases, the G2+M phase was 
around 2 hours. This increase in G l and S phases leads to an overall increase in the 
doubling time o f the cells, to about 17 hours (Rosenstraus el a l ,  1982), which 
correlates with the onset o f morphological changes and decrease in cell growth 
(Linder e /a / . , 1981).
In order for the cells to achieve the widespread changes mentioned before, it is 
obvious that major changes in gene expression must occur. Some o f the first to be 
investigated in the F9 system were proteins that had been shown to be important in
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the first stages of the mouse embryo. For example, parietal endoderm cells produce a 
thick basement membrane, known as Reichert’s membrane, which they lay down 
over the cells o f the trophoblast, the major components o f which are laminin, 
entactin, type IV collagen and heparan sulphate proteoglycan (Smith and Strickland, 
1981). It has been shown that differentiation o f F9 EC cells to PE causes increased 
synthesis o f all four o f these (Carlin et a l ,  1983; Strickland et a l ,  1980; Zhang a l,
1998), as well as plasminogen activator (Strickland and Mahdavi, 1978). Because o f 
the similarities between the embryonic and F9-derived parietal endodemi in regard to 
these proteins, they have been used as differentiation markers, i.e. proteins the 
expression o f which signifies production of parietal endoderm-like cells (e.g. 
Strickland et a l ,  1980).
Over the years, a large number o f genes whose expression is altered during 
differentiation have been identified. For example, alkaline phosphatase, Rex-1 and 
SSEA 1 expression have been shown to be repressed in PE cells, while Era-1, 
retinol-binding protein and transthyretin expression is induced (summarised in 
Alonso et al., 1991). Using cDNA microarrays, Harris and Childs (2002) were able 
to examine the gene expression pattern o f differentiating F9 cells on a larger scale. 
These researchers observed that induction o f gene expression exhibits a biphasic 
pattern, with an initial peak at around 8 hours following addition o f RA and db- 
cAMP and then a second peak around day 2, resembling the path o f differentiation 
from EC to primitive endoderm and then to parietal endoderm (Figure 1.5). On the 
other hand, repressed genes were a slowly rising population, probably reflecting the 
effect o f differentiation on global gene expression.
The regulation o f some individual genes and proteins has attracted more attention, 
because o f their involvement in cell growth and proliferation, differentiation and 
apoptosis. These will be described in more detail here.
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- Myc and Max
Reduction in c-myc expression, in response to differentiation o f F9 EC cells to PE, 
was first obseiwed by Campisi et al. (1984). They showed that there is a sharp 
decline o f c-wyc mRNA within 3 days after induction of differentiation by RA and 
db-cAMP. It was later shown that reduction o f c-myc mRNA occurs very^early 
following induction, with a significant decrease observed after 6 hours, while minute 
amounts could be observed at 24 hours (Dony et a l ,  1985). It was also observed that 
it was the half-life o f the c-myc mRNA, rather than the expression o f the c-myc gene, 
tl%at was reduced following induction o f differentiation, revealing a post- 
transcriptional method o f regulation (Dony et a l,  1985). Further supporting evidence 
came ftom the work o f Dean et a l  (1986), who also showed that the decrease in c- 
myc mRNA occurred very early after addition of inducing reagents (between 8 and 
12 hours), regulated at the post-transcriptional level. Significantly, c-myc mRNA 
levels were linked with proliferation, rather than differentiation, suggesting that c- 
myc is involved in the growth arrest observed in PE cells (Dean et a l,  1986). 
Investigation o f the c-myc gene itself revealed no gross deletions or insertions within 
the gene, and no amplification or difference in copy number was observed, 
comparing F9 EC DNA with PYS2 (a parietal endodenn cell line) or mouse liver 
DNA (Griep and DeLuca, 1986).
Experiments using different cell lines suggested that o-myc down-regulation was 
necessary for differentiation (Coppola and Cole, 1986; Lachman and Skoultchi, 
1984; Prochownik and Kukowska, 1986; Westin et a l,  1982). Griep and Westphal 
(1988) proposed a similar relationship between c-myc and differentiation in F9 cells, 
by showing that artificially decreasing c-myc levels, using antisense myc sequences.
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induces differentiation. However, Schulz and Gais (1989), employing the reverse 
method of overexpressing myc in F9 cells, showed that differentiation itself is not 
affected, but rather c~myc is involved in the regulation o f growth and proliferation, 
supporting the hypothesis proposed by Dean et al. (1986). To further complicate 
matters, a report from Nishikura et al. (1990) showed that enforced changes in c-myc 
mRNA levels, by using sense or antisense myc sequences, had no overall effect on 
proliferation or differentiation o f F9 cells. The authors suggested that c-myc, 
although important to growth and differentiation, is not by itself sufficient to induce 
the changes observed after treatment with RA and db-cAMP, and that the cells in 
tl^eir experiments compensated for the loss or overexpression o f myc by other 
mechanisms, with c-fos being a possibility. They also stated that, although appearing 
normal, their c-myc sense and anti sense clones were pushed near the limit o f their 
ability to compensate. These data overall suggest that c-myc plays an important role 
in the differentiation o f F9 EC cells, given that it is regulated very soon following 
induction o f differentiation, and that, at least in some systems, has direct effects on 
growth, proliferation and differentiation.
Another member o f the myc family o f proto-oncogenes, N-myc, which shares -40%  
homology with c-myc, has also been shown to be strongly down-regulated in 
differentiating F9 cells (Sejersen et a l ,  1986). As with c-myc, this reduction is the 
result o f post-transcriptional regulation, but its importance for F9 differentiation is 
not clearly understood, since it occurs much later than c-myc (Sumegi et a l ,  1986). 
Heterodimerisation with the Max protein is thought to be necessary for the function 
o f myc family members as transcriptional activators or repressors, at least for class II 
genes (reviewed in Grandori et a l,  2000). Max is essential for embryonic 
development, as max T  mice die soon after implantation, exhibiting a generalised 
developmental arrest o f both embryonic and extraembryonic tissues (including
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visceral and parietal endoderm). The timing of the lethality in max 7' embryos 
coincides with depletion of maternal Max stores (Shen-Li et a l ,  2000). Max 
expression is maintained throughout early embryogenesis, which is also true for 
differentiating F9 EC cells to parietal endoderm (Larsson et a i ,  1997; Shen-Li et a l ,  
2000). In the latter case, however, Max protein levels have been shown to decline 
(Larsson et a l ,  1997).
p53
In addition to its role as a tumour suppressor, p53 is known to be involved in the 
regulation o f the cell cycle and differentiation (Almog and Rotter, 1997; Gottlieb and 
Oren, 1996). The observation, therefore, that p53 null mice exhibited a normal 
phenotype was somewhat puzzling, suggesting its dispensability for normal 
development (Donehower et a l ,  1992). The precise function o f p53 in early 
embryogenesis is not known. In the F9 cell system, p53 seems to respond to 
differentiation in two ways, one concerning its activity and the other its levels. 
Although EC cells contain wild type p53 protein (Pennica et a l,  1984), it has been 
shown that it is transcriptionally inactive in unstressed cells, becoming activated in 
response to differentiation or DNA damage (Lutzker and Levine, 1996; Mayo and 
Berberich, 1996). This fact might account for the lack of selection for p53  gene 
mutations in testicular teratocarcinomas, since none has been reported in this type of 
tumour. Furthermore, in the case o f DNA damage, the F9 cells undergo p53- 
mediated apoptosis, which may explain the good response of human testicular 
tumours to chemotherapy (Lutzker and Levine, 1996 and references therein).
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Linzer and Levine (1979) first observed that F9 EC cells contain high levels o f p53 
protein when compared to normal cells -  with no adverse effects on cell viability and 
growth. Differentiation of these cells to parietal endoderm, by treatment with RA and 
db-cAMP, is followed by a marked decrease in p53 levels, at both mRNA and 
protein level (Oren et a l ,  1982; Reich et a l ,  1983) -  even though its transcriptional 
activity increases (see above). The amount o f translatable p53  mRNA decreased 
following differentiation by about 20-fold, with a concomitant decrease in protein 
levels, while the half-life o f p53 protein remained relatively unchanged (Oren et a l ,  
1982; Reich et a l ,  1983). It is worth noting that p53 half-life in F9 EC cells (~ 3 
hours) was found to be considerably longer than that of the p53 protein from the non- 
transforaied mouse cell line BALB/c 3T3 ( -  30 min) (Reich et a l ,  1983). In support 
o f a post-transcriptional mode o f regulation, Dony et a l (1985) showed that, while 
the rate o f transcription o f the p53  gene was relatively constant through 
differentiation, the amount o f p53  mRNA sharply declined 2-3 days after induction. 
Because o f the kinetics o f p53 down-regulation, coinciding with morphological and 
cell cycle changes in differentiating F9 cells, the authors suggested that it might be a 
secondary event, resulting from changes in the cell cycle. Using a slightly different 
system, Chandrasekaran et a l (1982) demonstrated the decrease o f p53 protein levels 
between F9 EC and PYS-2 (a parietal endoderm cell line) cells, relating it to the 
onset o f differentiation, rather than to changes in cell growth. In this report, however, 
decreased protein stability was suggested as a reason for the decline in p53 levels. 
Although it appears contradictory to another report, which suggests that protein 
stability is not affected in response to differentiation (Oren et a l,  1982), the 
difference between the chemically-induced F9 PE cells and the PYS-2 cell line could 
possibly account for the discrepancy. In contrast to these reports Kosaka et a l (1992) 
demonstrated that, following a rapid and transient decrease, p53  mRNA levels
61
increase in differentiated F9 cells. These researchers, however, used temperature- 
inducible F9 cells, where shifting the culture temperature to 39°C results in 
differentiation of particular F9 EC mutants to either primitive or parietal endoderm- 
like cells. Treatment o f these cells with RA leads to a decrease in p53 protein levels. 
Therefore, the authors suggested that reduced amounts o f p53 are not necessarily 
associated with F9 EC differentiation, but may be associated only with RA treatment. 
Similar observations were made using another differentiation inducer, sodium 
butyrate (Kosaka et a l ,  1991). Overall, it seems that regulation of p53 levels is 
linked to the differentiation o f F9 EC cells to PE, rather than to proliferation, with a 
question mark as to the necessity o f p53 down-regulation for differentiation to occur.
“ pRb/pl07/pl30
The product o f the retinoblastoma gene, pRb, appears to be essential for mouse 
development, as loss o f both alleles o f the Rb gene results in the death of the embryo, 
between 1 3 - 1 5  days o f gestation. Various abnormalities were observed in Rb'T 
embryos, especially in the haematopoietic and nervous system, as well as increased 
apoptosis (Clarke et a l,  1992; Jacks et a l,  1992; Lee et a l ,  1992). Expression o f the 
Rb gene could be detected at very low levels in early embryos (day 9.5 o f gestation), 
subsequently rising and peaking at day 14.5 (Bernards et a l ,  1989). Induction o f Rh 
expression has also been observed in a number of cell types in response to 
differentiation, such as erythroleukaemia and pre-B cells and myoblasts (Coppola et 
a l ,  1990). No such direct evidence exists for F9 cells, but in another embryonal 
carcinoma cell line, P I9, RA-induced differentiation to neuroectodermal cells
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(neurons and glia) is accompanied by a marked induction of Rh expression, with a 
subsequent accumulation o f Rb mRNA and protein (Slack et a l ,  1993).
Some indirect evidence concerning the expression of Rb in F9 cells before and after 
differentiation does exist. F9 EC cells have been shown to possess an ElA-like 
activity, which is down-regulated following differentiation (Impériale et a l,  1984). 
E l A is an adenoviral protein that is necessary for the expression of another, viral 
gene, E2A (Nevins, 1982). One way that E l A achieves this is by sequestering pRb, 
thus releasing the E2F transcription factor, which then activates E2A expression 
(Bandam and La Thangue, 1991; Raychaudhuri et a l,  1991; Zamanian and La 
Thangue, 1992). One explanation for the presence of an ElA -like activity in F9 EC 
cells might be that these cells contain very low amounts o f pRb. Differentiation- 
induced up-regulation o f Rb expression could then result in the disappearance of this 
E lA -like activity. Consistent with this hypothesis is the very short G1 phase o f  EC 
cells, where pRb is though to exert its negative influence on the cell cycle (reviewed 
in Zheng and Lee, 2001), and a lengthened G1 phase in differentiated F9 cells 
(Rosenstraus et a l,  1982).
Regardless o f the actual levels o f pRb in F9 EC and PE cells, there is no doubt that 
pRb function is regulated during differentiation, at least as part o f E2F regulation. 
Going back to the E lA -like activity, two proteins or protein complexes were shown 
to be required for the efficient transcription o f E2A in the absence of the El A 
protein: ECRE-3, originally called TF68, and E2F, also called DRTFl (for 
differentiation-regulated transcription factor 1), the activities of which are strongly 
down-regulated during differentiation o f F9 cells (Impériale et a l,  1984; La Thangue 
and Rigby, 1987; La Thangue et a l ,  1990; M unay et a l ,  1991). Using DNA binding 
assays, pRb was shown to be able to interact with E2F, to form pRb-E2F-DNA 
complexes, and that this interaction increased in F9 PE cells (Bandara and La
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Thangue, 1991; Partridge and La Thangue, 1991). Furthermore, the interaction 
between pRb and E2F has been shown to repress E2F-dependent transcription 
(Hiebert et a l ,  1992; Zamanian and La Thangue, 1992). Interestingly, ectopic 
expression o f pRb in F9 EC cells does not have an effect on E2F-dependent 
transcription, as one would expect (Zamanian and La Thangue, 1993). Although this 
might argue against the hypothesis that the very short G1 phase is due to low'levels 
o f pRb, there could be an additional mechanism in EC cells to ensure that pRb is kept 
inactive. For example, cyclin D l, a known down-regulator o f pRb, has been shown 
to exist at high levels in F9 EC cells, which decline during differentiation to paiietal 
eijdoderm (Li et a l ,  1999). Finally, expression o f the E l A protein in F9 EC cells 
ddes not lead to activation o f E2F-mediated transcription (Boeuf et a l ,  1990). Since 
E l A  activates E2F by sequestering pRb, this could be another indication o f the low 
levels o f pRb in F9 EC cells.
The other two members o f the retinoblastoma family, p i 07 and p i 30, are not 
individually essential for mouse embryo development, as plO TT  or p l3 0 '/ ' mice 
develop normally, indicating that the two proteins are able to substitute for each 
other functionally (Cobrinik et a l ,  1996; Lee et a l ,  1996a). Double Icnockouts, 
however, die perinatally, showing deregulated limb development (Cobrinik et a l ,  
1996), suggesting that p i 07 and p i 30 perform growth-regulatory functions that 
cannot be substituted for by pRb. As is the case with pRb, no direct evidence 
concerning the expression o f p i 07 and p i 30 in F9 EC and PE cells exists, although it 
has been shown that the ability of p i 07 to repress E2F-mediated transcription 
increases following differentiation (Zamanian and La Thangue, 1993). Ectopic 
expression of p i 07 in F9 EC cells does not lead to repression o f E2A transcription 
(Zamanian and La Thangue, 1993), suggesting that, even at increased levels, p i 07 
cannot override the cellular mechanisms that regulate E2A expression in F9 EC cells,
64
As mentioned before, F9 EC cells have a very short G1 phase, which is increased 
following differentiation (Rosenstraus et a l ,  1982). Progression through the G1 
checkpoint is controlled by the D- and E-type cyclins, complexed with CDK4/6 and 
CDK2, respectively (reviewed in Boonstra, 2003). In the F9 system, mRNA and 
protein levels o f cyclins D l, D3 and E, as well as protein levels o f CDK6 and 
activity of CDK4, have been shown to decline during differentiation to parietal 
endoderm (Faria et a l ,  1998; Li et a l ,  2004; Li et a l ,  1999). Furthermore, the CDK 
inhibitor p27*^‘’’ is up-regulated in PE cells (Li et a l ,  2004; Li et a l ,  1999). p27^'*’' is 
further activated by being released from cyclin D/CDK complexes, due to the 
reduction in cyclin D levels, and by reduced phosphorylation, due to the falling 
levels of cyclin E (Li et a l ,  2004). Surprising, cyclin D2 mRNA and protein levels 
increase following differentiation (Li et a l,  2004; Li et al., 1999). However, in 
addition to its role in promoting cell cycle progression in some cell systems, it has 
been suggested that cyclin D2 may function as a negative regulator of cell growth 
(Meyyappan et a l ,  1998), which might also be the case in differentiated F9 cells.
- R as/ER K  pathw ay
The Ras family o f proteins is involved in the transduction o f extracellular signals that 
play an important role in cell growth, proliferation and differentiation. Activation of 
Ras ultimately leads to the activation o f ERK, among other proteins (reviewed in 
Katz and McCoimick, 1997). The ras family contains three genes, K-, H- and N-rm', 
which are differentially expressed in mice, both in adult tissues and during 
development (Leon et a l ,  1987). Not all three genes are necessary for embryonic 
development, however, as N- and H-ra^ knockout mice are born and grow normally
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(Crespo and Leon, 2000; Umanoff et a l ,  1995). K-ras knockout mice, on the other 
hand, die after 12.5 days o f gestation, suggesting that the product o f this gene is 
essential for development (Johnson et a l ,  1997; Koera et a l ,  1997).
In differentiating F9 cells, H- and expression is not appreciably affected
(Lockett and Sleigh, 1987). Ras activity, however, increases when F9 EC cells are 
treated with retinoic acid (Verheijen et a l ,  1999), which when used by itself induces 
the formation o f primitive endoderm-like cells (Grover and Adamson, 1986). 
Furthermore, transient expression o f oncogenic H-Ras was shown to induce 
differentiation to primitive endoderm, a response mediated by ERK (Verheijen et a l ,
1999). Further differentiation to parietal endoderm, by treatment with parathyroid 
hormone (Chan et a l ,  1990; van de Stolpe et a l ,  1993), is accompanied by reduction 
in the activity of endogenous Ras. This is a necessary event, as ectopic expression of 
oncogenic Ras blocked parietal endoderm differentiation, but by itself was not 
sufficient for differentiation to occur. As before, the effects of oncogenic Ras were 
shown to be mediated by ERK (Verheijen et a l ,  1999).
1.2.4 Virus infection
F9 cells, and other embryonal carcinoma cell lines, have the interesting property o f 
being resistant to infection by a number o f viruses, which resembles the situation 
during the very early stages o f embryogenesis. Two well documented examples are 
two DNA viruses from the papovaviridae family. Simian Virus 40 (SV40) and the 
murine polyomavirus (PyV). Swartzendruber and Lehman (1975) showed that, 
following infection o f embryonal carcinoma cells by these two viruses, no viral 
antigens could be detected. Differentiated derivatives of these cells, on the other
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hand, were found to be susceptible to viral infection. Further experiments showed 
that the enhancer sequences o f both SV40 and PyV function poorly in F9 EC cells, 
but increase in activity as cells differentiate (Linney and Donerly, 1983; Sleigh and 
Lockett, 1985). An additional level o f repression was demonstrated by Segal et al. 
(Segal et a l ,  1979), who showed that the small amount of SV40 transcripts that were 
produced in EC cells were not processed into mature mRNA. RA-induced 
differentiation alleviated this block and allowed normal splicing o f SV40 mRNA to 
occur (Segal and Khoury, 1979).
Another well studied example is that o f the Moloney Murine leukaemia vims 
(MoMuLV), a C-type retrovirus. As with SV40 and PyV, the enhancer region of 
MoMuLV has been shown to function poorly in EC cells, with a subsequent increase 
in activity following differentiation (Linney et a l,  1984). It was observed that viral 
DNA becomes methylated in EC cells, but only after a considerable lag period 
following integration (Gautsch and Wilson, 1983; Stewart et a l ,  1982). This 
méthylation seems to provide an additional regulatory mechanism, since integrated 
viral genomes were not expressed in differentiated cells, even though enhancer 
activity was up-regulated. In contrast, production o f viral proteins in differentiated 
cells was observed from newly-infecting genomes, or from integrated genomes 
following 5-bromodeoxyuridine treatment (Niwa et a l,  1983).
Other viruses that have been shown to be differentially regulated in embryonal 
carcinoma cells and their differentiated derivatives include the minute virus o f mice 
(MVM), the mouse mammary tumour virus and the murine cytomegalovirus, 
whereas many other viruses, including vaccinia, influenza, vesicular stomatitis virus 
(VSV), and herpes simplex type 1 (HSV-1) replicate equally well in all cell types 
(reviewed in Kelly and Condamine, 1982).
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1.3 The Ubiquitin -  Proteasome System
1,3.1 Introduction
When protein homeostasis was being studied, the major focus for a long time was on 
gene expression and protein synthesis, with protein degradation relegated to an 
unregulated, non-specific mechanism. The discovery o f the ubiquitin-proteasome 
pathway helped transform the image o f protein degradation to that o f a highly 
regulated and complex process, which serves as the major proteolytic pathway in 
cells. Because o f its wide range o f substrates, some of which are presented below, the 
ubiquitin-proteasome pathway has been implicated in a large number of cellular 
processes. Cell cycle progression, cell growth and proliferation, differentiation and 
development, response to environmental stimuli and stresses, the immune and 
inflammatoiy responses and apoptosis are all, to some extent, regulated by targeted 
proteolysis o f key components (reviewed in Glickman and Ciechanover, 2002). This 
pathway is responsible for the degradation o f abnormal or misfolded proteins, while 
non-proteolytic functions have also been described (for reviews, see Aguilar and 
Wendland, 2003; Hicke, 2001). It is now believed that the majority o f protein 
breakdown in mammalian cells occurs via the ubiquitin-proteasome pathway, while 
the rest is carried out by the lysosomes (Figure 1.6).
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L3.2 Ubiquitin-mediated degradation
The main function o f the ubiquitin-proteasome pathway is the regulated degradation 
o f proteins, in response to various exogenous and endogenous signals. This process 
involves two discrete and successive steps. First, the protein to be degraded is tagged 
with multiple ubiquitin molecules, in the form of ubiquitin chains. This fag is 
subsequently recognised by the proteasome, which degrades the target protein and 
recycles the ubiquitin. Below, a brief description of the components involved in this 
processes is given, together with some details o f their interactions.
1.3.2.1 Ubiquitin
Ubiquitin is a highly conserved, 76-residue polypeptide. It was first isolated in 
thymus, but was later found in all tissues and organisms (Goldstein et a l ,  1975). This 
ubiquitous presence is, in fact, where ubiquitin got its name. Ubiquitin is essential for 
proteasome-mediated degradation (with a few exceptions), as it provides the 
recognition signal for the proteasome. Ubiquitin is conjugated to the substrate protein 
through its C-terminal glycine residue (G76), which forms an isopeptide bond with a 
lysine residue on the substrate. Since ubiquitin contains lysine residues, it is able to 
conjugate to itself, forming polymeric, branched structures, which can take the form 
o f chains (Hershko and Heller, 1985). In fact, degradation o f proteins requires, in 
most cases, the presence o f chains o f 4 or more ubiquitin moieties, linked to each 
other at a specific lysine residue (K48) (Chau et a l ,  1989; Thrower et a l ,  2000). The 
importance o f K48-linked chains was demonstrated in Saccharomyces cerevisiae, 
where a lysine-to-arginine mutation was shown to be lethal (Finley et a l ,  1994).
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Figure 1.6 Pathways of protein breakdown in mammalian cells
In mammalian cells, most proteins are degraded by the ubiquitin-proteasome 
pathway. Some o f the products from this pathway are used for class I antigen 
presentation. The lysosomal-endosomal pathway is utilised for the breakdown of 
extracellular and membrane proteins. This pathway provides peptides for class II 
antigen presentation.
1.3.2.2 Conjugating enzymes
In order for a substrate to be tagged with a polyubiquitin chain, the sequential action 
o f tliree classes o f conjugating enzymes is needed (Figure 1.7). The El enzyme 
activates ubiquitin and transfers it to an E2 protein. An E3 ubiquitin ligase, which 
imparts substrate specificity, then catalyses the conjugation of ubiquitin to the target 
protein.
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E l
Only one ubiquitin-activating enzyme, E l, has been found in most organisms, 
including humans and yeast, the deletion o f which has been shown to be lethal in S. 
cerevisiae (McGrath et a l ,  1991; Zacksenhaus and Sheinin, 1990). The chemistry of 
the E l -  ubiquitin reaction is well characterised (Haas and Rose, 1982) and involves 
the formation o f a high energy thiol ester between the enzyme and ubiquitin, in an 
ATP-dependent manner. This activated ubiquitin is then transferred to one o f several 
E2 enzymes (Figure 1.7). The high efficiency of the E l enzyme allows the 
production o f sufficient activated ubiquitin for all the downstream conjugation 
reactions (Pickart, 2001).
E2
S. cerevisiae contains 11 E2s (also called ubiquitin-conjugating enzymes, ubiquitin- 
carrier proteins or Ubcs), while many more have been identified in higher organisms 
(Pickart, 2001). All E2s share a conserved core domain of about 150 amino acids. 
This domain contains the active site cysteine residue that will accept the ubiquitin 
from E l, forming another high energy thiol ester bond. Interestingly, the E2 active 
site lacks any obvious residues that can catalyse this transfer, or the transfer o f 
ubiquitin to the substrate lysine. This has led to the suggestion that the El active site 
contributes to/catalyses the transfer from E l to E2. Similarly, the E3 enzyme, in 
addition to bringing the substrate in proximity to the activated ubiquitin (see below), 
assists in the catalysis o f the transfer (Pickart, 2001).
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Figure 1.7 The ubiquitin conjugation pathway
Ubiquitin is activated by the ubiquitin-activating enzyme E l, in an ATP-dependent 
reaction (step 1). The activated ubiquitin is then transferred to a ubiquitin- 
conjugating enzyme, E2 (step 2). Step 3 provides a simplified version o f the final 
conjugation reaction. An E3 ubiquitin ligase enzyme specifically recognises the 
substrate, brings it into proximity with the ubiquitin carrying-E2 and catalyses the 
transfer o f ubiquitin to the substrate. HECT family E3s accept the ubiquitin from E2, 
whereas in the case o f RING E3s, the ubiquitin is transferred directly from E2 to the 
substrate.
As is the case with E l, which can -  indeed, has to -  interact with multiple E2s, so 
can E2 proteins interact with different E3s. Thus, the same E2 can play a role in 
several different processes, depending on the associated E3. Because o f this, some 
E2s have overlapping functions, whereas others have more specific roles. For 
example, in S. cerevisiae, Ubc3/Cdc34 is essential for the transition from G1 to S
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phase, while Ubc2/Rad6 is required for degradation o f ‘N-end-rule’ substrates, but 
also DNA repair (Hershko and Ciechanover, 1998).
E3
The E3 ubiquitin ligases comprise the largest and most varied family o f enzymes in 
ubiquitin conjugation. The primary role o f these enzymes is to bring the substrate 
protein in close proximity to ubiquitin-carrying E2 and to catalyse the transfer of 
ubiquitin. The E3 family is divided into two major groups, the HECT and RING E3s. 
The HECT (homologous to E6-AP carboxyl terminal) E3s, as the name implies, 
contain a HECT domain o f about 350 amino acids, which mediates E2 binding. This 
domain contains a strictly conserved cysteine residue, which acts as a site for a thiol 
ester formation with ubiquitin. In this class o f E3s, therefore, the ubiquitin is 
transferred from E2 to E3 prior to conjugation to the substrate lysine. Substrate 
specificity is imparted by the unique N-tenninus o f each family member.
The best characterised example o f a HECT E3, and the prototype member o f the 
family, is E6-AP. In papillomavirus (HPV) -  infected cells, the viral E6 protein 
forms a complex with cellular E6~AP (E6-associated protein) and specifically targets 
the tumour suppressor p53 for proteasomal degradation (Scheffner et al., 1993). 
Cellular targets o f E6-AP in uninfected cells include some Src family tyrosine 
kinases (Ham s et a l ,  1999; Oda et a l ,  1999), the nucleotide excision repair factor 
EIHR23A (Kumar et a l ,  1999) and Mcm7, a subunit of the replication licensing 
factor (Kuhne and Banks, 1998).
The RING E3s take their name from the RING (really interesting new gene) finger 
domain. The characteristic feature o f this domain is a series o f histidine and cysteine
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residues which coordinate two zinc ions. Database searches have revealed hundreds 
o f proteins that contain this domain, implicated in a wide variety of cellular functions 
(reviewed in Borden, 2000; Deshaies, 1999; Joazeiro and Weissman, 2000). Because 
o f the structure o f the RING finger and its catalytic inactivity, it has been proposed 
that these domains function as molecular scaffolds, rather than chemical catalysts 
(Borden, 2000). Every known E3 without a HECT domain has a RING 'finger 
domain or a RING finger protein as its constituent. In contrast to the HECT E3s, 
however, ubiquitin is not transferred to RING E3s. Rather, it is transferred directly 
from the E2 enzyme to the substrate protein, although the E3 is still necessary for 
tl|is process.
RING E3s can be further subdivided into single-subunit and multi subunit enzymes. 
In the single-subunit E3s, the substrate recognition and RING finger domains are 
obviously in the same polypeptide, although they are structurally distinct. The RING 
finger and regions flanking it facilitate E2 binding and transfer o f ubiquitin to the 
target protein (Pickart, 2001). A well-known example of this type o f E3 is Mdm2, 
which is responsible for the targeting o f p53 for degradation (Haupt et al., 1997; 
Kubbutat et a l,  1997 and see below).
The multisubunit RING E3s are protein complexes containing a small RING finger 
protein. As was the case with the single-subunit enzymes, the RING finger protein, 
usually in conjunction with another protein in the complex, recruits the appropriate 
ubiquitin-charged E2. Substrate recognition is delegated to an altogether different 
protein. So far, three types o f multi subunit RING E3s have been described. Two of 
these, the SCF (Skpl/Cullin/F-box protein) and VCB (pVHL/Elongin B/Elongin C) 
complexes are similar in organisation (reviewed in Tyers and Jorgensen, 2000). Both 
contain the Rbxl RING finger protein, which, together with a cullin protein (Cull 
and Cul2, respectively) recruit the appropriate E2. Substrate specificity is imparted
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by the F-box proteins in SCF, or pVHL, the product o f the Von Hippel -  Lindau 
tumour suppressor gene, in VCB E3s. The third type of multisubunit E3, the APC 
(anaphase promoting complex), has a different structural organisation, with Ape 11 
playing the role o f the RING finger protein (Page and Hieter, 1999). Targets of the 
APC include mitotic cyclins, some anaphase inhibitors and spindle-associated 
proteins, as well as non-mitotic proteins (reviewed in Harper et a i ,  2002; P a ^  and 
Hieter, 1999).
1.3.2.3 The proteasome
The 26S proteasome is a very large (about 2.5 MDa), multicatalytic protease that 
degrades multiubiquitinated proteins into peptides 3 to 22 residues long (Kisselev et 
a l ,  1999). The importance o f the proteasome for the cell is highlighted by the fact 
that its subunits are highly conseiwed among all eukaryotes, and, in yeast, only three 
are not lethal when deleted (reviewed in Voges et a l ,  1999). Proteasomes are present 
in the nucleus and the cytoplasm o f all eukaryotic cells (Wojcik and DeMartino, 
2003).
The proteasome is composed of two functional subcomplexes, the 20S catalytic 
particle and the 19S regulatory pai'ticle (Figure 1.8). The 20S particle has a barrel­
like structure, consisting of four rings, with 7 different subunits each, stacked on top 
o f each other. The two imier rings, termed |3, contain the 6 catalytic sites of the 
proteasome, positioned on the inner surface of the barrel-like structure. The 
combination o f these catalytic sites allows the proteasome to cleave proteins and 
peptides between any two amino acids (reviewed in Orlowski and Wilk, 2000). The 
two outer rings, termed a , are thought to regulate the access to the catalytic core, as
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well as the interactions with the 19S particles, which cap both sides o f the 20S 
complex (Figure 1.8).
The 19S regulatory particle is responsible for recognising and binding the 
multiubiquitin chain, which it subsequently removes from the substrate. The 
untagged protein is then unfolded and translocated into the catalytic core o f the 
proteasome (Voges et a l ,  1999). The 19S complex is made up o f at least 16 sutmnits, 
divided into the base and the lid (Figure 1.8). The base consists of 6 different AAA 
ATPases, which exhibit chaperone-like activity and may contribute to the unfolding 
of the target protein, and two non-ATPase regulatory proteins. Because o f its 
interaction with the a  ring of the 20S particle, the base might also play a role in the 
translocation o f the target protein. The lid component o f the 19S complex consists of 
at least 8 subunits, most o f which are thought to be non-ATPase regulatory proteins. 
The exact function o f all the subunits is still unclear, although one, R pn ll/S 3 , has 
been shown to be able to remove multiubiquitin chains from substrates (Verma et a l,  
2002; Yao and Cohen, 2002). Deubiquitination of proteins is essential for their 
subsequent degradation.
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Figure 1.8 The 26S proteasome
A schematic representation o f the proteasome and its subunits. It is composed o f the 
20S catalytic particle and two 19S regulatory particle, one at each end. The 20S 
complex forms a barrel-shaped structure, made up o f four rings, two a  and two (3, 
each consisting o f 7 non-identical subunits, stacked on top o f each other. The 19S 
complex is responsible for the recognition o f tagged proteins and their preparation 
for degradation by the 20S core. It consists o f two subcomplexes, the base and the 
lid.
1.3.3 Degradation signals
Even though the enzymatic cascade responsible for the conjugation o f ubiquitin to a 
substrate protein and its ultimate degradation by the proteasome is fairly well 
characterised, the recognition signals required for marking proteins for proteolysis 
are only now beginning to be clarified. These degradation signals appear to be
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sequence or structural elements, mediating the interaction between the substrate and 
the appropriate E2/E3 complex.
The first of these elements to be identified was the destruction box o f the mitotic 
cyclins, A and B (Glotzer et a l ,  1991), and many other substrates o f the APC 
(Deshaies, 1999; Koepp et a l ,  1999; Page and Hieter, 1999). The minimal m otif is 9 
amino acids long and has the consensus sequence o f R-A/T-A-L-G-X-l/V-G/T-N, 
with the arginine (R) and leucine (L) residues being absolutely conserved (Yamano 
et a l ,  1996). Interestingly, the destruction box is neither ubiquitinated nor 
phosphoiylated (see below), so it may serve as a binding site for the ligase subunit o f 
tl|e APC.
Recently, phosphorylation o f the target protein has emerged as an important 
regulatory mechanism for the degradation o f many proteins. Indeed, phosphorylation 
o f numerous substrates seems to be necessary for recognition by the ubiquitin 
conjugation apparatus. For example, the Cdk inhibitor S iclp  and the ST ATI 
transcription factor are both targeted for degradation following phosphorylation (Kim 
and Maniatis, 1996; Sclineider et a l ,  1996). Rechsteiner and Rogers (1996) proposed 
that the PEST motif, a region rich in proline, glutamate, serine and tlireonine residues 
found in many short-lived proteins, might serve as a degradation signal. It has since 
been pointed out that PEST elements contain numerous S/TP sites, which are 
minimum phosphorylation sites for Cdks and other kinases (Yaglom el a l ,  1995). 
Indeed, in several, but not all, cases, phosphorylation o f residues within the PEST 
element are necessary for degradation, e.g. the yeast G1 cyclins Cln2 and Cln3, the 
mammalian G1 cyclins D l and E, IkB u and p-catenin (Flershko and Ciechanover, 
1998). In contrast, phosphoiylation in some cases actually prevents degradation, 
presumably by masking the degradation signal. This type of regulation has been
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demonstrated for c-Fos and c-Jim, following phosphorylation by MAP kinases 
(Musti et a l ,  1997; Okazaki and Sagata, 1995).
Another type of degradation signal, which has been demonstrated for the yeast 
mating type transcription factor a2 , is a hydrophobic surface on an amphipathic 
helix, recognised by a Ubc6/Ubc7-containing complex (Johnson et a l ,  1998).
A well-characterised degradation signal, but with so far only one possible 
physiological candidate, is the so-called ‘N-end rule’ (Varshavsky, 1996). Using 
artificial substrates, it was demonstrated that ubiquitination and degradation was 
determined by the nature o f the N-terminal amino acids. Rao et a l (2001) showed 
that a 33 kDa fragment produced during chromatid sister separation is degraded by 
the N-end rule pathway, an event that is essential for chromosome stability.
1.3.5 Cellular targets o f the ubiquitin-proteasome pathway
A large number o f proteins have been shown to be targeted to the proteasome for 
degradation. In recent years, in addition, non-degradation roles o f the ubiquitin- 
proteasome pathway have become apparent. As a result, the ubiquitin-proteasome 
pathway is involved in the regulation o f many cellular processes. A few examples are 
displayed in Table 1.1, along with particular cellular targets.
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Table 1.1 Targets of the ubiquitin-proteasome pathway
Process Target(s) References
Cell cycle e.g. cyclin A, B, D l, E, 
Cdk inhibitors
(Reed, 2003)
Transcription e.g. E2F-1, Fos, Jun, Myc, 
p53, H if la , p-catenin, 
IkBs
(Hershko and 
Ciechanover, 1998; 
Muratani and Tansey, 
2003)
Signal transduction membrane receptors, e.g. 
growth hormone receptor, 
platelet-derived growth 
factor receptor
(Hicke, 1999)
Antigen processing antigenic proteins (Sijts et al., 2001)
1 3 .6
&
Proteasome inhibitors
The identification o f substrates o f the ubiquitin-proteasome pathway, as well as o f 
cellular processes that it is involved in, has been greatly assisted by the development 
o f pharmacological inhibitors o f the proteasome. These compounds can readily enter 
cells and, reversibly or in'eversibly, block the proteolytic functions o f the 
proteasome.
The best characterised and most widely used class of proteasome inhibitors is the 
peptide aldehydes. Compounds like MG115, MG 132, ALLN and PSl are substrate 
analogues, primarily blocking the chymotryptic-like activity o f the proteasome, 
which is thought to be rate limiting (Lee and Goldberg, 1998). Inhibition by peptide 
aldehydes can be reversed simply by their removal from the growth medium. 
Although they are very potent, the do not significantly affect cell viability and 
growth for 10 to 20 hours (Lee and Goldberg, 1998). One drawback, however, is that 
they are not entirely specific to the proteasome, as they have been shown to inhibit 
certain lysosomal proteases and the calpains.
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Similar in structure, but chemically different, the peptide boronates are the newest 
and most potent proteasome inhibitors. They act by binding irreversibly to the active 
sites of proteasomes, without affecting the function o f other cellular proteases 
(Adams et a l ,  1998).
Lactocystin (or lactacystin), chemically and structurally different from the peptide 
inhibitors, is a naturally-occurring proteasome inhibitor, isolated from actinomycetes 
(Omura et a l ,  1991). It irreversibly blocks proteasome function by covalently 
binding to p subunits of the 20S particle, resulting in the inhibition o f the 
chymotryptic- and tryptic-like activities (Craiu et a l ,  1997; Fenteany et a l ,  1995). 
L^ttocystin, which converts into its active form p-lactone in aqueous solutions, can 
also inhibit cathepsin A (Ostrowska et a l ,  1997).
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1.4 Objectives
The specific down-regulation o f TFIIIB activity during the differentiation o f F9 
embryonal carcinoma cells to parietal endodeim-like cells has been demonstrated 
previously (Alzuherri and White, 1998; White et a l ,  1989). The aim o f thi&^tudy 
was to elucidate the precise mechanism by which this down-regulation occurs. Since 
differentiation o f these cells results in the loss of their transformed state, the 
mechanism by which pol III transcription is down-regulated could provide insights 
info the deregulation observed in transformed cells and tumours.
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CHAPTER 2
Materials and Methods
2.1 Cell culture
Cell culture was performed in a class II hood, using aseptic technique and sterile 
equipment and reagents. The F9 cell line was routinely cultured in DMEM 
(ïfïulbecco’s Modified Eagle Medium) containing 10% foetal bovine serum (FBS),
1 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin (all from 
Sigma) in a humidified atmosphere containing 5% CO2 at 37”C. From here on, this 
will be refeiTed to as growth medium. The stable cell lines derived from the F9 cells 
were cultured in growth medium which contained 500 pg/ml G418 sulphate (FAA 
laboratories) and refeiTed to as selection medium. Differentiation o f F9 EC cells was 
induced by addition of 0.1 pM retinoic acid (RA), 1 mM dibutyryl cyclic AMP (db~ 
cAMP) and 0.1 mM 3-isobutyl-1 -methylxanthine (IBMX) (all from Sigma) to 
growth medium, or selection medium for the stably-transfected clones, and will be 
referred to as differentiation medium from here on. Cells were kept in differentiation 
medium for 6-7 days, with the medium changed every 2 days.
F9 EC cells were passaged when subconfluent; approximately every 2 to 3 days. 
After media was aspirated from the flask, 2 ml o f buffered trypsin-EDTA (0.05% 
trypsin, 0.02% EDTA, Sigma) were added to the cells and then aspirated 
immediately. A further 2 ml were added and left for approximately 2 minutes at 
37°C. Following trypsinisation, fresh media was immediately added to the
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dissociated cells in order to neutralise the trypsin. Appropriate volume o f this cell 
suspension was then used.
Cryo-freezing was used for storage o f all cell lines. Cells were trypsinised as 
described above and, following pelleting by centrifugation, they were resuspended in 
a solution o f 80% DMEM, 20% FBS and 10% dimethylsulphoxide (DMSO, Sigma). 
Cells were aliquoted into cryo-tubes and frozen in stages, by initially being placed at 
-80"C overnight and subsequently being transfen’ed to liquid nitrogen storage. 
Thawing of cells was performed rapidly by placing cryo-tubes in a waterbath at 37°C 
until just thawed. Cells were then mixed with fresh media, centrifuged and the 
si^pematant aspirated o ff to ensure removal o f DMSO prior to resuspension in 
growth medium.
2.2 Optimisation of transfection using P™
galactosidase assays
In order to optimise the transfection process, vai'ying amounts o f CMV-P gal plasmid 
were transfected into cells using varying volumes o f either Superfect (Qiagen) or 
Lipofectamine (Invitrogen). At the time o f transfection, cells were -80%  confluent in 
a 6cm dish. After following the transfection protocol recommended by each 
manufacturer the transfected cells were washed twice in PBS, re-grown in 
DMEM/FBS and harvested in 400 pi IxRLB (Promega; 25 nM Tris-H3P0 4 , pH 7.8, 
2 mM 1,2-diaminocyclohexane tetraacetic acid, 2 mM dithiothrietol, 10% glycerol 
and 1% Triton X-100), microcentrifuged at 10,000 rpm for 5 minutes to remove cell 
debris and the lysates analysed for reporter gene activity.
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For the p-galactosidase assays, 100 pi o f cell lysate were incubated with 100 pi o f 2x 
p“  gal reagent (200 nM sodium phosphate buffer, pH 7.2, 2 nM magnesium chloride, 
100 mM P-mercaptoethanol, 1.3 pg/ml ONPG) and incubated at 37°C until a yellow 
colour developed. Reactions were stopped by the addition o f 600pl of IM  sodium 
carbonate and the activity was measured in a spectrophotometer (Pharmacia Biotech 
Ultraspec 1000) at 420 nm.
2.3 Stable transfection
F9 EC cells were plated out at 10^ cells/10 cm dish 24 hours prior to transfection, 
resulting in a confluency o f -7 0  -  80% at the time of transfection. Two 10 cm dishes 
were transfected with 12 pg o f pcDNA3.1-HA-Hs.67?Fi construct, while a further 
two 10 cm dishes were transfected with 12 pg of the empty pcDNA3.1-HA vector 
(Invitrogen). Mastennixes for each set o f 10 cm dishes were made up comprising the 
appropriate plasmid DNA and DMEM. Then, for each transfection, 24 pi of 
Superfect reagent was added, mixed gently and incubated at room temperature for 
10 minutes to allow DNA-Superfect complexes to form. While complexes were 
forming, cells were washed once with 2 ml of PBS. For each transfection, 2.4 ml of 
growth medium was added to the tube containing the complexes. This was mixed 
gently and the diluted complex solution overlaid onto the rinsed cells. Cells were 
incubated with the complexes for 3 hours at 37°C in a CO2 incubator. Following 
incubation, the media was aspirated o ff and the cells washed twice with PBS. Fresh 
growth medium was then added and the cells were allowed to grow for a further 
24 hours before adding the selection agent G418 sulphate, at a concentration of
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500 pg/ml, to the culture medium. Fresh selection medium was replaced every four 
days. After about five days cells began to die, but were split if  they reached 
confluency before massive cell death began. After two to four weeks, healthy G418- 
resistant colonies were isolated and transferred to individual plates or wells. Potential 
clones were then screened using HA-hBrfl specific assays to identify the clones with 
the highest levels o f HA-hBrfl. This was achieved by Western blot us&g an 
antibody against the HA tag.
2,4 Preparation of whole-cell extracts
k
All extracts were prepared from cells grown in 10 cm tissue culture dishes to 
facilitate scraping and were harvested at approximately 80% confluency or after 
6-7 days in differentiation medium. Preparation was performed on ice as rapidly as 
possible, and all solutions and tubes were kept ice-cold to maintain cell activity. Two 
different methods were employed. In the first, cells were washed twice with 5ml o f 
PBS before being scraped with a plastic spatula into 5 ml of ice-cold PBS. Cells were 
collected in 50 ml Falcon tubes and pelleted by slow centrifugation at 1500 rpni for 
5 minutes at 4°C. A small volume of fresh ice-cold PBS was used to resuspend the 
cell pellets and allow the cells to be transferred to eppendorf tubes. These were then 
microcentrifuged at 2000 rpm for 2 minutes at 4®C to re-pellet the cells and the PBS 
removed. The volumes o f the cell pellets were then estimated by comparing them 
with pre-measured volumes o f water. Microextraction requires pellets to be between 
5 0 -  150 pi, giving approximately 0.5 -  3 x 10  ^ cells; larger pellets were subdivided. 
An equal volume o f freshly made pre-cooled microextraction buffer (20 mM Hepes 
pH 7.8, 450 mM NaCl, 25% glycerol, 50 mM NaF, 1 mM DTT, 0.5 mM PMSF,
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0.2 mM EDTA, 40 pg/ml bestatin, 1 pg/ml tiypsin inhibitor, 0.7 pg/ml pepstatin, 
0.5 pg/ml aprotinin, 0.5 pg/ml leupeptin) was added to the cells and, following 
resuspension, the cells were immediately snap-frozen on dry ice. Cells were then 
placed in a 30°C waterbath until just thawed before being immediately returned to 
dry-ice. This freeze-thaw procedure was performed a total o f 3 times to ensure 
optimal cell lysis, with cells then being microcentrifuged at 13,000 rpm for 7 niînutes 
at 4°C after the third thaw. The supernatant was carefully transfeiTed into a fresh 
tube, ensuring that the cell debris was left behind, and then promptly aliquoted and 
snap frozen. These whole-cell extracts were then stored at -70®C. This method o f 
protein extraction was used for most experiments.
For experiments examining levels o f phosphorylated proteins, an alternative 
extraction protocol was followed. Extracts prepared in this way are termed cell 
lysates. Cells grown on 10 cm dishes were washed twice with PBS. After the second 
wash, care was taken to remove all the PBS from the dishes. Subsequently, the cells 
were scraped into 250 pi of lysis buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 25% 
glycerol, 50 mM NaF, 10 mM p-glycerophosphate, 1 mM Na]V 0 4 , 1 mM DTT, 
0.2 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 0.5 mM PMSF, 40 pg/ml bestatin, 
1 pg/ml trypsin inhibitor, 0.7 pg/ml pepstatin, 0.5 pg/ml aprotinin, 0.5 pg/ml 
leupeptin), transferred to eppendorf tubes and incubated on ice for 10 minutes. After 
the incubation was completed, the cells were passed thi'ough a 26-gauge needle three 
times and centrifuged at 4"C for 10 minutes. The supernatant, containing the soluble 
proteins, was finally transferred to another eppendorf tube and snap frozen. The cell 
lysates were then stored at -70°C.
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2.5 Measuring protein concentration
The protein concentration o f samples was determined using the Bradford assay.
Bradford reagent (Biorad) was diluted in distilled water (l-in-4 dilution). 1 ml o f the
diluted reagent was added to 1 pi o f protein extract and mixed. The absorbance o f the
sample was then measured in a UV spectrophotometer at 595 nm. To estimate the
protein concentration o f the sample, a standard curve was constructed, with a
concentration range of 0 to 12 mg/ml, using a 10 mg/ml stock solution of bovine
serum albumin (BSA). If the sample being measured fell outside the linear range of 
T
the standard set, appropriate dilutions were made and the samples re-measured.
2,6 Separation of proteins by polyacrylamide gel
electrophoresis
Proteins were resolved on denaturing polyacrylamide gels according to molecular 
weight by electrophoresis. Typically, 7.8% polyacrylamide resolving minigels 
(375 mM Tris pH 8.8, 0.1% SDS) were used with a stacking layer comprised o f 4% 
polyacrylamide gel (125 mM Tris pH 6.8, 0.1% SDS) based on the discontinuous 
buffer system described by Laemmli (1970). Samples were boiled for 2 minutes in 
Ix protein sample buffer (62.5 mM Tris pH 6.8, 0.5% SDS, 5% p-mercaptoethanol, 
10% glycerol, 0.125% bromophenol blue) prior to loading. Electrophoresis was 
performed in 1 x SDS running buffer (0.1% SDS, 76.8 mM glycine, 10 mM Tris, pH 
8.3) at a voltage o f 150-200 V. The progress o f the electrophoresis was monitored
using Rainbow molecular weight markers (Amersham Biosciences) or Prosieve 
colour protein markers (Cambrex).
2.7 Western blotting
Electrophoretic transfer of proteins resolved by SDS-PAGE to nitrocellulose 
(BioRad) or PVDF (Amersham Biosciences) membranes was achieved using the 
BioRad Mini Trans-Blot Electrophoretic Transfer Cell system. Transfer was carried 
out in 1 X transfer buffer (76.8 mM glycine, 10 mM Tris pH 8.3, 20% methanol) at 
50 V for 1 hour. Correct transfer and equal loading was ensured by washing the 
membrane in Ponceau S solution (0.1% Ponceau S, 5% acetic acid; Sigma) for 5 min 
and then rinsing it with distilled water until bands were clearly visible on the 
membrane. After washing the membrane clean o f dye, it was blocked in milk buffer 
[wash buffer (32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20), plus 5% skimmed 
milk powder (Marvel)] for 1 hour at room temperature. Membranes were incubated 
with primary antibodies (typically a 1:1000 dilution in milk buffer) for 2 hours at 
room temperature or overnight at 4®C. Excess primary antibody was removed by 
washing the blot 3 times for 3 minutes in wash buffer before incubating for 1 hour at 
room temperature with the appropriate horseradish peroxidase-conjugated secondary 
antibody (1:1000 dilution in milk buffer; DAKO). To ensure removal o f excess 
secondary antibody, the blot was sequentially washed in batches o f wash buffer, 
3 times for 3 minutes, followed by 2 washes for 15 minutes. After one further 
5 minute wash using 1 x TBS (2.5 mM Tris-HCl pH 7.6, 15 mM NaCl), the blot was 
developed using the enhanced chemiluminescence method (ECL and ECL+; 
Amersham Biosciences) as directed by the manufacturer.
2.8 Antibodies
Table 2.1 Antibodies
Antibody Source
anti-actin (C-11) Santa Cruz
anti-Bdpl (2663) (Schramm et ah, 2000)
anti-Brfl (128) (Cairns and White, 1998)
anti-Brfl (CSH145) Generously donated by Nouria Hernandez
anti-c-Fos (4) Santa Cruz
anti-CK2 a  & a ’ (H-286) Santa Cruz
anti-c-Myc (N-262) Santa Cruz
anti-cyclin D1 (72-13G) Santa Cruz
anti-HA (F-7) Santa Cruz
anti-laminin B1 (A-1) Santa Cruz
anti-M adl (C-19) Santa Cruz
anti-Mad2 (G-16) Santa Cruz
aftti-Mad3 (H-206) Santa Cruz
apti-Mad4 (N-19) Santa Cruz
anti-Max (C-17) Santa Cruz
anti-p44/42 MAPK (9102) Cell Signalling Technology
anti-p53 (1C 12) Cell Signalling Technology
anti-pl07 (C-18) Santa Cmz
anti-pl30 (C-20) Santa Cruz
anti-phospho-p44/42 MAPK (9106) Cell Signalling Technology
anti-phospho-pRb (9307) Cell Signalling Technology
anti-pRb (IF8) Santa Cruz
anti-TBP (58C9) Santa Cruz
anti-TFIIB (C-18) Santa Cruz
anti-TFIIIC110(4286) (Winter et ah, 2000)
2.9 Preparation of total cellular RNA
Total cellular RNA was isolated from cells when approximately 80% confluent, or 
after 6-7 days in differentiation medium, using TRI reagent (Sigma), a solution of 
guanidine thiocyanate and phenol, in accordance with the manufacturer’s 
instructions. Media was aspirated off cells grown in 10 cm tissue culture dishes and 
residual media removed with two washes using 5 ml ice-cold PBS. Cells from each 
dish were harvested by scraping in 1 ml o f TRJ reagent per dish and transferred to a
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sterile eppendorf tube. Cells were left to stand for 5 minutes at room temperature to 
ensure complete dissociation o f nucleoprotein complexes. 0.2 ml o f chloroform were 
then added to each tube and the samples vortexed for 15 seconds. The samples were 
then allowed to stand for a further 15 minutes at room temperature prior to being 
centrifuged at 13,000 rpm for 15 minutes at 4°C. This resulted in separation o f the 
samples into three phases: a lower red organic phase containing protein, a middle 
white interphase containing precipitated DNA and an upper colourless, aqueous 
phase which contains the RNA. These upper phases were carefully removed, 
ensuring no contamination from the remaining phases, and transferred to fresh 
eppendorf tubes. Isopropanol (500 pi) was added to each o f these tubes containing 
the aqueous RNA and thoroughly mixed by repeated inverting. Following 5 -  
10 minutes incubation at room temperature to allow maximal precipitation of RNA, 
samples were centrifuged at 13,000 rpm for 10 minutes at 4"C. The supernatant was 
then removed and the remaining RNA pellet was washed with 1 ml o f 75% ethanol 
made up with diethypyrocarbonate (DEPC)-treated dHzO (0.1% DEPC), thoroughly 
mixed into solution, left overnight at room temperature and then autoclaved to 
inactivate the remaining DEPC. The samples were vortexed briefly, subsequently 
microeentrifuged at 13,000 rpm for 5 minutes at 4^C and the supernatant aspirated 
off. Residual supernatant was removed with a P20 pipette following pulse 
microcentrifugation. Appropriate volumes o f DEPC-dHiO, pre-warmed to 65'^C, in 
the range o f 10 -  30 pi, were added to the RNA pellets and the samples were heated 
in a 65“C waterbath for 10 -  15 minutes to facilitate resuspension of the RNA. The 
samples were stored at -7 0 “C.
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2.10 Measuring RNA concentration
RNA concentration was determined by adding 4 pi of the RNA extract to 200 pi of 
lOmM Tris pH 7.6 and measuring the absorbance of the sample at 260 and 280 nm 
using a UV spectrophotometer. The calculation used was: RNA concentration 
(mg/ml) = absorbance at 260 nm x 40 x dilution factor / 1000. A ratio o f absorbance 
at 260nm to 280nm in the range o f 1.8 -  2 indicated the RNA samples were 
relatively free from contamination with phenol or protein.
2.11 Northern blot analysis of total cellular RNA
Typically, RNA samples o f 10 -  30 pg were used in analysis, made up to a total 
volume o f 10 pi with DEPC-dHiO. 10 pi of 2 x RNA sample buffer (1 x MOPS 
comprised o f solutions made up with DEPC-dHiO (20 mM MOPS pH 7.0, 8 mM 
sodium acetate, 1 mM EDTA pH 8.0), 4.4 M formaldehyde, 54% formamide) were 
added to each sample prior to heating at 65°C for 15 minutes to denature the RNA 
secondary structure. The samples were immediately transferred to ice to prevent any 
renaturation and 2 pi of 1 mg/ml ethidium bromide and 2 pi o f 10 x RNA loading 
buffer (50% glycerol, 1 mM EDTA, 0.25% bromophenol blue, 0.25% xylene cyanol 
FF) were added to each sample. Following a 20 minute pre-mn at 40 V o f a 
denaturing gel (1% agarose, 2.2 M formaldehyde, 1 x MOPS) in 1 x MOPS, samples 
were loaded and run for approximately 5 hours at 40 V in order to electrophoretically 
separate the different species o f RNA according to size. The gel was visualised under 
a UV transilluminator in order to confirm separation and photographed. It was then
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washed for 20 minutes in 20 x SSC buffer (3 M NaCl, 0.3 M sodium citrate pH 7.0) 
prior to eapillary transfer as described in Sambrook and Russell (2001)
The transfer procedure required the prepared gel to be placed, inverted, on a bridge 
o f Whatmann 3 mm chromatography paper supported on a glass plate and suspended 
over a reservoir o f 20 x SSC buffer. An appropriate size o f Hybond N nylon 
membrane optimised for nucleic acid transfer (Amersham Biosciences) was pre­
soaked in 20 X SSC and positioned over the gel, followed by a further two layers o f 
pre-soaked Whatmann paper; at each stage of layering, care was taken to ensure 
removal of air bubbles. This anangement was surmounted with a stack o f paper 
tc^wels and an appropriate weight in order to allow efficient capillary action. During 
transfer, the migration o f the RNA from the gel to the nylon membrane is facilitated 
b y  the passive movement o f the transfer solution through the gel. Plastic wrap was 
used to prevent a direct contact between the paper towels and the Whatmann bridge; 
this ensured movement of the buffer was only through the gel. In order to achieve 
high-transfer efficiency, the capillary action was allowed to proceed overnight. 
Following transfer, the RNA was fixed to the membrane by UV-crosslinking at 
1200 pJ and was then washed for 5 minutes in DEPC-dHiO.
Radiolabelled DNA probes complementary in sequence to a particular RNA of 
interest were used to locate it on the membrane. The pol III B2 gene probe was a 
0.2 kb EcoKi-Pstl fragment from pTB14 (White et a l,  1989) and the pol II acidic 
ribosomal phosphoprotein PO (ARPP PO) probe a 1 kb EcoR\-Hind\\l fragment from 
the mouse cDNA (Hurford et a l ,  1997). The probes were labelled using a 
Megaprime DNA labelling system (Amersham Biosciences) according to the random 
oligonucleotide priming method o f Feinberg and Vogel stein (1984). This method 
involved the addition of 5 pi o f random hexamer oligonucleotide sequences and the
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appropriate volume o f DEPC-dHzO for a final volume of 50 pi in the total reaction to 
25 ng o f purified DNA template, which was subsequently denatured by heating at 
95^C for 5 minutes. DNA synthesis is primed by the hexamer oligonucleotides which 
are able to anneal to the DNA during slow cooling to room temperature. Labelling 
was earned out at 37°C for 1 hour in 1 x reaction buffer (containing Tris-HCl pH 7.5, 
P-mercaptoethanol, M gCh; Amersham Biosciences) following the addition d f 4 pi 
each o f dATP, dGTP, dTTP (in Tris pH 8.0, 0.5 mM EDTA), 50 pCi o f [a-“ P] 
dCTP (10 mCi/ml, 3000 Ci/mmol; Amersham Biosciences) and 2 units DNA 
polymerase I Klenow fragment (in 100 mM potassium phosphate pH 6.5, 10 mM P- 
irtercaptoethanol, 50% glycerol). The reaction was stopped by heating at 80°C for 
5 minutes and kept at 4°C until the nylon membrane with bound RNA had been pre­
hybridised. This involved rotation in a hybridisation oven at 45°C for 45 minutes in 
20 ml of hybridisation buffer (0.2 M sodium phosphate buffer pH 7.2, 1 mM EDTA, 
1% (w/v) BSA, 7% (w/v) SDS, 45% (w/v) formamide in DEPC-dHzO). Following 
this, the radiolabelled probe was added to 20 ml of fresh hybridisation buffer, in 
which the membrane was incubated with rotation at 45°C overnight. The nylon 
membrane was then washed with rotation in wash buffer (40 mM sodium phosphate 
buffer pH 7.2, 1 mM EDTA, 1% (w/v) SDS in DEPC-dHzO) at room temperature for 
2 minutes and then twice for 15 minutes at 65^C in order to remove non-specific 
radioactivity before being exposed to autoradiography film overnight at -70^C. 
Membranes were stripped by incubating in boiling water for 5 minutes and pre­
hybridised again prior to being reprobed.
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2.12 Preparation of cDNAs
cDNAs were prepared from 3 pg o f RNA. Primer annealing was carried out in a final 
volume o f 24 pi with 0.67 x hexanucleotide mix (Roche) (diluted in DEPC-dHzO)
and allowed to proceed for 10 minutes before transfenal to ice. 8 pi o f 5 x Firsts
Strand Buffer (Invitrogen), 4 pi o f 0 .1 M DTT, 2 pi o f 10 mM dNTP mix (made up 
in DEPC-dHiO) and 1 pi (200 U) o f Superscript II Reverse Transcriptase (Invitrogen) 
was added to initiate reverse transcription, which was performed for 1 hour at 47°C 
before the reaction was stopped by heating at 70°C for 15 minutes.
2.13 Reverse transcriptase -  Polymerase chain 
reaction (RT-PCR)
PCRs were carried out using Proteus II (Helena Biosciences) or TC-312 (Techne) 
thermal controllers. 1 pi o f cDNA was amplified with 20 pmol o f the appropriate 
primers listed in Table 2.2. Amplification reactions contained 0.5 U o f Taq DNA 
polymerase (Promega) in 20 pi o f 1 x Taq DNA polymerase buffer (Promega) 
containing 1.5 mM MgCh, 0.2 mM o f each dNTP and 1.8 pCi o f [a-^^P] dCTP (10 
mCi/ml, 3000 Ci/mmol; Amersham).
PCR was performed under the following cycling parameters:
5S rRNA: 95°C for 3 minutes, 18 cycles o f [95°C for 30 seconds, 58°C for 30 
seconds, 72°C for 1 minutes], 72°C for 5 minutes.
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ARPP PO: 95”C for 2 minutes, 18 cycles o f [95°C for 1 minute, 58“C for 30 seconds, 
72”C for 1 minute], 72°C for 3 minutes.
B dpl: 95°C for 2 minutes, 25 cycles o f [95°C for 30 seconds, ôO'^C for 30 seconds, 
72°C for 1 minute], 72°C for 5 minutes.
H sBrfl: 95°C for 2 minutes, 25 cycles o f [95°C for 30 seconds, 60°C for 30 seconds, 
72°C for 30 seconds], 72°C for 5 minutes.
Hs & M mBrfl: 95°C for 2 minutes, 25 cycles o f [95°C for 30 seconds, 60°C for 30 
seconds, 72°C for 30 seconds], 72°C for 5 minutes.
M m Brfl: 95°C for 2 minutes, 25 cycles o f [95°C for 30 seconds, 58°C for 30 
seconds, 72°C for 30 seconds], 72°C for 5 minutes.
HPRT: 95°C for 2 minutes, 25 cycles o f [95°C for 30 seconds, 66°C for 30 seconds, 
12?C for 30 seconds], 72^C for 5 minutes.
tRNA^^": 95^C for 2 minutes, 30 seconds, 25 cycles of [95®C for 30 seconds, 68®C 
for 30 seconds, 72°C for 20 seconds], 72°C for 5 minutes.
Reaction products were resolved on 7% polyacrylamide sequencing gels containing 
7 M urea and 1 x TBE (45 mM Tris, 45 mM boric acid, 0.625 mM EDTA pH 8.0). 
Gels were pre-run for 30 minutes at 40 W in 1 x TBE and 1.5 pi o f each sample were 
loaded after being boiled at 95®C for 2 minutes and quenched on ice. Electrophoresis 
was carried out for a further 1 hour at 40 W and the gel subsequently vacuum-dried 
at 80°C for 1 hour, before being exposed to autoradiography film, in order to detect 
the radiolabelled products.
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Table 2.2 PCR primers
Gene Primers (5 ’ to 3 ’) Product
(bp)
5SrRNA GGCATACCACCCTGAACGC 107
CAGCACCCGGTATTCCCAGG
ARPP PO GCACTGGAAGTCCAACTACTTC 265
TGAGGTCCTCCTTGGTGAACAC
Bdpl ACCCAGTGAAGAGACCGAGA 194
TCAGGTCAGCACCTCTTCCT
HsBrfl CAGCCAGAATGCATGACTTCAG 95
AAATTCCGTGAGCCTCTTCCGCAGCG
Hs/MmBrfl CAGCCAGAATGCATGACTTCCG 95
AAATTCTGTGAGCCTCTTCCGTAGCG
MmBrfl GGGGAGAAGAACCATGAAGT 240
AGTGAGCTGACTGGTTGGAG
HPRT GTAATGATCAGTCAACGGGGGAC 186
CCAGCAAGCTTGCAACCTTAACCA
t^ A '- " " GTCAGGATGGCCGAGTGGTCTAAG 88
CCACGCCTCCATACGGAGACCAGAAGACCC
The first row in each primer pair represents the forward primer, while the second the 
reverse primer. Hs; Homo sapiens. Mm: Mus musculus
2.14 Transformation of competent cells
E.coli XL-1 Blue supercompetent cells (Stratagene) were transformed for plasmid 
storage and propagation. Cells, which were stored at -80°C and highly temperature 
sensitive, were thawed on ice to prevent loss o f transformation ability. 0.4 pi o f (3- 
mercaptoethanol, which enhances transformation efficiency, were added to the 50 pi 
o f cells that were required per transformation reaction to give a final concentration of 
25 mM. Typically 10 -  20 ng of plasmid DNA were then gently mixed into the 
chilled cells. The contents were gently tapped occasionally during a 30 minute 
incubation on ice, before being heat shocked at 42°C for exactly 45 seconds and then 
transferred to ice for a further 2 minutes. Cells were incubated at 37°C for 1 hour on
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an orbital shaker (225 -  250 rpm) following the addition o f 450 pi of preheated 
(42°C) SOC medium (LB broth, 0.04% glucose, 10 mM MgS0 4 , 10 mM MgCh). 
Typically 150 pi o f the transformation mixture was then plated on LB agar (2% LB, 
2% agar) plates containing 50 pg/ml ampicillin or kanamycin and the plates were 
incubated at 37”C overnight to allow growth and colony-formation o f the 
transformed cells.
2.15 Preparation of plasmid DNA
(
For large scale plasmid DNA preparation, a single isolated bacterial colony was 
selected from a freshly-streaked plate and used to inoculate 4 ml o f LB medium 
containing the selective antibiotic (50 pg/ml ampicillin or kanamycin). This was 
allowed to incubate with vigorous shaking at 37'^C for ~6 hours to form a mini- 
eulture and was subsequently used to inoculate 250 ml o f LB medium containing the 
appropriate antibiotic. Following an overnight incubation at 37"C on an orbital 
shaker (-300 rpm), cells were harvested by centrifugation at 6,000 g  for 15 minutes 
at 4®C and plasmid DNA retrieved using the QIAGEN Plasmid Maxi Kit.
The bacterial pellet was re suspended in 10 ml of Buffer PI (50 mM Tris pH 8.0, 
10 mM EDTA, 100 pg/ml RNase A) and then gently but thoroughly mixed with 
10 ml of Buffer P2 (200 mM NaOH, 1% SDS) to initiate an alkaline lysis reaction. 
This reaction was allowed to proceed for 5 minutes at room temperature before 
neutralising the lysate by the addition o f 10 ml o f chilled Buffer P3 (3 M potassium 
acetate pH 5.5) which subsequently resulted in formation o f a precipitate of 
potassium dodecyl sulphate. The SDS-denatured proteins and chromosomal DNA
98
were co-precipitated with the detergent whilst the plasmid DNA remained in solution 
due to a lack o f close protein associations. Precipitation was enhanced by a 
20-minute incubation on ice and the precipitate pelleted by centrifugation at 20,000 g  
for 30 minutes at 4°C. The supernatant containing plasmid DNA was promptly 
removed and applied to a QIAGEN-tip 500 pre-equilibrated with 10 ml o f Buffer 
QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton XrlOO). 
Gravity flow allowed the supernatant to pass through the anion-exchange resin to 
which plasmid DNA is able to tightly bind. The resin was then washed twice with 
30 ml o f Buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) and the 
pW fied plasmid DNA was subsequently eluted with 15 ml o f Buffer QF (1.25 M 
NaCl, 50 mM Tris pH 8.5, 15% isopropanol) and precipitated with 10.5 ml 
(0.7 volumes) o f room-temperature isopropanol. This was immediately followed with 
a 15,000 g  centrifugation at 4°C for 30 minutes. The plasmid DNA pellet was then 
washed with 70% ethanol, dried at room temperature for 5 - 1 0  minutes and 
resuspended in an appropriate volume o f sterile water or TE buffer, pH 8.0 (10 mM 
Tris pH 8.0, 1 mM EDTA).
2,16 RNA pol III in vitro transcription assay
In vitro transcription o f class III genes was reconstituted using 20 pg o f cell extracts 
to provide the basal pol III transcription components. This was supplemented with 
250 ng o f plasmid DNA containing a specific pol III template and reactions were 
carried out in a 25 pi volume with a final concentration o f 12 mM HEPES pH 7.9, 
60 mM KCl, 7.2 mM MgCh, 0.28 mM EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 
1 mM creatine phosphate, 0.5 mM each o f rATP, rCTP and rGTP and 10 pCi [a-^^P]
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UTP (400 mCi/mmol; Amersham Biosciences). Transcription components were 
assembled on ice and the reaction was performed at 30°C for 1 hour. In the case of 
assays incoiporating additional reagents, a 15 minute pre-incubation at 30°C was 
carried out prior to adding the nucleotides required to initiate transcription. 
Transcription was terminated by the addition of 250 pi o f 1 M ammonium 
acetate/0.1% SDS containing 20 pg o f yeast tRNA which acts as a stabiliser for the 
synthesised RNA. Phenol-chloroform extraction of the samples was performed to 
remove protein and DNA by adding 250 pi of a 25:24:1 ratio solution of 
phenol/chlorophoim/isoamyl alcohol. The samples were vortexed, microcentrifuged 
a t ' 13,000 rpm for 5 minutes and 200 pi of the upper aqueous layer was then 
transfeiTed to a fresh eppendorf tube containing 750 pi of 96% ethanol in order to 
precipitate the RNA. The samples were thoroughly mixed by repeated inversion, left 
at -20°C overnight before being microeentrifuged at 13,000 ipm for 20 minutes to 
pellet the precipitated RNA. The supernatant was carefully removed and 750 pi o f 
70% ethanol was added to each sample to wash the pellet. This was also carefully 
removed to avoid dislodging the pellet and the samples were heated at 42°C for 5 -  
10 minutes to dry. 4 pi of formamide loading buffer (98% formamide, 10 mM EDTA 
pH 8.0, 0.025% bromophenol blue, 0.025% xylene cyanol FF) was added to each 
sample, which was then vortexed for at least 30 minutes to ensure the RNA was fully 
redissolved. 1.5 pi o f each sample was loaded on a pre-run 7% polyacrylamide 
sequencing gel containing 7M urea and 1 x TBE (45 mM Tris, 45 mM boric acid, 
0.625 mM EDTA pH 8.0) after being boiled at 95°C for 2 minutes and quenched on 
ice. Electrophoresis was performed at 40 W for 1 hour in 1 x TBE before being dried 
and exposed to autoradiography film in order to detect the radiolabelled transcripts.
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The plasmid templates used for in vitro transcription assays were as follows: pVAl is 
a 221 bp Sall-Ball fragment o f adenovirus 2 DNA containing the VAl gene 
subcloned into pUC18 (Dean and Berk, 1988); pLeu is a 240 bp EcoRl-Hindlll 
fragment o f genomic DNA containing a human tRNA^^^" gene subcloned into 
pAT153 (McLaren and Goddard, 1986); p M 0 5 S l.l is a 436 bp Sacl-Nhel fragment 
o f mouse genomic DNA containing a 5S gene cloned into pBluescript KS-.
2.17 Electrophoretic mobility shift assay (EMSA)
EMSAs which were carried out using a [y-^^P] labelled oligonucleotide containing a 
consensus Myc-Max binding site [5 ’ -GGAAGCAGACCACGTGGTCTGCTTCC-3 ’ 
(E-box F) annealed to the complementary 3’ to 5’ strand (E-box R); bold-faced 
letters indicated the E-box sequence]. An oligonucleotide containing a mutated E- 
box sequence [5’-GGAAGCAGACCACGGAGTCTGCTTCC-3’ (Mut F) annealed 
to the complementary 3 ’ to 5’ strand (Mut R); bold-faced letters indicate the mutated 
E-box sequence] was employed to determine specificity o f binding. For use in 
EMSAs, oligonucleotides were 5’ end-labelled using T4 polynucleotide kinase 
(PNK). 40 ng of E-box F or Mut F oligonucleotide were assembled on ice with 10 U 
of polynucleotide kinase (PNK) in 1 x PNK buffer (Promega) and following the 
addition o f 20 pCi of [y-^^P] dATP (10 mCi/ml, 3000 Ci/mmol) to give a total 
volume o f 10 pi, the reaction was performed at 37^C for 1 hour. This was stopped by 
heating at 65”C for 10 minutes and was succeeded by phenol-chloroform 
precipitation of the labelled oligonucleotides. This was achieved by addition o f 50 pi 
o f PhOH/CFICri/IAA (25:24:1) followed by vortexing and microcentrifugation at
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13,000 rpm for 5 minutes. The aqueous layer was transferred to a fresh eppendorf 
tube and 5 pi of 3 M sodium acetate and 125 pi o f 100% ethanol added. Following a 
30-minute incubation on dry ice, the oligonucleotide was pelleted by 
microcentrifugation at 13,000 ipm for 10 minutes. The supernatant was removed and 
the pellet washed by sequential addition and removal o f 100 pi o f 70% ethanol to 
ensure removal of unincorporated label. The pellet was then dried by heating at 47°C 
for 10 minutes before being redissolved in 20 pi of TE buffer (10 mM Tris pH 8.0,
1 mM EDTA) by incubation at 30°C for 30 minutes. This was followed by heating at 
90'^C for 2 minutes in the presence o f unlabelled complementary oligonucleotide (E- 
bdx R or Mut R), which was added in 2.5-fold excess (100 ng) to ensure that all 
labelled oligonucleotide was annealed. The sample was then allowed to cool slowly 
overnight, after which it was stored at 4”C. Finally, the labelled probe was diluted to 
1 ng/pl using TE buffer.
Each binding reaction was perforaied in a total volume of 10 pi, with an optimal salt 
concentration range o f 6 0 -  100 mM KCl, and contained 1 pg o f poly(dl.dC), 5 pg o f 
cell extract and 1 ng o f labelled probe. A pre-incubation of 15 minutes at 30°C was 
carried out prior to addition of the probe, followed by a further 15 minutes at 30”C. 
For the competition experiments, 100 ng of unlabelled competitor oligonucleotide 
(E-box or Mut) were added before the pre-incubation. In the case o f the supershift 
experiments, the reactions were assembled as previously described, and, following 
addition of the probe (1 ng), pre-incubated at room temperature for 15 min. 
Recombinant c-Myc (400 ng) or antibodies (4 or 8 pg) were subsequently added and 
the reactions were incubated for 1 hour at 4°C.
Analysis o f the formation o f protein-DNA complexes was achieved by 
electrophoresis of samples on a pre-run, 4% non-denaturing polyacrylamide gel in
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1 X TAE buffer (40 mM Tris acetate, 1 mM EDTA pH 8.0) for 1 .5 - 2  hours at 4^C. 
The gel was dried for 1.5 hours at 80°C and exposed to autoradiography film 
overnight at -70°C.
2.18 In vitro proteasome assay
To determine proteasomal activity o f whole-cell extracts, the artificial proteasome 
substrate Succinyl-Leu-Leu-Val-Tyr-AMC (40 pM, Biomol International) was added 
to^dO pg o f cell extract and incubated for 2 hours at 37”C in assay buffer (10 mM 
Tris-HCl pH 7.8, 1 mM EDTA, 0.5 mM DTT, 5 mM MgCE). Where required, the 
proteasome inhibitor MG 132 (50 pM, Biomol International) was added to the cell 
extract prior to substrate addition and incubated at 37®C for 30 minutes. At the end o f 
the incubation period, free AMC was measured using a luminescence spectrometer 
(LS-50B, Perkin Elmer; excitation 343 nm, emission 437 nm) and the accompanying 
software (FL WinLab, Perkin Elmer). Cell extract was omitted for background 
measurements.
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CHAPTER 3
The protein levels of the TFIIIB complex 
decrease following differentiation
3.1 Introduction
T l^  study o f early mammalian embryogenesis is made difficult by factors such as
4'
heterogeneity of starting populations and insufficient numbers o f stem cells. These 
problems can be overcome by using cultured embryonal carcinoma (EC) cells. One 
o f the cell lines that has been widely used is the murine F9 cell line, originally 
isolated by Bemstine el al. (1973). The F9 EC cells have lost the ability to 
differentiate spontaneously, but, when treated with various chemicals, they 
differentiate into endoderm-like cells, as described in Chapter 1.2.
Early experiments using mouse embryos, from unfertilised oocytes up until the late 
primitive streak stage (7.5 days post-coitum), showed a strong regulation o f pol III 
transcription (Vasseur et a l ,  1985). This was achieved by monitoring the steady-state 
levels o f B2 transcripts, which increased substantially following fertilisation. In day 
4 blastocysts, high levels o f B2 transcripts could be seen in the inner cell mass, but 
decreased in the trophectoderm. By the late primitive streak stage, B2 production 
was limited to the embryonic ectoderm and mesoderm, but was severely reduced in 
the embryonic and extra-embryonic endodemi. Because o f the difficulty inherent in 
such a system (heterogeneity of cells and limited amount o f starting material), the F9 
teratocarcinoma cell line was used to further investigate the regulation o f pol III
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transcription following their differentiation into endoderm-like cells. As mentioned 
above, this cell system closely resembles the differentiation o f the inner cell mass 
into visceral or parietal endoderm cells (Martin, 1980). White et a l  (1989) showed 
that transcription o f valions pol III templates, including B2 and tRNA, is decreased 
from EC to PE cells. Using fractionated whole-cell extracts from the two cell types, 
they also showed that TFIIIB, but not TFIIIC, activity is reduced in PE cells. These 
findings were later confirmed by Alzuherri and White (1998) using more purified 
TFIIIB and TFIIIC fractions. Furthermore, it was shown that protein levels o f Brfl 
and TBP, the only two components o f mammalian TFIIIB that had been 
c^racterised  at that time, decrease following differentiation (Alzuherri and White, 
1998). Since then, it has become clear that mammalian TFIIIB is comprised, like its 
yeast counterpait, o f tliree polypeptides, namely TBP, Brfl (or BrfZ, as diseussed in 
the introduction) and B d p l.
This chapter serves to demonstrate that the cell system used throughout this thesis 
functions as previously demonstrated. It also presents data as to the effect o f cell 
differentiation on the levels o f the TFIIIB complex.
3.2 Results
3,2d Differentiation o f F9 embryonal carcinoma cells
F9 cells have been extensively used to study events in early embryogenesis because 
o f their ability to differentiate into various cell types, each with different 
characteristics, that resemble tissues o f the early mouse embryo (Figure 1.5). For 
example, treatment o f a monolayer culture o f F9 EC cells with retinoic acid (RA) and
105
dibutyryl cAMP induces differentiation into parietal endodemi (Strickland ei a i ,  
1980). My first objective, therefore, was to verify that the F9 embryonal carcinoma 
(EC) cells differentiated as previously described.
When the F9 EC cells are induced to differentiate to parietal endoderm, their 
morphology changes considerably. From tightly packed colonies with difficult to 
distinguish cell-cell boundaries, they become more rounded, move away from each 
other and often have processes that extend many cell diameters (Strickland et a l ,  
1980). These findings were verified by observation under a light microscope (results 
not shown). However, we also wanted to employ a biochemical approach to ensure 
tljat the cells were differentiating properly. One o f the markers for parietal endoderm 
is the production o f laminin (Strickland et a l ,  1980), which the cells use, in addition 
to .various other proteins, to foim a suitable extracellular matrix. Therefore, protein 
extracts were prepared from undifferentiated (EC) and fully differentiated (i.e., 
grown in differentiation medium for 7 days -  PE) cells and analysed by Western 
blotting, using an antibody against the (3-1 chain of laminin as the marker for 
differentiation. Figure 3.1 A shows that laminin B1 is virtually undetectable in EC 
cells, but is being produced at high levels following differentiation (compare lanes 1 
and 2 in the top panel). The bottom panel o f Figure 3.1 A shows the levels o f actin in 
the two extracts, which was used as a loading control. Identical results were obtained 
when a small volume o f growth medium from EC and PE cultures was analysed by 
SDS-PAGE and immunoblotting (results not shown).
Another feature of the differentiated F9 cells is their reduced proliferation rate 
(Alonso et a l ,  1991; Rosenstraus et a l ,  1982). To verify this, and also to determine 
optimum passaging conditions for tissue culture, a simple experiment was conducted 
to establish the rate of proliferation o f EC cells with or without differentiation- 
inducing chemicals in their growth medium. 5 x 1 0 “^ cells were seeded on 10-cm
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Figure 3.1 Differentiation o f F9 cells
A Whole-cell protein extracts (20 pg) were prepaied from undifferentiated (EC -  
lane 1) and differentiated (PE -  lane 2) cells, resolved on a SDS -  7.8% 
polyacrylamide gel and analysed by Western immunoblotting, using either an anti- 
laminin B1 antibody (A-1 -  top) or an anti-actin antibody (C-11 -  bottom). B 
Proliferation curve o f uninduced cells (EC) and cells induced to differentiate to 
parietal endoderm (PE), over a course o f 7 days. 5 x 10"^  cells were seeded per 10-cm 
plate on day 0 and cultured in growth medium (EC) or differentiation medium (PE). 
All media were renewed every two days. The values represent the mean o f three 
experiments ± standard deviation. Only viable cells were counted, as determined by 
trypan blue staining. C The data used for B were re-plotted on a semi-log graph (y- 
axis on logarithmic scale, x-axis on linear scale) and doubling times for the two cell 
types, at various stages during the differentiation, were calculated.
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dishes and were allowed to grow for 7 days. Half o f the cells were cultivated in 
normal growth medium and half in differentiation medium (for composition, see 
Chapter 2 -  Materials and Methods). Figure 3 .IB shows a graphical representation o f 
viable cell counts over a period o f 7 days following plating (day 0). Uninduced F9 
cells (denoted EC) grow exponentially until day 5, and to a cell count o f about 
1,45 X 10^, following which they become over-confluent and dissociate from the 
culture plates in massive numbers. In contrast, F9 cells that were induced to 
differentiate (denoted PE) proliferate much more slowly, with a maximum cell count 
o f about 4 x 10  ^ on day 7, at which point the experiment was terminated. The data 
olpfained are horn three experiments, each using three 10-cm culture plates per day 
pdr condition (EC or PE). The rate at which the cells proliferate, under the two 
conditions, changes over the 8 days that the experiment lasted (Figure 3.1C). They 
initially proliferate at a very similar, very slow rate until day 2, with a doubling time
(d.t.) o f about 48 hours. Between days 2 and 4, the EC cells exhibit their
characteristic high rate o f proliferation (Rosenstraus et a i ,  1982), with a d.t. of 
8 hours, whereas the induced cells (PE) have a slower d.t. o f about 14 hours. They
then slow down considerably, needing on average 51 hours to double their
population. The EC cells also slow down, but to a lesser extent.
3,2.2 RNA polymerase III transcription decreases during F9
cell differentiation
RNA polymerase 111 transcription has been previously shown to be down-regulated 
in this cell system (White et a l,  1989). Specifically, it was shown that, following 
differentiation of F9 EC cells to PE, the transcription o f B2 genes, a rodent-specific
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Figure 3.2
PE cells
RNA polymerase III transcription is reduced in
A Total RNA (10 pg) was extracted from F9 EC (lane 1) and PE (lane 2) cells and 
used for Northern blot analysis with a probe against the B2 transcript. The membrane 
was stripped and reprobed with an ARPP PO probe. B2 transcript levels were 
quantified and normalised against ARPP PO. The value obtained for EC was set as 
100%. B Whole-cell protein extracts prepared from undifferentiated (lanes 1, 3 and
5) and differentiated (lanes 2, 4 and 6) F9 cells were used for in vitro transcription 
assays. Reactions contain 20 pg o f  extract and 125 ng o f  template, and the templates 
used were tRNA‘*'*“ (lanes 1 and 2), V A l (lanes 3 and 4) and 5S rRNA (lanes 5 and
6 ).
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middle repetitive gene family with no known function, is greatly reduced, along with 
other class III genes, like those encoding tRNA. This decrease was attributed to the 
reduced activity o f the pol Ill-specific general transcription factor TFIIIB, an 
essential component o f the pol III transcription machinery. Crucially, extracts from 
PE cells were shown not to be deficient in TFIIIC activity, another essential 
component for most class III genes.
To verify these observations, the steady-state levels o f the B2 transcript in total RNA 
extracts were compared between EC and PE cells using Northern blotting. As can be 
seen in Figure 3.2A, there is a significant reduction in the levels o f B2 transcripts 
following differentiation o f EC (lane 1) to PE (lane 2) cells. A pol 11-transcribed 
gene, ARPP PO (acidic ribosomal phosphoprotein PO), was used as a loading control, 
as it has been previously shown to be constitutively expressed (Hurford et ah, 1997). 
Quantification (using the TotalLab software) and normalisation against the loading 
control (ARPP PO) revealed a 3-fold reduction in the levels of the B2 transcript in PE 
cells.
In addition to the Northern blot analysis, in vitro transcription assays, described in 
section 2.16, were employed to directly compare the ability o f cell-free extracts of 
EC and PE cells to transcribe pol III templates. In Figure 3.28, we can see that 
transcription o f a selection o f class 111 genes, in this case tRNA"^^", V A l and 5S 
rRNA, is reduced to varying degrees following differentiation (compare lanes 1, 3 
and 5 for EC with 2, 4 and 6 for PE).
Differentiation o f F9 cells, as mentioned before, was achieved by adding retinoic 
acid and cyclic AMP to the growth medium o f EC cells. To ensure that all cells are 
fully differentiated, cells were grown in this medium for 6 or 7 days. A question that 
arises is at which point during this process pol III transcription declines. To begin to 
answer this question, a time course experiment was conducted. Protein extracts were
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Figure 3.3 Time course of pol III down-regulation
A Cells were harvested before differentiation (lane 1) and on each day following  
induction o f  differentiation, until day 7 (lanes 2 - 8 )  (Time Course 1). Protein 
extracts prepared from these cells were used for in vitro  transcription assays, with 
tRNA ^“ as a template. Reactions contain 20 pg o f  extract and 250 ng o f  template. B 
Graphic representation o f  Time Courses 1 and 2. The signal obtained from 
differentiating cells (days 1 -  7) was quantified (TotalLab) and expressed as a 
percentage o f  that from EC cells.
112
prepared from each day of the differentiation process, as well as from 
undifferentiated cells, and were subsequently used in IVT assays. Figure 3.3A shows 
the in vitro transcription of the tRNA^^" template, with the extract from EC cells in 
lane 1 and extracts from cells on days 1 to 7 o f the differentiation process in lanes 2 -  
8 (Time Course 1). Figure 3.3B is a graphical representation o f two independent 
differentiation time courses, 1 and 2. In both cases the tRNA^'^" template was used, 
but similar results have been obtained with the VAl template. There seems to be two 
steps in the down-regulation of pol 111 transcription. An initial decrease at the very 
start o f the differentiation process, i.e., between days 0 and 1, and a secondary 
d e fea se  later on, between days 2 and 3.
3 2.3 Down-regulation o f TFIIIB components following
differentiation
The question still remains as to the exact molecular mechanisms that cause this 
decrease in pol 111 transcription. An insight was presented in the work by Alzuherri 
and White (1998), where, in addition to confirming that TFIIIB, as opposed to 
TFlllC, activity was limiting in PE cells, it was shown that the protein levels of two 
components o f TFIIIB, namely Brfl and TBP, decrease following differentiation. In 
contrast, the protein levels o f two components of the TFlllC complex, TFlllC 110 
and TF111C220, did not change, further supporting the idea that TFIIIB is the limiting 
activity. To verify these observations, protein extracts were prepared from EC and 
PE (lanes 1 and 2 respectively) and analysed by Western blotting, using antibodies 
against Brfl and TBP (Figure 3.4A), and against one component o f TFlllC, 
TFlllC 110 (Figure 3.4B). In addition, a previously unavailable antibody against
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Figure 3.4
TFIIIB
Differentiation causes a reduction in the levels of
A Whole cell protein extracts (50 pg) were prepared from undifferentiated (EC -  
lane 1) or differentiated (PE -  lane 2) F9 cells, resolved on a SDS -  7.8% 
polyacrylamide gel and analysed by Western immunoblotting. The membrane was 
cut and probed using either an anti-Bdpl antibody (2663 -  top panel), an anti-Brfl 
antibody ( 128 -  second panel), an anti-TBP antibody (58C9 -  third panel) or an anti- 
actin antibody (C -11 -  bottom panel). In the case o f  actin, the part o f  the membrane 
that was probed for TBP was stripped and re-probed with the anti-actin antibody. B 
As A, except that the membrane was cut in two, the top half was probed for 
TFIIIC 110 (4286) and the bottom half for actin (C -11).
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Bdpl was used (Figure 3.4A). Actin was used as a loading control. As we can see, 
the levels o f all three components o f the TFIIIB complex, B dpl, Brfl and TBP, seem 
to decline following differentiation, when compared to the levels of actin, but 
TFlllC  110 levels do not change (compare lanes 1 and 2 in all panels). These results 
support the previous findings and show that Bdpl levels also decline following 
differentiation.
3.2.4 Time course o f TFIIIB down-regulation
/
Since B dpl, Brfl and TBP are all part o f the same complex, an attractive hypothesis 
would be that they are all under a common regulatory mechanism. A simple way of 
looking at this question, at least initially, was by comparing the relative levels o f 
each protein, by Western blot analysis, throughout the differentiation process, similar 
to the experiment described in section 3.2.2. Whole-cell extracts were prepared 
before differentiation (lane 1) and on each day o f the differentiation process (lanes 2 
-  8) and analysed by Western immunoblotting using antibodies against B rfl, Bdpl 
and TBP, while TFllB was used as loading control (Figure 3.5A). It is immediately 
obvious that the levels o f all three TFIIIB proteins decrease between days 4 and 5 
(lanes 5 and 6), with Brfl and TBP and, to a lesser extent, Bdpl showing an increase 
towards the end o f the time course. The arrow indicates the position o f in vitro 
translated HA-tagged B rfl, run on the same gel. This comparison was repeated in a 
separate gel, with just whole-cell extract from undifferentiated cells (EC -  lane 1) 
and in vitro translated HA-Brfl (+ve -  lane 2) (Figure 3.5B). Figure 3.5C shows a 
graphical representation o f the experiment in A. The Bdpl, Brfl and TBP bands 
were quantified and corrected for loading against TFllB. Levels o f the three proteins
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Figure 3.5 Time course of TFIIIB decrease
A Whole-cell protein extracts (20 pg) were prepared from undifferentiated F9 cells
(lane 1) and cells undergoing differentiation (days 1 to 7 -  lanes 2-8), resolved on a
SDS -  7.8% polyacrylamide gel and analysed by Western blotting using an anti-
Bdpl antibody (2663 -  top panel), an anti-Brfl antibody (CSH145 -  second panel),
an anti-TBP antibody (58C9 -  third panel) or an anti-TFllB antibody (C-18 -  fourth
panel), as a loading control. The arrow next to the second panel shows the position o f
the Brfl band, as determined by using in vitro translated HA-tagged Brfl as
standard. For comparison, the Time Course 2 IVT also presented here. Lanes as in
Figure 3.3A B Verification o f the CSH145 anti-Brfl antibody. 20 pg o f whole-cell
extract were resolved on a SDS -  7.8% polyacrylamide gel alongside in vitro
translated HA-tagged Brfl (denoted as +ve). C Graphical representation o f A. B dpl,
Brfl and TBP bands were qualified and normalised against the loading control
(TFllB). The values before differentiation (EC) were set at 100%. The IVT time !
!
course was analysed as before (Figure 3.3). ^
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were then expressed as a percentage o f the EC value (set at 100%). The IVT time 
course was analysed as in Figure 3.3.
3.3 Discussion
3.3.1 Differentiation o f F9 cells
As mentioned before, the F9 cell system has been extensively used to study events in 
early mouse embryogenesis, and generally as a model for the analysis o f 
dfeerentiation, because of its ability to differentiate into various cell types that 
resemble tissues o f the early mouse embryo (Figure 1.5). Because o f this, it was 
necessary to check whether or not the cells I was using behaved in a similar manner 
to what was previously described. Morphological examination o f F9 EC cells treated 
with retinoic acid (RA) and dibutyryl cyclic AMP (db-cAMP) for 7 days under a 
light microscope revealed that they exhibited all the characteristics o f tenninally 
differentiated primitive endoderm (PE)-like cells. This includes the cells becoming 
more round and forming processes (data not shown), like previously described 
(Strickland et a l ,  1980). This was supported by biochemical analysis o f the induced 
cells for specific differentiation markers. Production o f laminin has been shown to 
increase in PE cells compared to the parental EC cells or the other possible 
derivative, visceral endoderm (Hogan et a l ,  1981; Strickland et a l ,  1980). Western 
blot analysis o f EC and PE extracts shows a dramatic increase in the production o f 
the p-1 chain o f laminin (Figure 3.1 A). Increased levels o f laminin p-1 were also 
found in the growth medium o f PE cells (results not shown), suggesting that the 
produced laminin is indeed secreted into the medium. The formation o f extracellular
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matrix by PE cells was further supported by empirical observation o f increased 
adherence to gelatinised plates, compared with EC cells. We have, therefore, two 
markers of differentiation, one morphological and one biochemical, which confirm 
that the cell system I used behaved as previously described.
F9 EC cells are known to grow very rapidly, with a doubling time o f about 
8-10 hours in the exponentially growing phase, due to a very short G1 phase 
(Rosenstraus et a l ,  1982). Differentiation causes a lengthening o f the G1 phase, with 
a subsequent decrease in the proliferation rate. Although I didn’t analyse the cell 
cycle characteristics o f my cells in any great detail, I did study the difference in 
prcdîferation between EC and PE cells by means o f a proliferation cui-ve, the results 
o f  which can be seen in Figui'e 3 .IB and C. Looking at absolute number o f cells 
(Figure 3.IB), there is not much difference between the two conditions during the 
first two days. At day 3, the EC population is almost double that of the PE. After 
that, there is an exponential increase in the number of EC cells, whereas the PE cells 
increase in number linearly. At day 5, which is the last day where EC cells were 
counted, there is a 6.3-fold difference in cell number between EC and PE. After day 
5, the EC cells grew too confluent and dissociated from the plates, making further 
counting impossible. By plotting the same data on a semi-log graph (with the y-axis 
in logarithmic scale and the x-axis in linear scale -  data not shown), 1 was able to 
calculate the doubling time o f the cells (Figure 3.1C). The initial, slow proliferation 
rate could probably be attributed to the very low seeding density. When EC cells, for 
example, were seeded at a higher density (1x10^), they exhibited their usual fast 
growth rate (doubling time o f about 8 hours). Even in the exponential phase, between 
days 2 and 4, we can see a clear difference between the uninduced (EC) and induced 
(PE) cells, which is much more pronounced in the last 3 days. It is worth noting that 
the PE cells continued to proliferate until day 7, when they were reaching almost
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100% confluency. If subcultured, however, they continue to proliferate, as was 
observed by Strickland et al. (1980).
3.3.2 Regulation o f pol III transcription in differentiated F9
cells
Earlier work (Alzuherri and White, 1998; White et a l,  1989) has shown that pol III 
transcription is decreased when F9 EC cells differentiate into PE, and that this 
decrease is due to a reduction in TFIIIB activity. Initially, this was achieved by 
fractionating EC and PE extracts. It was already known that two activities present in 
phosphocellulose column fractions, TFIIIB and TFIIIC, are necessary and sufficient 
for pol III transcription in vitro (Segall et a l ,  1980), when added to partially purified 
RNA polymerase III. Further purification o f these crude fractions showed that 
TFIIIB, but not TFIIIC, activity was reduced in F9 PE cells. It was also shown, using 
specific antibodies against Brfl and TBP, that the levels o f those two proteins are 
reduced following differentiation. The reduction in pol III transcription, and in the 
levels o f Brfl and TBP, was confirmed by our data (Figures 3.2 and 3.4A). 
Furthermore, using an anti-Bdpl antibody that was not available at the time o f the 
previous study, we showed that the levels o f the third component o f the TFIIIB 
complex are also reduced (Figure 3.4A). In a contradictory report, however, 
Meissner et a l  (1995) suggested that it is the TFIIIC activity that is limiting in F9 PE 
cells. They later retracted this (Meissner et a l ,  2002), suggesting instead that the 
down-regulation o f pol III transcription is due to a reduction in the activity o f 
TFIIIC 1, an ill-defined factor with respect to the proteins needed for reconstitution of 
its activity. The same group then claimed that TFIIIC 1 is, in fact, Bdpl (Weser et a l ,
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2004), and that its reduction is responsible for the down-regulation o f pol III in F9 
PE cells. They suggest the discrepancy between the earlier reports was due to 
differences in the fractionation o f the cell extracts. Finally, they claimed that TBP 
and Brfl are not regulated during the differentiation o f F9 cells. This does not agree 
with the data we have obtained, as we have seen Brfl protein and mRNA and TBP 
protein levels (Figures 3.4A and 4.5) decrease. Furthermore, Perletti et al. (2001) 
show that TBP is regulated via targeted proteolysis in the F9 system. Therefore, there 
are still some unresolved issues in this aspect of pol III regulation.
A problem that should be mentioned here is the absence o f suitable internal controls 
h ^ th e  in vitro transcription experiments. Errors can be introduced in this assay in a 
number o f steps. For example, there could be differential recovery o f proteins during 
protein extraction, as well as differential recovery o f RNA during the phenol -  
chlorophorm precipitation step. Therefore, these results should be viewed with a 
certain amount o f caution.
3.3.3 Timing of TFIIIB down-regulation
In Figures 3.5A and 3.5C we can see that the level o f all thiee components of the 
TFIIIB complex fall between days 4 and 5 (lanes 5 and 6) after induction of 
differentiation. This raises the possibility that these three proteins might be co­
regulated, in order, for example, to avoid having partial complexes (e.g., Brfl and 
TBP without Bdpl), that might sequester other transcription factors. If, however, we 
compare these data with the time course o f pol III transcription (Figure 3.3 and 
3.5A), we notice that there is a temporal discrepancy between the reduction in the 
levels of TFIIIB and the down-regulation o f transcription, the majority o f which
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occurs before day 4. A possible explanation for the discrepancy between TFIIIB 
protein levels and pol III transcription is that other factors that enhance or repress 
transcription are either up- or down-regulated in response to the differentiation o f F9 
EC cells. Although this idea seems to contradict earlier findings that TFIIIB activity 
is the limiting factor, it is quite plausible that the factor or factors that affect pol III 
transcription co-fractionated with TFIIIB. This hypothesis will be examined in a later 
chapter.
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CHAPTER 4
Brfl and Bdpl are not degraded by the 
proteasome
4.1 Introduction
Thembiquitin-proteasome pathway was initially considered to be responsible for the 
degradation o f damaged or misfolded proteins. Subsequent work has shown that it 
also targets a wide variety of other proteins, including cell cycle regulators, tumour 
suppressors, oncoproteins and transcription factors (reviewed in Pickart, 2001). In 
fact, it is now thought to be the major proteolytic pathway in eukaryotic cells (Figure 
1.6). With such a multitude o f cellular targets, it is not surprising that it is involved in 
the regulation o f many basic cellular processes, such as differentiation and 
development, cell cycle and division, DNA repair and apoptosis.
Degradation by this system involves the covalent attachment o f ubiquitin, a 76- 
amino-acid protein, to the target protein. This is achieved by the sequential action of 
three enzymes, which result in the attachment of a multiubiquitin chain on the target 
protein (Figure 1.7). The protein is subsequently recognised and degraded by the 26S 
proteasome, a large, multimeric proteolytic enzyme (Bochtler et al., 1999).
An important breakthr ough in the study of the ubiquitin-proteasome pathway was the 
development o f specific proteasome inhibitors. There are several classes of 
inhibitors, based on their chemical structure, and include the peptide aldehydes, 
peptide boronates, vinyl sulfones and lactacystin (Lee and Goldberg, 1998). O f these,
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the peptide aldehydes, such as MG132, M Gl 15 and ALLN, are the most commonly 
used. These molecules are substrate analogues and act by blocking, primarily, the 
chymotrypsin-like activity o f the proteasome (Rock et ah, 1994), which is thought to 
be the rate-limiting step in protein degradation. In addition to studying the effects 
that blocking the proteasome might have on intact cells, these molecules proved 
extremely useful in identifying proteins that are degraded by this pathway. Increase 
in the level of a protein, or blocking o f its decrease, after treatment with an inhibitor 
strongly indicates proteasome-mediated degradation. For example, in the regulation 
o f the transcription factor NF-kB, proteasome inhibition leads to the accumulation of 
pJi6sphorylated IkB (Palombella et al., 1994).
Another useful tool, especially for the definition o f the hydrolytic activities o f the 
proteasome, are the artificial fluorogenic substrates. For example, succinyl-Leu-Leu- 
Val-Tyr-AMC has been used to define the chymotrypsin-like activity of the 
proteasome (Orlowski, 1990). These compounds, when hydrolysed by the 
proteasome, release the fluorescent group 7-amino-4-methylcoumarin (AMC), which 
can be easily detected using a fluorescence spectrophotometer.
This chapter looks at the effect o f proteasome inhibition on the pol III transcriptional 
activity o f F9 EC and PE cells, but also on the levels of the TFIIIB protein complex. 
The levels o f B rfl, Bdpl and TBP mRNA are also examined, in untreated as well as 
MG132-treated EC or PE cells. Initially, however, the functionality of the 
proteasome inhibitor MG 132 and the overall activity o f the proteasome in EC and PE 
cells were assessed.
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Figure 4.1 Comparison o f three proteasome inhibitors
A F9 EC cells were treated with DMSO alone (lane 1), 25 fiM ALLN (lane 2), 
10 |iM M G l32 (lane 3) or 25 pM MGl 15 (lane 4) for 2 hours. W hole-cell extracts 
(20 pg) were then prepared, resolved on a SDS -  7.8% polyacrylamide gel and 
analysed by Western blotting, using antibodies against p53 (1C12 -  top panel) and 
cyclin D1 (72-13G -  bottom panel). TFIIB was used as both a negative and loading 
control. B Quantification o f  A. p53 and cyclin D1 was quantified using the TotalLab 
software, normalised against TFIIB and expressed as ‘fold increase’, compared to 
DMSO-treated EC cells.
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4.2 Results
4.2,1 Proteasome inhibition in F9 EC and PE cells
To examine if proteasome inhibition has any effect on F9 EC cells, they were treated 
with three commonly used peptide aldehyde inhibitors, namely M G l32, MG 115 and 
ALLN. The effect o f these inhibitors on the level of two proteins that have been 
previously shown to be degraded by the ubiquitin-proteasome pathway, p53
(Ciechanover et al., 1991; Maki et al., 1996) and cyclin D1 (Diehl et al., 1997), was
y
tlien investigated. Figure 4.1 A shows that levels of both proteins are increased 
following treatment o f the cells with proteasome inhibitors (ALLN -  lane 2, M Gl 32 
-  lane 3, M Gl 15 -  lane 4), compared to DMSO-treated EC cells (lane 1). TFIIB was 
used as both negative control for proteasomal inhibition and as loading control for 
the electrophoresis. Quantification revealed that the efficiency o f M Gl 32 and 
M Gl 15 is quite comparable, while ALLN appears to perfonn slightly better (Figure 
4 .IB). This experiment serves as a positive control for proteasome inliibition in EC 
cells. The question, however, is whether or not the inhibitors work equally well in 
differentiated PE cells. I selected M G l 32 for the rest o f my experiments, because of 
its specificity and potency and because it has been previously used in this cell system 
(Perletti et a l ,  2001). When whole-cell extracts from PE cells treated with M G l32 
were analysed by Western blotting for p53 and cyclin D l, a clear stabilisation o f both 
proteins was observed (Figure 4.2A and B). There were no phenotypic changes in 
response to M G l32 treatment, as determined by light microscopy (results not 
shown).
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Figure 4.2 MG132 is functional in F9 PE cells
A F9 PE cells were treated with DMSO alone (lane 2) or with the proteasome 
inhibitor MG 132 (10 pM -  lane 3) for 4 hours, harvested and used for preparation o f  
protein extracts. 20 pg were resolved on a SDS -  7.8% polyacrylamide gel, alongside 
20 pg o f  extract from EC cells treated with DMSO for 4 hours (lane 1), and analysed 
by Western blotting using an anti-p53 antibody (1C12) or an anti-TFllB antibody 
(C-18). B As A, except the loading order is different (EC -  lane 1, PE -  lane 2, 
PE + MG 132 -  lane 3) and the membrane was probed using an anti-cyclin Dl 
antibody (72-13G). TFIIB was again used as negative and loading control.
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4.2.2 In vitro proteasome assay
Before examining the proteins o f interest, i.e. B rfl, B dpl, etc., for possible 
degradation by the proteasome, it was decided to investigate whether or not the 
ubiquitin-proteasome pathway itself is affected by the differentiation o f F9 cells to 
parietal endoderm. This was accomplished by using an in vitro assay to compare the 
proteasomal activity of EC and PE whole-cell extracts (Figure 4.3). This assay 
utilises the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC), 
whjch, when cleaved by the chymotryptic-like activity of the proteasome (Stein et 
ah, 1996), releases the fluorescent group AMC (7-amino-4-methylcoumarin). This 
can then be efficiently detected using a fluorescence spectrophotometer. Therefore, 
whole cell extracts from EC (columns 1 and 2) or PE (columns 4 and 5) cells that 
were treated with DMSO (columns 1 and 4) or M G l32 (columns 2 and 5), were 
incubated with the substrate, Suc-LLVY-AMC, for 2 hours. The fluorescence was 
then measured, as described in Materials and Methods, and expressed as a percentage 
o f that observed for untreated EC cells (Figure 4.3). As a positive control for 
proteasome inhibition by M G l32, DMSO-treated EC or PE extracts were incubated 
with inhibitor prior to addition of the substrate (columns 3 and 4). As we can see, 
complete inhibition was achieved.
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Figure 4.3 In vitro proteasome assay
F9 EC (columns 1 -  3) or PE (columns 4 - 6 )  cells were treated with DMSO 
(columns 1, 3, 4 and 6) or MG 132 (50 pM -  columns 2 and 5) for 4 hours prior to 
harvesting. Resulting whole cell extracts (10 pg) were then incubated with DMSO 
(columns 1, 2, 4 and 5) or M G l32 (50 pM -  columns 3 and 6) for 30 min at 37‘’C, 
before adding the artificial proteasome substrate Suc-LLVY-AMC (40 pM) and 
incubating for 2 hours at 37"C. The fluorescence o f released AMC was measured 
using a fluorescence spectrophotometer (LS-50B, Perkin Elmer) and expressed as 
percentage o f  that from untreated EC cells. The values represent the average o f  four 
(for EC) or three (for PE) experiments, ± standard deviation, with background values 
(substrate alone) subtracted.
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4.2.3 Proteasome inhibition does not affect the levels o f Brfl
and Bdpl, nor pol III transcription
Having established that M G l32 could indeed block the proteasome, both in EC and 
PE cells, leading to the accumulation of known degradation targets, p53 and cyclin 
D l, its effects on the TFIIIB components, Brfl and B dpl, were investigated. Figure 
4.4A shows Western blot analysis o f extracts from EC (lane 1) or PE cells treated 
with M G l32 (lane 2) or DMSO (lane 3). Probing with the anti-Brfl antibody (top 
panel) reveals that Brfl levels are not stabilised by proteasome inhibition (the 
asterisk indicates the position o f B rfl, verified by running in vitro translated protein 
alongside it -  results not shown). The actin blot (bottom panel) serves both as 
negative and loading control. Similarly, Bdpl levels are also unaffected by M G l32 
treatment (Figure 4.4B). F9 EC (lanes 1 and 2) or PE (lanes 3 and 4) cells were 
treated with either DMSO (lanes 1 and 3) or MG 132 (lanes 2 and 4). Whole-cell 
extracts from these cells were analysed by Western blotting with an anti-Bdpl 
antibody (top panel), revealing no stabilisation of the protein either before (lanes 1 
and 2) or after (lanes 3 and 4) differentiation. Again, actin was used as both loading 
and negative control.
RNA polymerase III transcription is regulated by a variety o f mechanisms (White, 
1998; White, 2004a). Therefore, it is possible that the proteasome, by influencing 
one o f those mechanisms, might have an indirect effect on pol 111 transcription. This 
hypothesis was tested by comparing the capacity of extracts from control or M Gl 32- 
treated cells to transcribe a pol III template in vitro. Figure 4.4C shows a 
representative experiment, using whole-cell extracts from EC (lanes 1 and 2) or PE 
(lanes 3 and 4) cells, that were treated with MG 132 (lanes 1 and 3) or DMSO (lanes
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Figure 4.4 Effect of proteasome inhibition on TFIIIB levels
and pol III transcriptional activity
A Whole-cell extracts (20 |ig) from EC (lane 1) or PE (lanes 2 and 3) cells, treated 
with DMSO (lane 1 and 3) or 25 pM M G l32 (lane 2) for 4 hours prior to harvesting, 
were resolved on a SDS — 7.8% polyacrylamide gel and analysed by Western 
blotting using either an anti-Brfl antibody (145 -  top panel) or an anti-actin antibody 
(C-11 -  bottom panel). The asterisk next to the top panel indicates the position of 
B rfl, as determined by using in vitro translated HA-tagged B rfl as standard. B 
Whole-cell extracts (20 pg) from EC (lanes 1 and 2) or PE (lanes 3 and 4) cells, 
treated with DMSO (lane 1 and 3) or 25 pM  M G l32 (lanes 2 and 4) for 4 hours prior 
to harvesting, were resolved on a SDS -  7.8% polyacrylamide gel and analysed by 
Western blotting using antibodies against Bdpl (2663 -  top panel) or actin (C-11 -  
bottom panel). C Protein extracts (20 pg) from EC (lanes 1 and 2) or PE (lanes 3 and 
4) cells, treated with DMSO (lane 2 and 4) or 25 pM M G l32 (lanes 1 and 3) for 4 
hours prior to harvesting, were used to in vitro transcribe a V Al template (250 ng).
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2 and 4), to transcribe a VAl template. As we can see, there is no effect of 
transcription before (lanes 1 and 2) or after (lanes 3 and 4) differentiation. The 
apparent decrease in the MG132-treated PE extract (lane 3) was not reproducible.
4.2.4 RT-PCR analysis o f TFIIIB components
In addition to a post-translational control mechanism, there could be other levels at
which the differentiating cells could regulate the amount o f TFIIIB, and therefore pol
III ^ transcription, since it seems to be the limiting factor in this system (Alzuherri and 
4'
White, 1998; White ei a l,  1989). The possibility of regulation at the transcriptional 
or post-transcriptional level was therefore examined, by comparing the abundance o f 
B dpl, Brfl and TBP mRNAs in EC and PE cells. This was accomplished by reverse 
transcription-PCR (RT-PCR), where cDNAs are prepared by reverse transcription of 
total RNA extracted from cells. Specific PCR primers are then used to amplify the 
sequence of interest, using a radioactively-labelled nucleotide for increased 
sensitivity. When RNA extracts from EC and PE cells were analysed in this way 
(Figure 4.5A), a small, but consistent, decrease in the levels of Bdpl and Brfl 
mRNAs (top two panels) was observed following differentiation o f cells (EC -  lane 
1, PE -  lane 2). Surprisingly, TBP mRNA levels were found to increase following 
differentiation (Figure 4.5A). The primers that were used in these PCR reactions 
were designed to only amplify the mature transcript, so there is no way to make a 
distinction between transcriptional and post-transcriptional regulation. The transcript 
levels o f two pol III products, namely tRNA'^^" and 5S rRNA (third and fourth panels 
-  Figure 4.5A) were also examined, as a positive control for the down-regulation o f 
pol III transcription in PE cells. The levels o f primary tRNA transcripts offer an
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Figure 4.5 RT-PCR analysis o f EC and PE RNA
A cDN As were generated by reverse transcription o f  total RNA (3 pg), extracted 
from undifferentiated (EC -  lane 1) and differentiated (PE -  lane 2) F9 cells, and 
were amplified by PCR using primers for Bdpl (top panel), Brfl (second panel), 
1 BP (third panel), tRNA' (fourth panel), 5S rRNA (fifth panel) and ARPP PO 
(bottom panel). B The levels o f  B dpl, Brfl and TBP mRNA (from 4, 3 and 2 
experiments, respectively) were quantified, normalised against ARPP PO, averaged 
and expressed as ‘fold change’ in response to differentiation.
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accurate picture o f the rate o f ongoing transcription (Cormack and Struhl, 1992), 
since the intron sequences are processed and degraded very fast. The primers used in 
this case were designed to amplify part o f the intron sequence, thus revealing the 
levels o f the primary tRNA^^“ transcript. This, therefore, shows that pol III 
transeription is dramatically reduced following differentiation, as was observed 
previously using other techniques (Figure 3.2; White et a l ,  1989). Similarly, 5S 
rRNA expression is markedly reduced following differentiation. The effects seen 
here are specific, since the levels o f ARPP PO mRNA (bottom panel) remain 
unehanged following differentiation. Quantification of 4 (for B dpl), 3 (for B rfl) or 2 
( ^  TBP) experiments revealed that there is a 0.59-fold decrease in Bdpl mRNA 
levels and a comparable 0.66-fold decrease in Brfl mRNA levels in PE cells, 
compared to EC cells, while levels o f TBP increase by an average o f 1.6-fold (Figure 
4.5B).
4,2,5 Time course analysis o f TFIIIB mRNAs
To try to address a question posed previously, about the possible co-regulation o f the 
TFIIIB components, we analysed RNAs extracted from cells throughout the 
differentiation process using RT-PCR. Similar to the protein time course, RNA was 
extracted from EC cells (Figure 4.6 -  lane 1) and from differentiating cells over a 
course of 7 days (Figure 4.6 -  lanes 2-8). The resulting cDNAs were used in PCR 
reactions with primers for Bdpl (top panel), Brfl (second panel) and TBP (third 
panel). As we can see, Bdpl and Brfl mRNA levels show a similar pattern during 
differentiation, with a rapid decrease by day 2 (lanes 1-3) and then an increase, 
peaking at day 4 (lanes 4 and 5), after which the levels decrease again (lanes 6 and 7,
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Figure 4.6 
RT-PCR
Time course analysis o f differentiating cells using
cDNAs were generated by reverse transcription o f  total RNA (3 pg) extracted from 
undifU'erentiated F9 cells (lane 1) and cells undergoing differentiation (days 1 to 7 -  
lanes 2-8) and were amplified by PCR using primers for Bdpl (top panel), Brfl 
(second panel), TBP (third panel) and ARPP PO (bottom panel).
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although there is a difference between Brfl and Bdpl at this point). Finally, there is 
an inerease at the very last day o f the time course (lane 8). On the other hand, TBP 
mRNA levels show a markedly different pattern during the same time period. There 
is an initial and strong increase between days 0 and 1 (lanes 1 and 2), presumably 
due to the increased requirement o f the cells for polll transcription when entering the 
differentiation process. With the exception of day 2 (lane 3), TBP levels are 
maintained at high levels, higher than in EC cells, throughout the differentiation 
process. As before, this behaviour seems to be specific, as the levels o f the control 
transcript (ARPP PO, bottom panel) remain relatively unchanged.
4,2,6 mRNA levels o f the TFIIIB complex are affected by
proteasome inhibition
Because o f the wide-ranging effects blocking the proteasome might have, we decided 
to check whether MG132 treatment affected the mRNA levels o f B rfl, Bdpl and 
TBP. As we saw above, Brfl and Bdpl mRNA levels fall following differentiation of 
F9 cells (Figure 4.5A), whereas TBP mRNA levels seem to increase (Figure 4.5A). 
The previous observations were confirmed, i.e., Bdpl and Brfl mRNA show a 
reduction, while TBP shows a slight increase (compare lanes 1 and 2 of Figure 
4.7A). In EC and PE cells, however, that had been treated with MG 132 (lanes 3 and 
4, respectively), there seems to be a reversal of the reduction o f Bdpl and Brfl 
mRNAs, now showing a slight increase or no change, respectively, when cells 
differentiate. TBP levels show the same pattern as before. Like previously, ARPP PO 
was used as a control pol 11 transcript. Figure 4.7B shows PCR analysis o f the same 
cDNAs for two pol III transcripts, B2 and 5S rRNA. As before, there is a down-
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Figure 4.7 Effect o f proteasome inhibition on the mRNA
levels o f various genes
cDNAs were generated by reverse transcription o f  total RNA (3 pg), which was 
extracted from EC (lanes 1 and 3) or PE (lanes 2 and 4) cells, treated with DMSO  
alone (lanes 1 and 2) or 25 pM MG 132 (lanes 3 and 4) for 4 hours. Primers for B d p l, 
B rfl, TBP and ARPP PO (A) and B2 and 5S rRNA (B) were used for PCR analysis 
o f the cDNAs.
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regulation in the transeription of both genes following differentiation (compare lanes 
1 and 2). When the cells are treated with the proteasome inhibitor (lanes 3 and 4, for 
EC and PE respectively), B2 and 5S rRNA transcript levels exhibit the same pattern 
as the control cells, i.e., their transcription is not affected by the presence o f MG132.
4.3 Discussion
4,3,1 Proteasome inhibition in F9 EC and PE cells
/
Before looking at TFIIIB protein levels, and how they might be affected by 
inhibition o f the proteasome, we needed to ensure that the inhibitor was functional in 
both EC and PE cells, i.e. that it entered the cell and demonstrably blocked the 
proteasome. To this end, the levels o f two known targets of the ubiquitin-proteasome 
pathway, p53 (Maki et al., 1996) and cyclin D1 (Diehl et ah, 1997) were first 
examined. Both proteins are stabilised in the presence of MG132, both in EC and PE 
cells (Figures 4.1 A and 4.2). Furtheimore, comparison between three peptide 
aldehyde inhibitors, ALLN, M Gl 15 and MG 132, revealed no significant differences 
in their ability to stabilise p53 and cyclin D1 (Figure 4 ,IB). For further experiments, 
one o f the inhibitors was selected, namely M Gl 32, primarily because it had been 
used previously in F9 cells (Perletti ef a i ,  2001). These data suggest that the 
proteasome inhibitors tested, and in particular M G l32, can enter EC and PE cells and 
block the proteasome, but to what extent? To try to answer this question, we 
employed in vitro proteasome assays to directly measure the activity o f the 
proteasome in whole-cell extracts from EC and PE cells. This assay makes use o f an
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artificial, fluorogenic substrate, which, when degraded by the proteasome, releases a 
fluorescent group, AMC, that can be easily measured using a fluorimeter. Data from 
these assays are presented in a graphical view in Figure 4.3. The first thing we can 
observe is that proteasomal activity in untreated PE cells (column 4) is reduced by 
about 70% compared to untreated EC cells (column 1). This suggests a previously 
undescribed down-regulation o f the overall activity o f the proteasome during F9 cell 
differentiation, although if it is reduction in the actual protein levels or due to 
inhibition is still unknown. Another important observation is that treating the cells 
with M G l32 (columns 2 and 5) only slightly reduces proteasome function (36% in 
E p a n d  11% in PE cells). The proteasome is still responsive to inhibition by M G l32, 
however, as complete inhibition is seen if  the protein extracts are incubated with 
M Gl 32 prior to addition o f the substrate (columns 3 and 6). A possible explanation 
for this is that this modest inhibition is sufficient to stabilise the proteins examined 
(p53 and cyclin D l), Alternatively, one could argue that the proteasome is 
adequately inhibited in the cell (i.e. before protein extraction), but, because o f the 
reversible nature of the inhibition by MG 132, it is derepressed during protein 
extraction and the course of the assay.
4,3,2 Brfl and Bdpl protein levels and pol III transcription in
M G l 32-treated PE cells
Figures 4.4A and B show no stabilisation of Brfl and Bdpl, respectively, following 
proteasome inhibition by M G l32. Although this strongly suggests that these two 
proteins are not regulated by the ubiquitin -  proteasome pathway, the possibility 
cannot be wholly excluded. The extracts that were used in these experiments were
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from cells grown in differentiation medium for 7 days. If the cells receive a signal to 
down-regulate pol 111 transcription by degrading TFIIIB at an earlier day, combined 
with the reduced transcription o f Brfl and Bdpl (Figure 4.5) and the down- 
regulation of other pol 111 activators (or up-regulation o f repressors -  discussed in a 
later chapter), treatment of the cells with M Gl 32 on the seventh day after induction 
would likely have little demonstrable effect on Brfl and Bdpl levels. One thing that 
might argue against such a hypothesis is that, in the work o f Perletti et a i  (2001) on 
TBP degradation, a clear stabilisation o f the protein can be seen even after eight days 
following induction o f differentiation. Furthermore, M G l32 stabilises TBP even in 
undifferentiated F9 cells, which is not the case for Brfl (data not shown) or Bdpl 
(Figure 4.4B -  compare lanes 1 and 2).
Somewhat more suiprising is the fact that blocking the proteasome has no effect on 
pol III transcription, in EC or PE cells (Figure 4.4C), considering the plethora of 
proteins that is regulated by this pathway and also the variety o f mechanisms that 
have an impact on pol 111 regulation. For example, p53 has been shown to repress pol 
111 transcription through TFIIIB (reviewed in Brown et a l ,  2000), yet, even in 
M G l 32-treated EC cells, where TFIIIB is still abundant (Figure 3.4A) and p53 
stabilised (Figure 4.1 -  compare lanes 1 and 3), pol III transcription levels are 
unaffected (Figure 4.4C -  compare lanes 1 and 2 for EC and 3 and 4 for PE cells).
4,33 Co-regulation o f TFIIIB components
In the previous chapter, the possibility o f coordination in the down-regulation o f the 
TFIIIB subunits was raised. As we saw in section 4.2.3 of this chapter, proteasome 
inhibition has no effect on TFIIIB levels, strongly suggesting that they are not
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degraded through the ubiquitin -  proteasome pathway. Time course analysis TFIIIB 
mRNA revealed that Brfl and Bdpl mRNA levels follow a similar pattern over the 8 
days (Figure 4.6). TBP, on the other hand, behaves rather differently than Brfl and 
Bdpl. Although TBP mRNA levels thiough the differentiation period show a few 
similarities with Brfl and B dpl, if  we just take the beginning and end o f the time 
course (Figure 4.5A), we see that TBP mRNA levels actually increase in PE cells 
compared to EC cells.
Surprisingly, changes in Brfl and Bdpl mRNA levels do not appear to reflect the 
changes seen in protein levels (Figure 3.5A). This could reflect the difference in 
sensitivity between the two methods used. It is also worth noting that the two 
analyses were performed on extracts (protein or RNA) from different time courses, 
which might influence the results observed. Furthermore, the PCR analysis was only 
perfoimed once. Further experiments are needed to ensure that the pattern observed 
is accurate.
4.3.4 RT-PCR analysis o f M Gl 32-treated cells
As described above (section 4.2.6), Brfl and Bdpl mRNA levels decrease following 
differentiation. RT-PCR analysis o f EC and PE cells that had been treated with 
M G l32, however, revealed that proteasome inhibition actually affects Bdpl and Brfl 
transcript levels (Figure 4.7A). From the reduction seen in control cells (compare 
lanes 1 and 2 for EC and PE respectively), we now see an increase in Bdpl mRNA, 
while Brfl stays relatively unchanged (lanes 3 and 4). TBP mRNA levels, on the 
other hand, are not affected by M G l32 treatment, as they show the same pattern in 
both conditions (Figure 4.7A -  row 3). These data agree with those obtained from the
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mRNA time course (Figure 4.6), where BRFl and BDPl show a similar pattern of 
expression, different from that o f TBP. A  possible explanation for the effect o f 
M G l32 on Brfl and Bdpl mRNA levels is that proteasome inhibition could stabilise 
a transcription factor (or factors), involved in BDPl and BRFl expression, that is 
normally kept at low levels in PE cells. Alternatively, the half-life o f the mRNA 
might be affected, with a protein that stabilises Brfl and Bdpl mRNA increasing in 
levels due to proteasomal inhibition. An interesting observation is that the increased 
mRNA level is not reflected in the overall protein levels. This could be attributed, for 
example, to regulation at the translational level. Thus, higher levels o f mRNA would 
not lead to increased protein synthesis.
Two pol Ill-transcribed genes, 5S rRNA and B2, were also tested (Figure 4.7B). 
There appears to be no effect o f the proteasome inhibitor on the transcription o f the 
two genes (eompare lanes 1 and 2 with 3 and 4), which agrees with the absence o f an 
effect o f proteasome inliibition on pol III transcription seen in in vitro transcription 
assays (Figure 4.4C).
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CHAPTER 5
Over-expression of Brfl does not rescue pol 
III transcription
5.1 Introduction
Because most pol Ill-transcribed genes are essential for normal cellular metabolism 
(e.g., 5S rRNA for ribosome biogenesis, tRNA for translation and U6 small nucleai' 
RNA for mRNA processing), pol III transcription is under strong regulation in 
response to a variety o f external stimuli (reviewed in White, 2002). For example, 
during the cell cycle, pol 111 transeription is activated during the Gi/S transition, due 
to release from pRb-mediated repression, and repressed at mitosis (White et al., 
1995a; White et al., 1995b; White et al., 1996). Pol 111 transcription is also repressed 
by p53 (Cairns and White, 1998). Both tumour suppressors, pRb and p53, bind to 
and inactivate TFIIIB. TFIIIB, and consequently pol III transcription, is also 
activated directly by the oncogene product c-Myc (Gomez-Roman et al., 2003) and 
the kinases CK2 (Johnston et a l ,  2002) and ERIC (Felton-Edkins el a l ,  2003a). All 
o f these suggest that TFIIIB is the pivotal initiation factor in the pol 111 system 
(Figure 1.4).
Most pol III promoters in higher eukaryotes (and all in yeast) require a TFIIIB 
complex comprised o f Bdpl, Brfl and TBP. Consequently, many studies have tried 
to determine which of these components are most important for pol III regulation.
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Work in yeast has shown that Brfl is the limiting factor (Schramm and Hernandez, 
2002), though the situation in mammals is still unclear.
To try to address some o f the questions raised earlier about Brfl regulation in 
differentiating F9 cells, 1 decided to establish an F9 cell line stably expressing HA- 
tagged human B rfl, driven by the constitutively active human cytomegalovirus 
immediate early promoter. The HA tag will be of use in monitoring the protein levels 
through differentiation, and the different promoter structure might help address the 
question of transcriptional control.
5.2 Results
5.2.1 HA-hBrfl is overexpressed in stably transfected cells.
As described in the Materials and Methods chapter, F9 EC cells were transfected 
using the Superfect protocol with either the pcDNAS.l-HA-hBrfl plasmid or the 
empty vector pcDNA3.1-HA. They were subsequently grown in G418-containing 
medium, to select for those cells that had taken the plasmid up. O f the resulting 
G418-resistant clones, several were selected and grown further. Extracts from these 
cells were analysed by Western immunoblotting for expression o f H A -hBrfl. Clones 
from cells that were originally transfected with the hBrfl-containing plasmid were 
called B l, B2, etc. (B for B rfl) and those with the empty vector C l, C2, etc. (C for 
control cells). Figure 5.1 A shows the expression levels o f exogenous HA-hBrfl (top 
panel) in clones B l, B2, B3, B7, B9, BIO, B l l  and B16. Actin was used as loading 
control. O f these we can see that clones B l, B9 and BIO express HA-hBrfl at high 
levels, with B9 being the highest. Clones B2, B7 and Bl 1 also express HA-hBrfl,
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Figure 5.1 Screening o f G418-resistant clones
G 418-resistant clones, containing either the pcDNA3-HA-hBrfl plasmid or the 
empty vector (generated as described in Materials and Methods), were used to 
prépaie whole-cell extracts, which were resolved in a SDS -  7.8% polyacrylamide 
gel and analysed by Western immunoblotting for Brfl levels. A Protein extracts 
(50 pg) from clones stably transfected with the HA-hBrfl plasmid (B l-3, 7, 9-11, 
16) were probed with an anti-HA antibody (F-7 -  top panel) and an anti-actin 
antibody (C-11 -  bottom panel). B and C G418-resistant clones, stably transfected 
with the control vector (C l-8) were probed with an anti-HA antibody (F-7 -  top 
panel in B) or an anti-Brfl antibody (128, which can recognise both exogenous and 
endogenous Brfl -  top panel in C). Actin was used as loading control. In B, in vitro 
translated HA-Brfl was used as positive control (lane 9).
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but at very low levels. No signal was observed with clones B3 and B16 (see 
Discussion in this chapter about clone B16). The three high expressing clones, B l, 
B9 and BIO, were therefore used for further experiments.
Eight clones o f vector-transfected cells (Cl -  C8) were also tested (Figure 5 .IB and 
C) in a similar manner. When probed for HA-hBrfl (top panel in 5 .IB), C7 gave a 
weak signal and was therefore discarded. This was possibly due to contamination 
with HA-hBrfl -expressing cells during tissue culture. The rest were probed for total 
Brfl (top panel in 5.1C), which revealed no significant differences between the 
clones. Any one o f them could therefore be used as a control cell line.
For these stable cell lines to be useful, it was important to show that the total levels 
of B rf l, both protein and mRNA, are higher in the HA-hBrfl cells compared to the 
controls, as the cells could compensate for the overexpression o f exogenous Brfl by 
reducing endogenous Brfl production. Figure 5.2A shows that this is not the case, as 
the B9 clone shows higher levels o f total Brfl protein than both untransfected cells 
and a control clone (compare lane 2 with lanes 1 and 3). The antibody used here 
against Brfl (145) recognises both the mouse and the human protein. Quantification 
revealed an almost 4-fold increase in the total protein levels o f B rfl. Similar analysis 
was carried out with the other two clones that express high levels o f HA-hBrfl (B 1 
and BIO -  results not shown). When RT-PCR analysis was carried out (Figure 5.2B), 
using cDNAs from two HA-hBrfl clones (B9 and BIO) and two control clones (Cl 
and C8) and primers that recognise both human and mouse sequences, it was 
revealed that the HA-hBrfl clones contain higher levels of the Brfl mRNA than the 
control clones (compare lanes 1 and 2 with 3 and 4). The pol Il-transcribed gene 
ARPP PO was used as internal control.
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Figure 5.2 Total Brfl levels in HA-hBrfl clones
A Whole-cell extracts (20 pg) from either untransfected cells (EC -  lane 1 ), HA- 
hBrfl eells (B9 — lane 2) or control cells (C8 -  lane 3) were resolved on a SDS — 
7.8% polyacrylamide gel and analysed by Western blotting using an anti-Brfl 
antibody (145, which recognises both exogenous and endogenous Brfl -  top panel) 
or an anti-actin antibody (C-11 -  bottom panel), as loading control. Total levels of 
Brfl were quantified (TotalLab), normalised to actin and expressed as a percentage 
o f EC. B eDNAs were generated from total RNA (3 pg) extraeted from HA-hBrfl 
cells (B9 and BIO -  lanes 1 and 2) or control cells (Cl and C8 -  lanes 3 and 4), and 
analysed by PCR using primers for Brfl (top panel) or ARPP PO (bottom panel). The 
Brfl primers used here amplify the same sequence from both mouse and human 
Brfl.
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5.2,2 Overexpression o f Brfl does not affect the proliferation
rate o f  F9 EC cells
Previous work in the laboratory has shown that mouse embryonic fibroblasts 
overexpressing Brfl proliferate twice as fast as control cells (Marshall and White, in 
preparation). We, therefore, wondered if  overexpressing Brfl in F9 EC cells would 
result in faster proliferation. To investigate this, a simple proliferation experiment 
was performed, in which cells from either an HA-hBrfl clone (B9) or a control clone 
(C8) were plated at a density o f  1 x 1 and numbers of viable cells monitored over a 
6 day-period. A graphical representation of the average of three independent 
experiments, with the same cell lines, can be seen in Figure 5.3. It is immediately 
obvious that there is no difference in the proliferation rates of Brfl overexpressing 
cells, compared to control cells.
5.2.3 Levels o f HA-hBrfl are not affected by differentiation or
MG132 treatment
The primary reason for establishing these stable cell lines was to allow for easier 
observation o f Brfl during the differentiation of F9 cells, courtesy o f the HA tag at 
its N-terminus. Western immunoblotting, using an antibody against the HA tag of 
hB rfl, revealed that, when HA-hBrfl cells (Bl clone) were induced to differentiate, 
no reduction in the levels of the exogenous protein were observed (Figure 5.4A -  
lanes 3 and 4). Similarly, when HA-hBrfl was monitored throughout the 
differentiation process by means o f a time course, no variation in its levels was
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Figure 5.3 Proliferation curves of HA-hBrfl and control cells
HA-hBrfl (B9) or control (C8) cells were plated at a density o f 1 x 1 on day 0 and 
cultured in growth medium. Viable cell counts, determined by trypan blue staining, 
were taken in triplicate every day for 5 or 6 days after seeding. The results from three 
independent experiments were averaged and plotted on a semi-logarithmic graph, ± 
standard deviation.
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Figure 5.4 Levels of HA-hBrfl in differentiated, stably
transfected cells
A Whole-cell extracts (50 pg) from untransfected (lanes 1 and 2) or clone B l (lanes 
3 and 4) ceils, before (EC -  lanes 1 and 3) and after (PE -  lanes 2 and 4) 
differentiation were resolved on a SDS -  7.8% polyacrylamide gel and analysed by 
Western blotting using an anti-HA antibody (F-7 -  top panel) or an anti-actin 
antibody (C-11 -  bottom panel) as loading control. B Whole-cell extracts (20 pg) 
from EC B9 cells (lane 1) or from each day during differentiation o f these clones 
(lanes 2-8) were analysed as in A, except that TFIIB was used as loading control 
(antibody C-18). C Total RNA (3 pg), extracted from B9 (lanes 1 and 3) or C8 (lanes 
2 and 4) clones, before (lanes 1 and 2) or after (lanes 3 and 4) differentiation, was 
used to generate cDNAs by reverse transcription. Levels o f Brfl were determined by 
PCR analysis, using primers that recognise only the human mRNA. HPRT was used 
as internal control. B refers to the B9 clone and C to the C8 clone.
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observed (Figure 5.4B). The band that appears below HA-hBrfl in Figure 5.4A and 
B is thought to be a cross-reacting protein and is discussed later in this chapter.
A small reduction in the mRNA levels o f Brfl has been previously observed (Figure 
4.5), suggesting a possible transcriptional regulation in response to differentiation. 
Although under the control o f a different promoter, i.e. the constitutively active 
CMV promoter, it was interesting to examine whether or not exogenous Brfl mRNA 
was regulated in response to differentiation, either at transcriptional or post- 
transcriptional level. RNA was extracted from B9 and C8 clones, before and after 
differentiation. RT-PCR analysis using primers that recognise only human Brfl (and 
therefore only the exogenous Brfl in these cells) revealed no reduction in HA-hBrfl 
levels following differentiation (Figure 5.4C -  compare lane 1 with lane 3 in the top 
panel). HPRT, the product o f a constitutively expressed gene, was used as an internal 
control.
Experiments using C 0S7 cells (from monlcey kidney tumours) suggested that HA- 
hBrfl might be ubiquitinated and degraded by the proteasome (data not shown). 
Similar experiments in F9 cells lead to an interesting observation. When a plasmid 
containing the ubiquitin gene, under the control of the CMV promoter, was 
transfected into an undifferentiated HA-hBrfl clone (EC-B9), the protein levels of 
both Bdpl and HA-hBrfl were reduced (Figure 5.5A). When, however, EC or PE B9 
cells were treated with the proteasome inhibitor M G l32, no effect on the levels of 
HA-hBrfl was observed (Figure 5.5B, compare lanes 1 and 2 for EC and 3 and 4 for 
PE).
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Figure 5.5 Stability o f H A-hBrfl in EC and PE cells
A EC Bl clones were transiently transfected with a vector containing histidine- 
tagged ubiquitin, under the control o f a constitutive promoter, using the Superfect 
protocol (see Materials and Methods). Cell lysates were prepared from these cells, 
resolved on a SDS -  7.8% polyacrylamide gel and transferred onto PVDF. The 
membrane was subsequently probed for Bdpl (antibody 2663 -  top panel) and HA- 
hBRFl (HA probe, F-7 -  middle panel). Actin was used as both loading and negative 
control. B B9 cells were treated with DMSO (lanes 1 and 3) or the proteasome 
inhibitor MG 132 (50 pM -  lanes 2 and 4) for 4 hours prior to harvesting and protein 
extraction. Whole-cell extracts from these cells were analysed by Western blotting 
using an anti-HA antibody (F-7 -  top panel) or an anti-actin antibody (C-11 -  bottom 
panel).
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5.2.4 Effect o f HA-hBrfl overexpression on pol HI
transcription
The fact that HA-hBrfl levels did not decline following differentiation raised the 
possibility that pol III transcription might also be affected in PE cells. First, however, 
we needed to examine if overexpression o f HA-hBrfl had any effect on pol III 
transcription in undifferentiated cells. To do this, in vitro transcription assays were 
carried out, using extracts from untransfected EC cells or stably transfected B9 or C8 
clones. Figure 5.6A shows that pol III transcription of a tRNA^^“ template is elevated 
in the B9 clones compared to untransfected or control cells (compare lane 2 with 
lanes 1 and 3). When these cell lines were induced to differentiate, however, a 
reduction in pol III transcription could still be observed, similar to that for 
untransfected F9 cells (see Figure 3.2B). As we can see in Figure 5.6B, transcription 
o f a tRNA^^“ template is reduced in differentiated B9 cells (compare lanes 1 and 2), 
even though they contain comparable Brfl levels to the undifferentiated cells (Figure 
5.4). The control cells, C8, show a similar reduction. As in the case o f the wild-type 
F9 cells (see Figure 4.4C), proteasome inhibition does not affect pol III transcription 
following differentiation (Figure 5.6C). EC (lanes 1 and 2) or PE (lanes 3 and 4) B9 
cells were treated with M Gl 32 (lanes 1 and 3) or DMSO (lanes 2 and 4) for 4 hours 
prior to harvesting and protein extraction. In vitro transcription assays o f a 
template using these extracts show no changes in pol III transcription in response to 
M G l32 treatment (compare lane I with lane 2 and lane 3 with lane 4). Since these 
extracts are obtained at the start and the end of the differentiation process, i.e. days 0 
and 7 respectively, there is no indication as to the levels of pol III transcription in the 
intervening period. To address this, extracts were prepared before induction and at
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Figure 5.6 
transcription
Effect o f Brfl over-expression on pol III
A Whole-cell extracts (20 pg) from untransfected EC cells (lane 1) and B9 (lane 2) 
or C8 EC clones were used to in vitro transcribe a tRNA’ template (250 ng), B In 
vitro transcription o f a tRNA’^ " template (125 ng) by EC (lanes 1 and 3) or PE (lanes 
2 and 4) whole-cell extracts from B9 (lanes I and 2) or C8 (lanes 3 and 4) clones. C 
EC (lanes 1 and 2) or PE (lanes 3 and 4) B9 cells were treated with MGl 32 (50 pM -  
lanes 1 and 3) or DMSO (lanes 2 and 4) for 4 hours. Whole-cell extracts from these 
eells were used to in vitro transcribe a tRNA’^ "^ template (250 ng).
157
each day during differentiation o f HA-hBrfl clones. Figure 5.7A shows the in vitro 
transcription o f tRNA’^ ‘^“ using extracts from B9 cells, although the experiment was 
repeated with B l and BIO cells as well. We can see here that transcription remains at 
high levels until day 5, compared to day 2 in untransfected F9 cells (Figure 3.3A), 
although there is a small reduction between days 2 and 3. The same experiment was 
performed with the B l and BIO clones, the autoradiographs were quantified 
(TotalLab) and the results averaged and presented graphically in Figure 5.7B (blue 
line). From the graph we can see an initial reduction by about 20% for the first two 
days following induction of differentiation, and then a further decline between days 3 
and 5. RNA polymerase 111 transcription levels reach a minimum level at day 6 o f the 
differentiation. The red line represents the same experiment done with untransfected 
F9 cells (also presented in Figure 3.3B), and is included here for easier comparison.
5,2.5 Recombinant hBdpl does not restore pol III transcription
following differentiation
As was discussed previously, when F9 EC cells are induced to differentiate, pol III 
transcription is down-regulated due to a reduction in one or more activities found in a 
protein fraction containing the TFIIIB complex (Alzuherri and White, 1998). The 
HA-hBrfl clones we made contain high levels o f Brfl even after differentiation, but 
if  there is no free Bdpl ,  the only other, pol Ill-specific component o f TFIIIB, then the 
additional Brfl might not become incorporated into functional complexes. PE 
extracts from B9 clones were, therefore, pre-incubated with recombinant human 
Bdpl (rhBdpl) and then used these for in vitro transcription o f a tRNA’ ^^" template. 
In Figure 5.8, we can see that rhBdpl has no effect on pol III transcription when it is
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Time-course of pel III down-regulation in HA-
A B9 cells before (lane 1) and during differentiation (lanes 2-8) were used to prepare 
whole-cell protein extracts. 20 pg o f  the extracts were then used for the in vitro 
transcription o f a tR N A ^“ template (250 ng). B Graphical representation o f three 
independent time-course experiments (blue line), ± standard deviation. The down- 
regulation o f pol III transcription in untransfected F9 cells is also shown here (red 
line), for easier comparison (see also Figure 3.4B).
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used to supplement extract from Brfl -overexpressing cells (compare lanes 3 and 4 
with lane 2). EC extracts from the same cells (lanes 1 and 5) indicate the level o f 
transcription before differentiation.
5.3 Discussion
5 3  A Establishment o f an HA-hBrfl overexpressing cell line
It is known that expression o f some viral proteins in early mouse embryogenesis is 
severely restricted or absent, and that it is activated subsequently during development 
(Kelly and Condamine, 1982). As a further testament to their close resemblance to 
the iimer cell mass (ICM) o f the early mouse embryo, F9 EC cells also exhibit this
block to viral expression. Viruses whose expression is limited in F9 cells include the
polyoma and SV40 viruses (members o f the polyomaviridae family), the retroviruses 
Moloney murine leukaemia virus and mouse mammary tumour virus, as well as 
murine cytomegalovirus (belonging to the herpesviridae family). This was cause for 
some concern, since the HA-hBrfl construct had been cloned into the pcDNA3.1 
plasmid, which contains the human cytomegalovirus promoter and enhancer 
sequences. Transient transfections demonstrated that HA-hBrfl was indeed 
expressed in F9 EC cells (results not shown). This was verified when G418-resistant 
clones were screened for expression o f HA-hBrfl (Figure 5,1 A). The differences 
observed in expression could be the result o f the efficiency o f transfection, the 
number o f plasmids integrated in the genomic DNA and the site of those 
integrations. For that reason, although the B9 clone was predominantly used, most of
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Figure 5.8 Recombinant Bdpl add-back
Bacterially expressed recombinant human Bdpl (rhBdpl) was assessed in its ability 
to restore pol III transcription o f PE extracts from HA-hBrfl cells (B9 clone). PE 
extracts were preincubated with 0, 1.5 and 3 pi o f rhBdpl and subsequently used to 
in vitro transcribe a tRNA'^" template (lanes 2-4, respectively). EC extracts from the 
same cell line were used for comparison (lanes 1 and 5). 20 pg o f cell extract and 
250 ng template were used in the assay.
161
the experiments were repeated with the other two high-expressing clones (i.e. B1 and 
BIO). Another thing to note is that clone B16 showed an extremely high level of 
expression during the first screening stage. As can be seen in Figure 5.1 A (lane 8), 
this expression was subsequently lost. Therefore, whenever new clones were brought 
up from liquid nitrogen storage, and at various times thereafter if  grown for long 
periods (more than a month), HA-hBrfl expression was verified by Western blot 
analysis.
5,3.2 Proliferation rate o f F9 EC cells overexpressing HA-
hBrfl
As discussed in the introduction, TFIIIB is under intense regulatory control by a 
number o f factors and enviromnental conditions, most of which focus on the Brfl 
subunit of TFIIIB. Fuilhennore, work in mouse embryonic fibroblasts has shown that 
regulated overexpression o f Brfl leads to an increase in the proliferation rate o f the 
cells (Marshall and White, in preparation). FIA-hBrfl overexpression in F9 EC cells 
results in increased pol III transcription (Figure 5.6). This suggests either that human 
Brfl can functionally interact with the mouse pol III machinery (particularly TBP 
and B dpl, to form TFIIIB), or that it can sequester inhibitory factors, for example 
pRb and p53. When the proliferation rate o f the cells was assessed, however (Figure 
5.3), no difference was observed between HA-hBrfl and control cells. This suggests 
that pol III activity in F9 EC cells is not rate limiting for progression through the cell 
cycle. This is not surprising, considering the transformed status o f the cells and the 
very high proliferation they exhibit normally (Rosenstraus et aL, 1982).
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5.3.3 HA-hBrfl levels in response to differentiation and
proteasome inhibition
In the case o f wild-type, untransfected F9 cells, we previously saw that 
differentiation causes a small reduction in the mRNA levels o f Brfl and Bdpl 
(Figure 4.5), which is accompanied by a larger decline in protein levels (Figure 3.4). 
However, since we are dealing with different techniques (with different sensitivities), 
direct comparisons can be misleading. Nevertheless, these data, combined with the 
lack o f stabilisation o f these proteins by the proteasome inhibitor MG132 (Figure 
4.4A and B), suggest that BrH and Bdpl regulation may occur at transcriptional, 
post-transcriptional or translational level. Establishing a BrH-overexpressing F9 cell 
line allowed us to investigate this further, since HA-hBrfl is controlled by the 
constitutively active human CMV promoter. The possibility o f transcriptional 
control can be thus examined, since it is likely to have different transcription factor 
requirements from endogenous Brfl (this is not a certainty, since regulation o f BRFJ 
expression has not been studied).
As we can see in Figure 5.4, HA-hBrfl levels are not reduced following 
differentiation either at protein (A and B) or mRNA level (C). In comparison, 
endogenous Brfl is reduced at both levels (Figures 3.4 and 4.5). These data further 
argue against regulation o f Brfl at protein level, considering the similarity between 
the mouse and human Brfl (almost 90% identity). Exogenous Brfl mRNA is also 
not affected by differentiation (Figure 5.4C, compare lanes 1 and 3), suggesting that 
transcriptional (or post-transcriptional) regulation is different for endogenous and 
exogenous B R F l.
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The lower band in Figure 5.4A and B appears to be a protein, whose expression is 
induced during differentiation, that cross-reacts with the HA antibody. This is 
supported by the fact that it can be seen even in untransfected F9 PE cells (Figure 
5.4A, lanes 2).
The data obtained from the experiment where ubiquitin was transfected into an HA- 
hBrH clone (Figure 5.5A) were quite surprising, since Brfl and Bdpl were not 
stabilised by MG132 in F9 EC cells (Figure 4.4B for Bdpl and data not shown for 
B rfl). Overexpression o f ubiquitin, however, seems to drive the degradation o f FIA- 
hBrH and Bdpl in the B1 clone that was used for the experiment. Although not 
shown in Figure 5.5A, this degradation was somewhat blocked by MG132, but levels 
for both proteins were still lower than the mock-transfected cells. A possible 
explanation for this can be found in the fact that ubiquitin is thought to be a limiting 
factor for the proteasome pathway (Hay, R. T., personal communication). Its 
overexpression, therefore, could allow the degradation o f proteins that would, under 
physiological conditions, not be targeted to the proteasome. This also suggests that 
both of these proteins contain the necessary signals for proteasomal degradation. 
Nevertheless, proteasome inhibition in the same cells, without the overexpression of 
ubiquitin, does not lead to stabilisation o f HA-hBrH (Figure 5.5B), before or after 
differentiation.
5.3.4 RNA polymerase III transcription in HA-hBrfl clones
We saw that EC extracts from B9 cells have higher transcriptional activity than either 
control or untransfected F9 EC cells (Figme 5.6A) and that HA-hBrfl protein levels 
do not decrease following differentiation (Figures 5.4A and B). It was therefore
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surprising to see that, following differentiation o f the B9 cells, pol III transcription of 
the same template (tRNA^^^) decreased (Figure 5.6B -  compare lanes 1 and 2). This 
decrease was similar' to that observed using extracts from the C8 cells (lanes 3 and 4 
in Figure 5.6B). Based on these data, it would seem that, in F9 PE cells, Brfl is no 
longer limiting for pol III transcription. Bdpl also decreases in differentiated cells. 
The extra HA-hBrfl might, therefore, not be able to form functional TFIIIB 
complexes due to absence o f Bdpl. When B9 PE extracts were pre-incubated with 
recombinant hBdpl and used for IVT assays, however, no restoration of transcription 
was observed (Figure 5.8). These data suggest that TFIIIB is not limiting in F9 PE 
cells. This appears to contradict earlier findings (Alzuherri and White, 1998; White 
et a i ,  1989), that TFIIIB is the limiting activity in F9 PE cells. Since those findings 
were based on protein fractionation, it is possible that another pol III activator, which 
C O -fractionates with TFIIIB, is limiting in PE cells. This possibility will be discussed 
in the following chapter.
When we look at the down-regulation o f pol III transcription over the whole o f the 7 
days that the cells are induced to differentiate, we see that there a difference exists 
between untransfected and HA-hBrH clones (Figure 5.7B -  red and blue lines, 
respectively). Although the level o f pol III transcription is similar between the two 
cell lines at the end o f the differentiation period (days 6 and 7), the decline is delayed 
until day 4 or 5. O f particular note is that the initial decrease (days 1 and 2) is only 
about 20%, compared to around 50% in the untransfected cells, which seems to be 
responsible for the delay observed later on. The large error bars for the HA-hBrH 
cells could be due to the fact that different clones (B l, B9 and BIO) were used for the 
experiments, in order to get a more accurate picture, and these express HA-hBrfl at 
different levels. It, therefore, seems that overexpression of Brfl does have an effect 
on differentiating F9 cells, but only until a certain time point, i.e. around day 4 or 5
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after induction o f differentiation. After that, other factors that affect pol III 
transcription might become limiting.
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CHAPTER 6
Regulation of other pol III regulators 
during differentiation
6.1 Introduction
In Section 1.1.6, a number o f key regulatory proteins were presented, all o f which 
seem to exert their effect thi'ough TFIIIB. A diagram is presented in Figure 1.4. It is 
immediately obvious that the proteins involved encompass a large number of 
regulatory pathways, which, in response to different stimuli, can activate or repress 
pol III transcription.
It has been previously shown that TFIIIB is activated at the G l/S  transition during 
the cell cycle (White el aL, 1995a), at about the same time that the retinoblastoma 
protein (pRb) is inactivated (Weinberg, 1995), raising the possibility that the two 
events might be connected. Subsequent work showed that overexpression of pRb in 
transfected cells leads to reduced pol III activity (Chu el a l ,  1997; White el ciL, 
1996), and that recombinant Rb has the ability to repress pol III transcription in vitro 
(Larminie el aL, 1997; White el a l ,  1996). When the Rb gene was inactivated by 
site-directed mutagenesis in mice, tRNA and 5S rRNA synthesis increased by about 
5-fold (White el a l ,  1996), and extracts obtained from these mice exhibited a 
specific increase in TFIIIB activity (Larminie el a l ,  1997). Furthermore, co- 
immunoprecipitation and pull-down experiments showed that pRb physically 
interacts with TFIIIB (Chu el a l ,  1997; Larminie el a l ,  1997). All these data pointed
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to a specific effect o f pRb on pol III transcription, the mechanism o f which became 
clear a few years later, when Sutcliffe et al. (2000) showed that pRb exerts its 
repressive effect by dismpting the interactions of TFIIIB with TFIIIC and the 
polymerase itself.
The retinoblastoma protein, pRb, belongs to a small family o f structurally and 
functionally related proteins, collectively referred to as the pocket proteins (reviewed 
in Grana et a l ,  1998; Mulligan and Jacks, 1998). Because of those functional 
similarities, the possibility o f involvement of p l07  and p i 30 in the regulation o f pol 
III transcription was examined (Sutcliffe et a l ,  1999). Similar to pRb, 
overexpression o f p i 07 and p i 30 was found to repress pol III transcription in 
transfected cells, while recombinant p i 07 and p i 30 inhibited pol III transcription in 
vitro (Sutcliffe et a l ,  1999). Co-immunoprecipitation experiments showed that 
endogenous p i 07 and p i 30 associated with the Brfl subunit o f TFIIIB. In addition, 
p l07  and p i 30 co-fractionated with TFIIIB activity, suggesting a stable interaction 
(Sutcliffe et a l ,  1999). Fibroblasts from plO TT plSO T  double knockout mice 
exhibited increased pol III activity, as was the case when p i 07 and p i 30 were 
specifically inactivated by the E7 oncoprotein o f human papillomavirus (Sutcliffe et 
a l ,  2000). Therefore, p i 07 and p i 30, like pRb, have the ability to bind to TFIIIB and 
repress transcription by pol III.
Although no direct comparisons o f pRb, p i 07 and pl30, as far as protein levels are 
concerned, have been made between F9 EC and PE cells, it has been shown that pRb 
and p i 07 E2F-associated activity is low in EC but elevated in PE cells (Partridge and 
La Thangue, 1991; Zamanian and La Thangue, 1993). In addition, it has been shown 
that the Rb gene is induced in a variety o f mouse cell lines, other than F9, following 
differentiation (Coppola et a l ,  1990; Endo and Goto, 1992; Richon et a l ,  1992;
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Slack et a l ,  1993). No reports deal with the third member o f the family, p i 30, in F9 
cells.
As well as pRb, p53, an umelated tumour suppressor (reviewed in Levine, 1997), 
also has the ability to repress transcription by pol III. Chesnokov et a l  (1996) 
originally showed that wild-type p53 can inhibit transcription o f some class III genes, 
both in vitro and in vivo. These observations were later extended to include other 
genes transcribed by pol III (Caims and White, 1998). Furthermore, it was shown 
that p53 exerts its effect by binding to TFIIIB through the TATA-binding protein, 
disrupting the interactions o f TFIIIB with TFIIIC and pol III (Crighton et a l ,  2003). 
Since TFIIIC is responsible for recruiting TFIIIB to most pol Ill-transcribed genes, 
p53 induction leads to a reduction in TFIIIB, and therefore pol III, present at class III 
promoters (Crighton et a l ,  2003). Conversely, promoter occupancy, as well as tRNA 
and 5S rRNA synthesis, increases in fibroblasts obtained from p53-lcnockout mice 
(Cairns and White, 1998; Crighton et a l ,  2003).
Testicular teratocarcinoma cells, from which the F9 cell line is derived, never contain 
p53  gene mutations, even though these tumours express high levels o f p53 protein 
(Lutzker and Levine, 1996). Specifically, F9 EC cells have been shown to contain 
wild-type p53 (Pemiica et a l ,  1984), the levels o f which, both mRNA and protein, 
decrease following differentiation into parietal endodenn-like cells (Dony et a l ,  
1985; Oren et a l ,  1982). However, it has been reported that, although p53 is present 
in F9 EC cells, it is functionally inactive (for example Mayo and Berberich, 1996; 
Schmidt-Kastner et a l ,  1998), but is activated in response to UV irradiation (Mayo 
and Berberich, 1996) or other DNA damaging agents (Lutzker and Levine, 1996). 
Furthermore, RA-induced differentiation results in increased p5 3-mediated 
transcriptional activity, even though p53 levels decrease (Lutzker and Levine, 1996).
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The first indication that CK2 might be involved in pol III transcription came from 
work in yeast, where it was shown that it stimulates the transcription o f the 5S rRNA 
and tRNA genes (Hockman and Schultz, 1996). Further work in yeast demonstrated 
that CK2 phosphorylates the TBP component of TFIIIB, thus enhancing its 
recruitment to promoters o f class III genes and activating pol III transcription 
(Ghavidel and Schultz, 1997; Ghavidel and Schultz, 2001; Hockman and Schultz, 
1996).
Work in mouse and human cells showed that CK2 activity is equally important in 
mammalian cells, since its inhibition resulted in a reduction o f pol III transcription 
both in vivo and in vitro (Johnston et al., 2002). It was also shown that, like in yeast, 
CK2 activity affects recruitment o f TFIIIB to class III promoters by TFIIIC 
(Johnston et a l ,  2002), a step that, at least in yeast, is rate-limiting for pol III 
transcription (Rameau et a l ,  1994). However, while, in yeast, TBP alone is 
phosphorylated efficiently by CK2 in vitro (Ghavidel and Schultz, 1997), all three 
human TFIIIB components, TBP, Brfl and Bdpl, are phosphorylated directly by 
CK2 in vitro (Johnston et a i ,  2002). Overall, these data suggest that CK2 
involvement in pol III transcription is maintained thi'ough evolution, consistent with 
the very high degree of conservation that is displayed by CK2.
Studies concerning CK2 in F9 cells have focused on the effects that 
chemotherapeutic agents, like cisplatin and carboplatin, have on its levels and 
activity, especially in relation to p53 and Mdm2 as part o f the apoptotic response 
(e.g. Siemer et a l ,  1999 and references therein). No investigations have been made 
into the effects o f cell differentiation on CK2 levels and activity.
The mitogen-activated protein kinase (MAPK) pathway, o f which the Ras/ERK 
pathway is but a branch, exists in all eukaiyotes and controls fundamental cellular 
processes, such as proliferation, differentiation, survival and apoptosis. It was not
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surprising, therefore, to find that ERK plays a role in the regulation o f RNA 
polymerase III, the output of which (e.g. tRNA and 5S rRNA) is essential for growth. 
Serum induction o f quiescent cells results in an immediate increase in pol III 
transcription, which is mediated by the ERK pathway, as inhibition o f kinase just 
upstream of ERK (MEK) by PD98059, or Ras (by FTI-277), causes a reduction in 
the expression o f class III genes (Felton-Edkins et a l ,  2003a). Further experiments 
showed that ERK binds to and phosphorylates B rfl, thus increasing TFIIIB binding 
to TFIIIC (similar to CK2), but also to the polymerase. As before, inhibition of MEK 
activity by a chemical reagent (U0126) significantly reduced this effect (Felton- 
Edkins et a l ,  2003a). Activation o f pol III transcription by ERK is, therefore, 
conditional on its prior activation (phosphorylation) by MEK.
As mentioned before, differentiation o f F9 cells from EC to PE is a two-step process, 
with the cells initially adopting a primitive endoderm-like morphology and 
characteristics, induced by retinoic acid. Subsequently, in response to elevated cyclic 
AMP levels, they differentiate into parietal endoderm-like cells (Figure 1.5). The 
Ras/ERK pathway has been shown to play an important role in both of these 
processes. Specifically, it was shown that RA-induced differentiation into primitive 
endoderm is accompanied by activation o f endogenous Ras and ERK, whereas 
differentiation into parietal endoderm has the opposite effect, with Ras and ERK 
activity being reduced (Verheijen et a l ,  1999). Furthermore, expression of 
constitutively active forms of Ras, R af and MEK in F9 EC cells were shown to 
induce differentiation toward a primitive endoderm-like phenotype, while inhibiting 
the subsequent differentiation to parietal endoderm (Verheijen et a l ,  1999).
The myc/max/mad network is a group o f transcription factors that have been shown 
to greatly affect cell behaviour (for reviews see Amati et a l ,  1998; Bouchard et a l ,  
1998; Facchini and Penn, 1998; Grandori et a l ,  2000). c-Myc, and its relatives N-
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and L-Myc, are proto-oncogenes, whose expression generally correlates with cell 
proliferation. Through dimérisation with Max, they are able to bind to particular 
DNA sequences (Myc E-boxes) and activate expression o f target genes. Max can 
also bind another small family o f proteins, M adl, Mad2 (or M xil), Mad 3 and Mad4. 
Mad-Max heterodimers exert the opposite effect to Myc-Max dimers, repressing the 
transcription of target genes, using the same E-box sequences as Myc-Max. So, in 
effect, Myc and Mad family members compete with each other for binding of Max, 
to activate or suppress expression o f genes containing E-box sequences.
Myc is known to be involved in regulating cell growth through induction o f a 
number o f growth-related genes (Dang, 1999), transcribed by RNA polymerase II. It 
has been recently shown, however, that c-Myc directly activates RNA polymerase 
III, through interactions with the TFIIIB complex (Gomez-Roman et a l ,  2003). 
Furthermore, it is present at tRNA and 5S rRNA genes in several cell types (Felton- 
Edkins et a l ,  2003b; Gomez-Roman et a l ,  2003). Fibroblasts obtained from c-Myc 
knockout mice, as well as Myc-depleted HeLa cells, exhibit increased pol III activity, 
while overexpression leads to decreased transcription o f tRNA and 5S rRNA genes 
(Felton-Edkins et a l ,  2003b; Gomez-Roman et a l ,  2003). These data suggest that c- 
Myc contributes significantly to pol III transcription in normal cycling cells, 
expanding the involvement o f c-Myc in cell growth control.
Because o f its importance in cell growth and differentiation, the behaviour of c-Myc 
during differentiation of F9 EC cells has been studied extensively. Induction of 
differentiation by retinoic acid and dibutyryl cAMP results in a strong down- 
regulation o f e-myc mRNA at an early stage, within 24 hours following induction 
(Dean et a l ,  1986; Dony et a l ,  1985). The rate of transcription o f the myc gene, 
however, is not affected by retinoic acid and cAMP (Dony et a l ,  1985), suggesting a 
post-transcriptional method o f regulation. Further work suggested that c~myc mRNA
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down-regulation is related to growth arrest rather than differentiation. Decreased 
proliferation o f F9 EC cells, in the absence o f differentiation, was accompanied by 
reduced o-myc mRNA levels (Dean et a l ,  1986), whereas cells constitutively 
expressing c-myc became completely differentiated upon treatment with retinoic acid 
and cAMP, although they exhibited prolonged proliferation once they were fully 
differentiated (Schulz and Gais, 1989).
Contrary to the situation with c-Myc, the volume o f data for other proteins in this 
network in F9 cells is quite limited. Nevertheless, it has been shown that 
differentiation to PE causes a gradual reduction in Max protein levels, although there 
is little variation to max mRNA, suggesting a post-transcriptional regulation (Larsson 
et a l ,  1997). The same authors also state that madl mRNA was undetectable in F9 
EC or PE cells.
This chapter examines the protein levels of these regulatory proteins in 
differentiating F9 cells and the possible implications for the regulation o f 
transcription by RNA polymerase III.
6.2 Results
6,2.1 The pocket proteins, pRb, p i 07 and p i 30, are
differentially regulated during F9 cell differentiation
The relative levels of the three pocket proteins, pRb, p i 07 and p i30, were 
investigated by Western immunoblotting o f extracts from F9 EC and PE cells. As we 
can see in Figure 6.1A, p l07  and p l30  levels do not change following differentiation 
(top two panels). In contrast, pRb levels are strongly up-regulated in PE cells (third
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Figure 6.1 The pocket proteins are differentially regulated in
differentiating F9 cells
A W hole-cell extracts (20 pg) from EC (lane 1) or PE (lane 2) cells were resolved on 
a SDS -  7.8% polyacrylamide gel, transferred onto PVDF membrane and analysed 
by Western blotting using antibodies against p i 30 (C-20 -  top panel), p i07 (C-18 -  
second panel), pRb (IF8 -  third panel) and TFIIB (C-18 -  bottom panel). B W hole­
cell extracts (20 pg) were prepared from EC (lane 1) or differentiating (day 1-7 -  
lanes 2-8) cells and resolved on a SDS -  7.8% polyacrylamide gel. Following 
transfer onto PVDF membrane. Western blot analysis was performed, with 
antibodies against pRb (IF8 -  top panel) and TFIIB (C-18 -  bottom panel).
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panel). This up-regulation seems to start around day 2 after induction, with 
maximum pRb levels being reached by day 4 (Figure 6.1B -  top panel). It has been 
previously shown that cyclin D- and E-dependent phosphorylation o f pRb abolishes 
interaction with TFIIIB (Scott et a l ,  2001). The observed increase in pRb levels 
would, therefore, be meaningless, in the context of pol III transcription, if  the 
proteins became phosphorylated throughout the differentiation process. I, therefore, 
examined the levels o f an important regulator o f pRb phosphorylation, cyclin D l. In 
Figure 6.2A we can seen that, in the same extracts used for Figure 6 .IB, cyclin D l 
levels fall dramatically after the first day o f differentiation (compare lanes 2 and 3). 
To directly examine the phosphorylation state o f pRb, cell lysates (see Materials and 
Methods) from EC and differentiating cells were analysed by Western 
immunoblotting, using an antibody against pRb phosphorylated at serine 773 (Figure 
6.2B). Phosphorylation at this site requires cyclin D l in vivo (Geng et a l ,  2001). As 
we can obseiwe, Ser773 phosphorylation is reduced significantly within 24 hours of 
induction o f differentiation (compare lanes 1 and 2), with a ftirther reduction evident 
between days 2 and 3 (lanes 3 and 4). Figure 6.2C is a graphical representation of 
phospho-pRb levels, taking the levels in the EC cells as 100%.
6.2.2 Protein levels o f the tumour suppressor p53 do not change
when F9 EC cells differentiate into PE
Contrary to previous reports (Oren et a l ,  1982), p53 protein levels do not seem to 
change following induction o f differentiation. As we can see in Figure 6.3, Western 
blot analysis o f extracts from EC or differentiating cells reveals that p53 levels are 
constant throughout the 7-day period, when compared to the loading control, TFIIB.
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Figure 6.2 Déphosphorylation of pRb
A Whole-cell extracts (20 pg) were prepared from EC (lane 1) or differentiating (day 
1-7 -  lanes 2-8) cells and resolved on a SDS -  7.8% polyaerylaniide gel. Following 
transfer onto PVDF membrane, Western blot analysis was performed, with 
antibodies against cyclin D l (72-13G -  top panel) and TFIIB (C-18 -  bottom panel). 
B Cell lysates (20 pg) were prepared from EC (lane 1) or differentiating (day 1-6 -  
lanes 2-7) cells and analysed as in A, using an antibody against the phosphor-pRb 
(9307 -  top panel). TFIIB was used as loading control (bottom panel). C Graphical 
representation o f the phosphorylation status o f pRb during differentiation. The signal 
obtained from differentiating cells (B, lanes 2-6) was quantified by densitometry 
(TotalLab) and expressed as a percentage o f that from EC cells (B, lane 1).
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p53 levels remain unchanged during
Whole-cell extracts were prepared from undifferentiated EC cells (lane 1) or at each 
day following induction o f differentiation (PE 1-7 -  lanes 2-8). 20 pg were then 
resolved on a SDS -  7.8% polyacrylamide gel and analysed by Western blotting, 
using an anti-p53 (1C12 -  top panel) or an anti-TFIIB (C-18) antibody.
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6,2,3 Levels o f  the catalytic subunits o f casein kinase 2 (CK2)
are reduced in PE cells
Previous work concerning CK2 in F9 cells has focused on the involvement o f the 
kinase in the apoptotic response, especially in relation to p53 (e.g. Siemer et a i ,  
1999). Since CK2 has been previously shown to also have an effect on pol III 
transcription (Johnston et al., 2002), I decided to investigate its levels during F9 cell 
differentiation.
As we can see in Figui'e 6.4A, both catalytic subunits o f CK2, a  and a \  are down- 
regulated at the protein level in differentiating cells, although down-regulation o f the 
a  subunit seems to precede that o f a ’ by about 2 days. The levels o f the regulatory (3 
subunit do not change in response to differentiation (Figure 6.4B).
6,2,4 Active, but not total ERK, is down-regulated in PE cells
F9 EC or PE cells were harvested in a lysis buffer that enables the detection of 
phosphorylated proteins (see Materials and Methods) and analysed by Western 
immunoblotting. Figure 6.5A shows a comparison of the levels o f total vs. active (i.e. 
phosphorylated) ERK. While total ERK levels do not change following 
differentiation, it is evident that active ERK levels are reduced. TFIIB was used as 
loading control. The reduction observed in PE extracts is similar to that observed 
when F9 EC cells are treated with the MEK inhibitor PD98059 (Figure 6.5B). MEK 
(a MAPK kinase) phosphorylates and activates ERK, and its inhibition leads to 
reduction in phosphorylated ERK (middle panel in Figure 6.5B), while it has no
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CK2 protein levels are reduced during
A Whole-cell extracts were prepared from undifferentiated EC cells (lane 1) or at 
each day following induction o f differentiation (PE 1 -7 -  lanes 2-8). 20 pg were then 
resolved on a SDS -  7.8% polyacrylamide gel and analysed by Western blotting, 
using an anti-CK2a antibody (H-286, which cross-reacts with a ’ -  top panel) and an 
anti-TFIIB antibody (C-18) as loading control. B Western blot analysis of EC or PE 
extracts (20 pg -  lanes 1 and 2 respectively) using an anti-CK2(3 antibody (top panel) 
and an anti-actin antibody (C-11 -  bottom panel) as loading control.
180
ATotal ERK 
Active ERK 
TFIIB
EC PE
B
Total ERK 
Active ERK 
TFIIB
EC
+  PD 98059
Figure 6.5 Levels o f active ERK are reduced in F9 PE cells
A F9 EC (lane 1 ) and PE (lane 2) cells were harvested in lysis buffer (see Materials 
and Methods). 20 pg o f the cell lysates were resolved on a SDS -  7.8% 
polyacrylamide gel and analysed by Western immunoblotting, with antibodies 
against total ERK (9102 -  top panel) or active (i.e., phosphorylated) ERK (9106 -  
middle panel). TFIIB (antibody C-18) was used as loading control. B F9 EC cells 
were treated with DMSO or the MEK inhibitor PD98059 (50 pM) for 6 hours, 
harvested in lysis buffer and resolved on a SDS -  7.8% polyacrylamide gel. Western 
immunoblotting was performed using antibodies against total ERK (9102 -  top 
panel), phosphorylated ERK (9106 -  middle panel) and TFIIB (C-18 -  bottom 
panel).
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effect on total ERK levels (Figure 6.5B, top panel) or TFIIB (bottom panel), which 
was used as loading control.
6.2.5 Members o f  the myc/max/mad network are down-
regulated in PE cells
In addition to its function as a transcription factor when complexed with Max, c-Myc 
directly activates pol III transcription through interactions with TFIIIB (Gomez- 
Roman el a l ,  2003). It has been previously demonstrated that c-Myc is strongly 
down-regulated within a few hours after induction of differentiation. To verify this, 
extracts from differentiating cells were analysed by Western immunoblotting for c- 
Myc protein levels. As we can see in Figure 6.6A, there is a sharp decrease in c-Myc 
within 24 hours o f differentiation induction. The two bands observed are both c-Myc, 
representing the p67 (top band) and p64 (bottom band) forms o f the protein, which 
arise through initiation of translation at two different start codons (Hann and 
Eisenman, 1984). A graphical representation o f the decline in c-Myc levels can be 
seen in Figure 6.6C. Note that both bands (p64 and p67 c-Myc) were included in the 
measurements, since both have an effect in pol III transcription.
F9 EC and PE extracts were also analysed for other members o f the myc/max/mad 
network, the results o f which can be seen in Figure 6.6B. Max protein levels decline 
only slightly (top panel), whereas the decrease in the levels o f Mads 2, 3 and 4 is 
much more striking. No M adl could be detected by Western blotting in F9 cells, EC 
or PE, which agrees with previous observations (Larsson et a l ,  1997). It is also 
noteworthy that, in the EC extracts tested, Mad3 levels were considerably lower than 
either Mad2 or Mad4 (results not shown). This difference is not obvious in
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Figure 6.6 Levels of the Myc/Max/Mad network proteins in
F9 EC and PE cells
A Whole-cell extracts were prepared from undifferentiated EC cells (lane 1) or at 
each day following induction o f differentiation (PE 1-7 -  lanes 2-8). 20 pg were then 
resolved on a SDS -  7.8% polyacrylamide gel and analysed by Western blotting, 
using an anti c-Myc (N-262 -  top panel) or an anti-TFIIB antibody (C-18 -  bottom 
panel). B Whole-cell extracts (20 pg) from EC (lane 1) or PE (lane 2) cells were 
resolved on a SDS -  7.8% polyacrylamide gel and analysed by Western blotting, 
using antibodies against Max (C-17 -  top panel), Mad2 (G-16 -  second panel), Mad3 
(H-206 -  third panel) and Mad4 (N-19 -  fourth panel). Actin was used as loading 
control (bottom panel). C Graphical representation o f the reduction in c-Myc levels. 
The signal obtained from differentiating cells (B, lanes 2-6) was quantified by 
densitometry (TotalLab) and expressed as a percentage of that from EC cells (B, lane 
1). Note that both bands, representing the p64 and p67 forms o f c-Myc, were 
considered in this analysis.
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Figure 6.6B, because different exposure times were used to obtain a similar EC 
signal. The possibility, however, that the Mad3 antibody is poorer than the Mad2 and 
Mad4 antibodies cannot be excluded.
6,2,6 Recombinant c-Myc can partially restore pol III
transcription in PE extracts
To test whether or not increased c-Myc levels could enhance pol III transcription in 
F9 cells after differentiation, PE extracts were pre-incubated with recombinant c- 
Myc and then utilised in an in vitro transcription assay, using tKNA^^" as template. 
As we can see in Figure 6.7, increasing amounts of c-Myc lead to increased pol III 
transcription (compare lanes 2, 3 and 4). Transcription, however, is not restored to 
the levels seen in EC extracts (lanes 1 and 5), even when higher amounts of 
recombinant c-Myc were used (results not shown).
In the previous experiment, the recombinant c-Myc was incubated with the extract 
prior to addition of the template and nucleotides. There is, therefore, no way o f 
knowing which stage of transcription is activated. To investigate this, c-Myc or 
buffer were added to F9 PE extracts either 15 min prior to addition of the tRNA*"®“ 
template (Figure 6.8 -  lanes 1 and 2), simultaneously with the addition o f the 
template (lanes 3 and 4), or 15 min after the addition of the template (lanes 5 and 6). 
Subsequently, nucleotides were added to allow transcription. The last two lanes in 
this experiment represent the ability of c-Myc to activate transcription of a pre­
formed initiation complex. We can clearly see that addition o f c-Myc at any of the 
tlrree time-points results in increased transcription, suggesting that it might act before 
or after pre-initiation complex assembly.
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Figure 6.7 Recombinant c-Myc restores pol III transcription
in PE extracts
F9 PE extracts (20 pg) were incubated with 0, 100 ng or 200 ng (lanes 2, 3 and 4, 
respectively) o f recombinant c-Myc for 15 min at 30“C and subsequently used for the 
in vitro transcription o f a tRNA' ‘'*“ template (125 ng). EC extracts (20 pg) are also 
shown (lanes 1 and 5) for comparison.
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Figure 6.8 Recombinant c-Myc can activate pol III
transcription before or after assembly of the pre-initiation complex
F9 PE extract (20 pg) was pre-incubated for 15 min at 30^C before the addition of 
pLeu (125 ng). After a further 15 min, nucleotides were added and transcription was 
allowed to proceed. Buffer (lanes 1, 3 and 5) or recombinant c-Myc (200 ng -  lanes 
2, 4 and 6) were added to the reactions at the indicated times.
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6,2,7 The DNA-binding activity o f c-Myc is reduced in PE cells
Electrophoretic mobility shift assays (EMSAs) were employed to study the DNA- 
binding capacity of Myc-Max heterodimers in F9 EC or PE extracts. To do this, 
oligonucleotides containing either a consensus Myc-Max binding site (E-box 
oligonucleotide), or a mutated E-box, were designed (for sequence details see 
Materials and Methods). When EC or PE extracts were incubated with radiolabelled 
E-box oligonucleotide, a single band was observed, marked by an anow, the signal 
o f which decreases when PE extract was used (Figure 6.9A, compare lanes 2 and 3). 
This band was not detected when the extracts were incubated with the mutant 
oligonucleotide (Figure 6.9A, lanes 5 and 6). In addition to this strong band, two 
more bands can be detected lower in the gel, marked by asterisks in Figure 6.9A. To 
determine if they are specific or not, excess o f unlabelled E-box or mutant 
oligonucleotides were added to reactions containing radiolabelled E-box probe and 
EC or PE extracts (Figure 6.9B). Predictably, the top band disappeared when E-box 
competitor was added, but not when the mutated oligonucleotide is used (compare 
lanes 1 and 2 with 3 and 4). The lower o f the weaker bands is not affected by any of 
the competitor sequences, suggesting that it is due to non-specific binding. On the 
other hand, the middle band seems to disappear in lanes 1 and 2, i.e. when the E-box 
competitor is used. This might indicate another type of protein-DNA complex, and 
will be discussed later.
The competition experiments established that the prominent band seen in the 
previous figure had specificity for an E-box Myc/Max recognition sequence, but did 
not establish that c-Myc was part o f the complex. In order to verify this, 1 employed 
two methods. Recombinant c-Myc was added to some reactions, to test if the
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intensity o f the band would increase. To the rest, anti-myc or control antibodies were 
added in order to super shift the bands (i.e. form antibody-protein-DNA complexes). 
Figure 6.10 shows a typical experiment. In lanes 2 and 3 EC or PE extracts were 
used, similar to figure 6.9A (lanes 2 and 3). Like before, we can see a decrease in 
complex formation in PE cells, compared to EC. When recombinant c-Myc is added 
to the reactions (lanes 4 and 5), both EC and PE bands increase in intensity (compare 
lane 4 with lane 2 and lane 5 with lane 3). The presence o f an anti-myc (lanes 6-9), 
but not of a control (anti-fos -  lanes 10-13), antibody leads to the appearance o f a 
slower-migrating band (marked with an asterisk in Figure 6.10), with a concomitant 
decrease in the initial band. We can therefore conclude that the prominent band seen 
in these two figures (6.9 and 6.10) contains c-Myc, probably as a Myc-Max-DNA 
complex.
6.3 Discussion
6.3.1 pRb/pl07/pl30
It has been previously reported that the E2F-associated activity o f pRb and pi 07, i.e. 
their ability to influence transcription by RNA polymerase II, is elevated in F9 PE 
cells (Partridge and La Thangue, 1991; Zamanian and La Thangue, 1993). 
Examining the protein levels of these proteins, I found that pRb is strongly induced 
during the differentiation of F9 cells (Figure 6.1 A -  third panel and Figure 6.1 B -  top 
panel). On the other hand, p i 07 levels remain unchanged during this process (Figure
6.1 A -  second panel), which might argue against the previous findings. Since, 
however, the reports mentioned previously look at E2F-associated activity, as
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Figure 6.9 Binding to a consensus E-box sequence is reduced
in PE extracts
A Electrophoretic mobility shift assay (EMSA) using 1 ng o f radiolabelled E-box 
(lanes 1-3) or mutated E-box (lanes 4-6) oligonucleotides, 1 pg o f poly[dI-dC] 
competitor and 5 pg o f EC (lanes 2 and 4) or PE (lanes 3 and 5) whole-cell extract, 
or no extract (lanes 1 and 4), B Reactions contain 1 ng o f radiolabelled E-box 
oligonucleotide, 1 pg o f poly[dl-dC] competitor and 5 pg o f F9 EC (lanes 1 and 3) or 
F9 PE (lanes 2 and 4) extract. Unlabelled E-box (lanes 1 and 2) or mutant E-box 
(lanes 3 and 4) oligonucleotides (100 ng) were also added.
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Figure 6.10 Binding to a consensus E-box oligonucleotide 
increases in the presence of recombinant c-Myc
Electrophoretic mobility shift assay (EMSA) containing 1 ng o f  radiolabelled E-box 
oligonucleotide, 1 pg o f poly[dI-dC] competitor, 5 pg of F9 EC (lanes 2, 4, 6 ,7 , 10 
and 11) or F9 PE (lanes 3, 5, 8, 9, 12 and 13) extract, or no extract (lane 1). 
Reactions were supplemented with 400 ng o f recombinant c-Myc (lanes 4 and 5) or 
an anti-myc antibody (4 pg in lanes 6 and 8, 8 pg in lanes 7 and 9) or a control anti- 
fos antibody (4 pg in lanes 10 and 12, 8 pg in lanes 11 and 13).
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opposed to protein levels, one must also look at the behaviour o f pR b/pl07/pl30- 
regulatory proteins, such as the D-type cyclins, which mediate the Cdk4/6-dependent 
phosphoiylation and inactivation o f pRb (reviewed in Zheng and Lee, 2001) and 
p l07 /p l30  (reviewed in Classon and Dyson, 2001) in the G1 phase o f the cell cycle. 
When cyclin D1 levels were monitored, it was observed that the protein is quickly 
and strongly down-regulated upon induction o f differentiation (Figure 6.2A). This is 
in agreement with a previous report, which shows that cyclin D l, D3 and E levels are 
reduced in PE cells (Li et a l,  2004; Li et a l ,  1999). Surprisingly, both groups also 
show that the levels o f cyclin D2 increase following differentiation. There are 
indications, however, that cyclin D2 may function as a negative regulator o f cell 
growth (Meyyappan et a l,  1998). These data show that the proteins that normally 
inactivate p i 07 (i.e. cyclins D and E) are down-regulated, possibly leading to the 
elevated p i 07 activity observed previously (Zamanian and La Thangue, 1993). A 
similar situation might be envisaged for p i30, the protein levels o f which are also 
unchanged in PE cells (Figure 6.1 A -  top panel), although its regulation in the F9 
system has not been reported previously.
One o f the many targets o f the pocket proteins is the TFIIIB complex, as was 
described previously. By binding to and inactivating this protein complex, pRb, pi 07 
and p i 30 can repress transcription by pol III (reviewed in White, 2004b). Down- 
regulation by the pocket proteins, therefore, could be one o f the mechanisms 
contributing to the reduction in pol 111 activity when F9 cells are induced to 
differentiate. Although the induction o f pRb seen in Figure 6 .IB does not explain the 
initial reduction in pol III transcription observed between days 0 and 1 (Figure 3.3B), 
it could enhance the inhibition o f pol III transcription at a later time. More important 
than overall levels, however, is the phosphorylation status of pRb, since only the 
underphosphorylated form can bind TFIllB and repress pol III transcription (Scott et
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a l,  2001). In particular, it was demonstrated that cyclin D- and E-dependent 
phosphorylation stimulates pol III transcription. Direct examination of the 
phosphorylation status o f pRb revealed that phosphorylation at serine 773 decreases 
during differentiation (Figure 6.2B). Since this site is phosphorylated in a cyclin D- 
dependent manner, there is a strong possibility that the observed reduction might lead 
to activation o f pRb and repression o f pol III. Significantly, the kinetics of the 
dephosphorylation (Figure 6.2C) resemble closely the reduction in pol III 
transcription seen earlier (Figure 3.3B). Although this is by no means absolute proof 
that elevation in pRb activity is solely responsible to the observed down-regulation 
o f pol III transcription, pRb might play a significant role in the early decrease in 
transcription seen during the first few days.
6,3,2 pS3
As mentioned in the introduction o f this chapter, F9 EC cells were reported to 
contain high levels o f wild type p53 protein (Pennica et a l ,  1984), the levels o f 
which, both mRNA and protein, decline following differentiation into parietal 
endoderm (Dony et a l ,  1985; Oren et a l,  1982). The p53 protein, however, seems to 
be inactive in EC cells, whereas it becomes activated after retinoic acid-induced 
differentiation (Lutzker and Levine, 1996). DNA damage by UV irradiation or 
chemical agents also activate p53 in EC and PE cells (Lutzker and Levine, 1996; 
Mayo and Berberich, 1996).
Western blot analysis o f differentiating F9 cells showed that p53 protein levels 
persist throughout the process (Figure 6.3), contradicting previous reports. p53 can 
still be stabilised by a proteasome inhibitor (MG132), as seen in Figures 4.1 and
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4.2A, which suggests that tum-over o f the protein is not affected. Although 
proteasome inhibition has a multitude of effects, p53 stabilisation could lead to 
repression o f pol III transcription, as shown previously (reviewed in White, 2004b). 
This is not the case, however, as extracts from MG132-treated EC or PE cells do not 
exhibit increased pol III activity (Figure 4.4C). This would be consistent with the 
reports showing that p53 is not fimctional in EC cells, but inconsistent with p53 
becoming activated by RA-induced differentiation (Lutzker and Levine, 1996). A 
possible explanation for this could be that, over time, the cells I used acquired a 
mutation that, first, reversed the differentiation-induced decrease in protein levels 
and, second, eliminated the proteins ability to influence pol III transcription. This 
possibility needs to be examined further, by looking at p53 activity in differentiating 
F9 cells, in relation to both pol II and pol III transcription.
6.3.3 CÆ2
CK2 protein levels and activity have not been previously described in F9 PE cells. 
Here I have seen down-regulation o f both catalytic subunits, a  and a \  at protein 
level (Figure 6.4A). The regulatory subunit |3, on the other hand, does not decrease 
following differentiation (Figure 6.4B). The effect of CK2 on RNA polymerase III 
transcription in mammalian cells has been reported previously (.lohnston et a l ,  
2002). Specifically, CK2 binds to and phosphorylates TFIIIB, thus activating it. 
Therefore, one could imagine that CK2 might be directly involved in the down- 
regulation o f pol III transcription in PE cells, although an indirect involvement 
through one o f CK2’s many targets cannot be ruled out at this point.
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6,3,4 ERK
Another kinase that has been shown to affect pol III transcription is ERK, a mitogen- 
activated protein kinase (MAPK). In response to serum induction, ERK becomes 
phosphorylated and activated by MEK and in turn it binds to TFIIIB, through Brfl. 
This leads to phosphoiylation of B rfl and activation of TFIIIB and subsequently pol 
III transcription (Felton-Edkins et a l,  2003a). When F9 EC cells were induced to 
differentiate into PE, I observed a reduction in active ERK levels, while total protein 
levels were unaffected (Figure 6.5A). This is in agreement with an earlier report 
showing that ERK activity is reduced when F9 cells differentiate into PE (Verheijen 
et a l ,  1999). Therefore, the reduced levels o f active ERK could be an additional 
factor in the down-regulation of pol III transcription in F9 PE cells.
6,3,5 Myc/Max/Mad network
One o f the earliest events following induction of differentiation in F9 cells is the 
reduction in the levels o f e-myc mRNA (Dean et a l ,  1986; Dony et a l ,  1985). These 
two groups showed that mRNA levels are reduced to almost zero very early in the 
differentiation process, within 24 hours of addition o f the inducing chemicals. They 
did not, however, examine the protein levels in differentiating cells, although the 
short half-life o f this protein (Hann et a l ,  1985) means that the protein is unlikely to 
persist for more that 2-3 days. It was, therefore, surprising to see that PE extracts 5 or 
6 days following induction o f differentiation contain some c-Myc (Figure 6.6A). A 
more recent report shows that, although c~myc mRNA is strongly down-regulated by 
day 2 o f differentiation, very low levels o f transcript can be seen even at day 5
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(Larsson et a l,  1997). A striking feature seen in Figure 6.6A is the two bands that 
react with the anti-myc antibody. These most likely represent the p64 and p67 forms 
o f c-Myc. p64 is considered to be the predominant form o f c-Myc, initiating from an 
AUG start codon in exon 2. The p67 form contains an N-terminal extension, 
resulting from translation initiation from an alternative codon (CUG) located in exon 
1. A report by Hann et a l (1994) suggests that the two forms o f c-Myc differentially 
regulate (pol II) transcription, by using different DNA-binding sites. c-Myc-mediated 
activation o f pol III transcription, however, is unaffected by the DNA-binding 
activity o f c-Myc, since the TFIIIB binding site lies within the N-terminal part o f the 
protein. Both forms o f c-Myc, therefore, should have a similar effect on pol III 
transcription, although this has not been specifically examined. As a result, both 
proteins are included in the measurements represented in Figure 6.6C. Taken 
together, we can see that there is a sharp decrease in c-Myc within 24 hours of 
induction o f differentiation, similar to what has previously been reported, which 
could play, together with pRb discussed earlier, a significant role in the initial 
decrease in pol III transcription.
Reduction in c-Myc levels was verified by EMSA, using a consensus E-box 
sequence as probe (Figures 6.9 and 6.10 -  lanes 2 and 3). Once more, although a 
clear decline in Myc/Max binding to the probe can be seen, it is not abolished in PE 
extracts. It is worth noting that both forms o f c-Myc, p64 and p67, bind consensus E- 
boxes with similar efficiency (Hann et a l,  1994). The identity o f the prominent band 
was verified by addition o f specific antibodies to the reaction. The anti-Myc, but not 
the control anti-Fos, antibody super shifts the band (Figure 6.10 -  compare lanes 6-9 
with lanes 10-13), suggesting that the band seen contains a Myc-DNA complex. 
Curiously, two different Max antibodies failed to supershift the band (data not 
shown). This could be due to the epitopes recognised by the antibodies being
198
obscured when Max is bound to the DNA probe. Another indication that the band 
observed is a Myc-containing complex comes from the fact that addition of 
recombinant c-Myc leads to an increase in band intensity, without any change in 
mobility (Figure 6.10 -  compare lanes 4 and 5 with lanes 2 and 3).
Studies so far have revealed a clear link between M ad  expression and terminal 
differentiation (for a review see Grandori et a l,  2000). Here, however, I see that the 
levels o f three o f the Mad proteins, Mad2, 3 and 4, decline following differentiation 
(Figure 6.6B). It has been previously shown that mad3 expression is confined to the 
S phase o f proliferating cells (Queva et a l ,  1998), so the fact that Mad3 protein 
levels are reduced in PE cells is not entirely surprising. It would be interesting to see 
at which day after induction do the levels o f Mad2 and Mad4 decrease. M adl was 
not detected in EC or PE cells, which is in agreement with the observation that m adl 
mRNA is absent from F9 cells (Larsson et a l ,  1997). In the same report, it was 
described that Max protein levels gradually decline during differentiation. Although 
to a lesser extent, I also observe a slight reduction in Max protein levels (Figure 6.6B 
-  top panel). Since max appears to be expressed at a constant rate, both in 
differentiating F9 (Larsson et a l ,  1997) and other cell types (Berberich et a l ,  1992), 
this opens the possibility o f post-transcriptional control of this protein.
In agreement with the proposed direct activation o f pol III transcription by c-Myc 
(Gomez-Roman et a l ,  2003), addition of recombinant c-Myc to PE extracts partly 
restores pol III transcription in in vitro assays (Figure 6.7). Activation of pol 111 
transcription by c-Myc is not influenced by formation o f the pre-initiation complex, 
as revealed in Figure 6.8. This suggests that c-Myc does not enhance initiation 
complex assembly, but acts at a later stage. Note that in PE extracts, all three 
subunits of the TFIIIB complex are reduced (Figure 3.4A). We must therefore
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assume that enough TFIIIB remains to serve as a target for c-Myc activation, 
although an indirect role for c-Myc cannot be excluded.
6,3,6 Concluding remarks
Although it has been previously suggested that TFIIIB is the limiting factor in 
differentiating F9 cells, and that its down-regulation is responsible for the marked 
reduction in pol III transcription in PE cells (Alzuheni and White, 1998), 
experiments in previous chapters have cast some doubts. For example, time course 
analysis revealed that the reduction in TFIIIB protein levels occur after the initial 
reduction in pol III transcription (compare Figures 3.5 and 3.3). Therefore, although 
one cannot exclude that reduction in TFIIIB levels have an impact on pol III 
transcription, additional factors must be responsible for the observed down- 
regulation in the first few days after induction o f differentiation. A possible 
explanation for the discrepancy could reside in the fact that fractionated extracts 
were used to demonstrate that TFIIIB activity, as opposed to TFIIIC, was limiting in 
F9 PE cells. It has since been shown that c-Myc, pRb, p i 07, p i 30 and p53 co- 
fractionate with TFIIIB (Cairns and White, 1998; Gomez-Roman el a i,  2003; 
Larminie et a l ,  1997; Sutcliffe et a l ,  1999), although in those cases extract from 
HeLa cells was used. It is therefore quite plausible, indeed almost certain, that one or 
more o f these proteins were included in the TFIIIB fraction used in reconstitution 
assays (Alzuherri and White, 1998).
One o f the most likely candidates for the initial reduction in pol III activity is c-Myc, 
considering that c-myc mRNA levels decline within hours following induction of 
differentiation, and the effect of recombinant c-Myc on pol III transcription in in
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vitro transcription assays (Figures 6.7 and 6.8). Since numerous c-Myc targets are 
involved in protein synthesis (Shiio et a l , 2002), involvement o f c-Myc in regulation 
o f pol III transcription, whose output is essential for the protein synthetic machinery, 
would place it in a perfect position to globally regulate cell growth, and therefore 
proliferation, in differentiating F9 cells.
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CHAPTER 7
Discussion
Expression o f pol III transcripts, as monitored by in situ hybridisation, appears to be 
tightly regulated in the early stages of mouse embryonic development (Vasseur et a i ,  
1985). As a result, approximately 7.5 days post-coitum, pol III activity is high in the 
ectodeiTn and mesoderm layers, but low in endodermal tissues.
The differentiation o f the ICM to endodermal cell types in the early mouse embryo 
can be mimicked in culture by the F9 cell line. Under particular culture conditions, 
the stem cells o f this line, called embryonal carcinoma (EC) cells, can differentiate 
into visceral or parietal endoderm-like cells (Hogan et a i ,  1981; Strickland et a l ,  
1980). As shown in Figure 1.5, the first common step of the differentiation pathway 
is the formation o f primitive endoderm-like cells, as a result o f treatment with 
retinoic acid alone (Grover and Adamson, 1986). White et a l  (1989) showed 
previously that the activity o f pol III during the differentiation o f EC cells to parietal 
endoderm (PE)-like cells resembles that observed in vivo, when the ICM 
differentiates to form (parietal) endoderm. Complementation experiments 
demonstrated that crude fractions containing TFIIIB could restore transcription in 
extracts from PE cells, whereas similar fractions containing TFIIIC did not have this 
effect (White et a l ,  1989). It was, therefore, proposed that TFIIIB activity decreases, 
and becomes limiting for pol III transcription, as F9 cells differentiate.
Further purification of the crude TFIIIB and TFIIIC fractions verified the previous 
observations, i.e. that TFIIIB activity is limiting in F9 PE cells (Alzuherri and White,
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1998). It was also shown that the protein levels o f one o f the TAF components o f 
TFIIIB, B rfl, declined during differentiation, suggesting a possible mechanism for 
the observed decrease in pol III transcription. Importantly, addition o f recombinant 
Brfl did not restore transcription in PE cell extracts, indicating that Brfl is not the 
only factor for pol III transcription that is deficient in PE cells. Interestingly, 
significantly less TBP was found in the TFIIIB fraction, whereas TBP levels were 
unaffected by differentiation in fractions containing SNAPc, TFIID or SL-1 
(Alzuheiri and White, 1998). At the time of that study, the behaviour o f  the third 
subunit of TFIIIB, B dpl, could not be examined.
My studies initially focused on the regulation o f the TFIIIB complex in response to 
differentiation. Brfl levels were seen to decline, as was observed previously 
(Alzuherri and White, 1998). Using an antibody previously unavailable, I showed 
that Bdpl protein levels also decrease following differentiation. I also noted a 
decrease in the overall levels of TBP, which has been described previously 
(Alzuherri and White, 1999) and attributed to a decrease in the TBP levels contained 
within the TFIIIB fraction (Alzuherri and White, 1998). Furthermore, a recent report 
shows that TBP is targeted for ubiquitin-mediated degradation in response to 
differentiation (Perletti et a l ,  2001). These data are in disagreement with the report 
by Meissner et a l  (1995), which claims that no significant differences in the overall 
levels of TBP could be observed between EC and PE extracts.
Based on the observations o f Perletti et a l  (2001) that TBP is degraded by the 
proteasome, I examined whether or not Brfl and Bdpl levels are also regulated by 
this pathway. Treatment o f cells with proteasome inhibitors, however, failed to 
stabilise either Brfl or B dpl, before or after differentiation, suggesting that they are 
not targeted for degradation. As a control, two known targets o f proteasomal
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degradation were used, p53 and cyclin D l, both o f which responded as expected. 
Importantly, proteasome inhibition did not affect the levels o f pol III transcription in 
PE cells. This will be discussed in more detail later on.
An alternate mechanism for down-regulating Brfl and Bdpl could involve regulation 
o f the two genes at transcriptional or post-transcriptional level. Therefore, the mRNA 
levels o f each gene were examined using RT-PCR. This analysis revealed that both 
mRNA species declined following differentiation. It is worth noting that the design 
o f the primers for the RT-PCR allows the detection of mature mRNA, and, therefore, 
the results represent the ‘steady-state’ levels o f the mRNA species, i.e. their total 
levels at the time the RNA was prepared. This means that the down-regulation 
observed in PE extracts could be due to reduced transcription o f the genes or 
increased turnover / reduced stability o f the mRNAs themselves during the 
differentiation process. Additionally, translational regulation cannot be ruled out, 
TBP mRNA levels, on the other hand, do not decrease, and in fact appear to increase, 
following differentiation. This supports the proposed post-translational regulation o f 
TBP during differentiation (Perletti et a l ,  2001).
The presence o f B rfl, Bdpl and TBP in the TFIIIB complex in a 1:1:1 stoichiometry 
opens up the possibility of co-ordinate regulation o f the three proteins, as incomplete 
complexes could be harmful to the cell. It has already been mentioned that this is 
probably not the case for TBP, since it seems to be regulated differently at the 
mRNA level. But what o f Brfl and B dpl? Time-course analysis o f the differentiation 
process revealed that the levels o f both proteins decrease significantly at the same 
time point, i.e. between days 4 and 5. It is interesting that TBP is also down- 
regulated at the same time, suggesting that there might be some sort o f co-ordination, 
or that it is a general effect associated with the reduction in proliferation rate. In 
support of a co-regulatory mechanism, RT-PCR analysis o f RNA extracts throughout
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the differentiation process revealed the same pattern o f change for Brfl and Bdpl 
mRNAs. This pattern, however, is not accurately reflected in the protein levels. This 
could be due to translational regulation, as mentioned before, or simply due to the 
difference in sensitivities between the two methods used (Western immunoblotting 
vs. RT-PCR).
It has been demonstrated that TFIIIB activity is limiting in PE cells. This could 
indicate either a reduction in TFIIIB levels or changes in the activity o f its regulators 
in response to differentiation. Using the same protein extracts in in vitro transcription 
assays, I observed that there is a significant decrease in pol III transcription very 
early, i.e. within 24 hours o f induction of differentiation, with a further decrease 
between days 2 and 3. As both o f these events precede the reduction in TFIIIB 
protein levels, it seems quite likely that reduction in TFIIIB levels is not responsible 
for the initial decrease in pol III transcription.
In parallel with these experiments, I constructed an F9 cell line that stably expresses 
HA-tagged human Brfl (HA-hBrfl). Following differentiation o f these cells, the 
levels of the exogenous protein were monitored. I found that HA-hBrfl levels did not 
decrease in PE cells. They were similarly unaffected by treatment of the cells with 
proteasome inhibitors, either before or after differentiation. These data support the 
idea that Brfl regulation is not post-translational, since the exogenous gene is under 
the control o f a different promoter (the human cytomegalovirus promoter) than 
endogenous BRFL  It is worth noting here that differentiated derivatives of 
embryonal carcinoma cells exhibit enhanced expression o f some viral genomes 
compared to the undifferentiated cells. One o f these is the murine cytomegalovirus 
(reviewed in Kelly and Condamine, 1982). Therefore, possible HA-hBrfl 
degradation by the proteasome in PE cells could be masked by increased expression
205
of the exogenous gene driven by the human CMV promoter. If that was the case, 
however, proteasome inhibition would have a pronounced effect on the levels o f HA- 
hB rfl. I have also observed, by RT-PCR analysis, that synthesis o f human (i.e. 
exogenous) B rfl mRNA does not change following differentiation. Furthermore, 
other reports (e.g. Zamanian and La Thangue, 1993) have demonstrated that 
constructs containing the human CMV promoter and enhancer sequences function 
with similar or equal activity in EC and PE cells. It is, therefore, my conclusion that 
the endogenous and exogenous BRFl genes are regulated differently in response to 
differentiation.
Another interesting observation came from examining the levels o f pol III 
transcription in stably-transfected EC and PE cells. I found that the observed down- 
regulation o f pol III in PE cells was not rescued by the increased levels o f H A -hB rfl. 
This observation indicates that Brfl is not the limiting factor in F9 PE cells, in 
contrast to yeast, where it has been shown that Brfl is limiting for pol III 
transcription both in vitro and in vivo (reviewed in White, 2002). The possibility that 
the human protein is not functional in a murine environment is countered by the fact 
that pol III transcription is enhanced in F9 EC stables, compared to untransfected or 
mock-transfected cells. It is not possible to distinguish at this point, however, 
whether this increase is due to direct activation o f pol III transcription by HA-hBrfl 
or to de-repression o f the endogenous protein, by sequestration o f inhibitory factors. 
In addition, human and mouse Brfl are almost 90% identical, making it quite likely 
that one can substitute for the other.
This is not to say, however, that overexpression o f HA-hBrfl has no effect on pol III 
transcription in differentiating F9 cells. Time course analysis o f pol III activity, using 
the in vitro transcription o f a tRNA®^ *^  ^ template as an indicator, revealed that its 
down-regulation is somewhat delayed, at least during the first 5 days.
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A possible explanation for the inability o f HA-hBrfl to rescue pol III transcription in 
PE cells might be linked to the concurrent down-regulation o f the other TAF in 
TFIIIB, i.e. Bdpl. However, addition o f recombinant human Bdpl to extracts from 
HA-hBrfl-expressing cells does not restore transcription. As with HA-hBrfl, it is not 
guaranteed that human Bdpl can substitute for its murine homologue in functional 
pre-initiation complexes. The two proteins, however, are approximately 62% 
identical, including 100% identity in the SANT domain and 84% identity in the 
region just upstream o f it.
The intricate pathways that cells use to regulate pol III transcription are slowly being 
elucidated (reviewed in White, 2004a). For example, two unrelated tumour 
suppressors, p53 and pRb, can reduce the transcriptional capacity o f pol 111, while 
oncogenic factors, like c-Myc and ERK, have the opposite effect. At the heart of 
these regulatory networks lies TFIIIB, directly and indirectly up- or down-regulated 
(Figure 1.4). In most cases, these changes in TFIIIB activity are reflected in the 
output o f pol III. Since many o f these regulatory proteins physically interact with 
TFIIIB, it is possible that they are contained in the same protein fractions as the 
transcription factor. This has been shown to be the case for c-Myc, pRb/pl07/pl30 
and p53 (Cairns and White, 1998; Gomez-Roman et a l,  2003; Larminie et a i ,  1997; 
Sutcliffe et a i,  1999). Therefore, it is possible that the reduced activity observed in 
TFIIIB-containing fractions from PE cells could be attributed to one or more of these 
proteins, rather than TFIIIB itself.
The regulation of these proteins during F9 differentiation reported previously in the 
literature is covered elsewhere. My own observations support some o f these findings. 
pRb protein levels increase markedly following differentiation, while levels o f cyclin 
D l, an important down-regulator o f pRb, are reduced. Importantly, the inactive,
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hyperphosphorylated form o f pRb also decreases during differentiation. The latter, in 
particular, occurs with kinetics strongly resembling the down-regulation of pol III 
transcription itself, as measured by in vitro transcription experiments. pRb is 
therefore expected to be active, and present at high levels, in PE cells, perhaps a 
contributing factor to the reduced proliferation rate. As it is a known repressor of pol 
III transcription, and also found in TFIIIB fractions, it is plausible that it is involved 
in the down-regulation of pol III transcription in response to differentiation. The 
levels o f the other two pocket proteins, p i 07 and p i 30, do not seem to change much 
during differentiation. Both o f these proteins, however, are phosphorylated, and 
inactivated, by cyclin-dependent kinases, and as such their activity might increase as 
cells differentiate and cyclin levels fall.
Contrary to previous reports, I have found that p53 levels are unaffected during the 
differentiation of F9 EC cells to PE. p53 has been shown to be inactive in EC cells, 
increasing in transcriptional activity as the cells differentiate. Although class III do 
not contain p53-binding sites, the DNA-binding activity o f p53 is essential for the 
repression o f pol III transcription. It is, therefore, possible that activation of p53 
could contribute to the repression of pol III transcription. An argument against this is 
that although proteasome inhibitors stabilise p53 in PE cells, they have no effect on 
pol III transcription.
The Ras/ERK pathway has been shown to play an important role in F9 cell 
differentiation (Verheijen et a i ,  1999). Thus, although the activity o f Ras (and hence 
ERK) increases in the initial steps of differentiation -  formation of primitive 
endoderm -  it decreases during parietal endoderm formation. My own results verify 
this. Although I did not examine the situation in primitive endoderm, PE cells have 
reduced levels o f phosphorylated (active) ERK, even though total levels o f ERK are
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unchanged. Since ERK directly activates pol III transcription, it is likely to 
contribute to its down-regulation in PE cells.
Another kinase that activates TFIIIB is CK2. I have found that the levels o f the 
catalytic subunits, a  and a ’, decline during differentiation. The a  subunit, however, 
seems to decline earlier than a ’, which persists until late in the time period 
monitored (day 6). Combined with the fact that the levels of the regulatory subunit 
do not change, CK2 might be active after the observed reduction in pol III 
transcription.
Finally, an important regulator o f pol III activity that has recently come to light is the 
oncoprotein c-Myc. It has been previously reported that c-Myc is strongly down- 
regulated following differentiation. 1 have observed a similar response, with the 
protein levels o f c-Myc rapidly declining following induction of differentiation. This 
decrease, therefore, will quite likely have an impact on pol III transcription. This is 
supported by the observation that adding recombinant c-Myc into PE extracts partly 
restores transcription o f a tRNA^^“ template, in a dose-dependent manner. 
Interestingly, c-Myc activates pol III transcription irrespective o f  the timing o f its 
addition, i.e. before or after pre-initiation complex (PIC) assembly. It is, therefore, 
possible that, rather than PIC assembly and the first round o f transcription, c-Myc 
enhances downstream events, e.g. recycling of the polymerase and re-initiation.
I have also noted that, although Max levels are not significantly altered, the levels of 
Mad family proteins decrease markedly in PE cells. This was unexpected, since 
decreased proliferation is often associated with high levels o f Mad proteins 
(reviewed in Grandori et a l ,  2000).
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Taking all these data together, it seems that most regulators of pol III transcription 
are affected by differentiation in such a way as to bring about a decrease in pol III 
transcription. Thus, pRb is up-regulated and activated, p i07 and p i 30 activity 
probably enhanced, the activity o f the kinases CK2 and ERK decreased and the 
oncogene c-Myc down-regulated. In addition, there is a moderate change in the 
expression levels of BR F l and BD Pl mRNA, and a clear reduction in the levels of 
the two proteins (and TBP). The decrease in pol III transcription is, therefore, 
inevitable. The question that remains, however, is which o f the factors, if  any, is 
more important than any other. To begin to answer this question, we must look at the 
temporal control o f the various processes, taking the time course of pol III 
transcription down-regulation as the benchmark.
The initial reduction in pol III transcription, observed within 24 hours o f induction, 
could be attributed to the reduction in c-Myc levels and the activation 
(dephophosphorylation) of pRb. The second observable reduction in pol III 
transcription occurs between days 2 and 3. A possible candidate for this is the pocket 
proteins. pRb phosphorylation decreases further and, although the levels of p i 07 and 
p i 30 do not change, it is quite likely that their activity also increases. This is 
supported by the observed reduction in cyclin D1 levels. Similarly, Li et al. (1999) 
showed that cyclin D3 levels fall during the first few days after induction. This 
would result in a decrease in cyclin D-dependent kinase activity, and thus activation 
(hypophosphorylation) o f the pocket proteins. Other regulators o f Cdk activity, like 
the Cdk inhibitors p21^‘'’‘ and p27'^'^‘ are targets o f c-Myc. Therefore, the down- 
regulation o f c-Myc will also have a strong impact on pRb/p 107/130 activity. It 
seems plausible that the combination o f these two pathways is sufficient for the early 
down-regulation o f pol III transcription, occurring before the reduction in B rfl, Bdpl 
and TBP levels. A supporting fact for the level of activation o f pRb in response to
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differentiation comes from studying the cell cycle chai'acteristics o f the 
differentiating cells. Rosenstraus et a l (1982) demonstrated that the most 
pronounced changed in the cell cycle is a lengthening o f the G1 phase, exit from 
which is determined to a large extent by pRb. One argument against the importance 
o f pRb up-regulation in the decrease o f pol III transcription in PE cells comes from 
early mixing experiments, where it was shown that addition o f increasing amounts of 
PE extract to EC extract resulted in stimulation o f transcription, rather than its 
inhibition (White et a/., 1989). This suggests that the reduced transcriptional capacity 
of PE extracts is due to the absence of a positive activity, rather than the presence of 
a negative activity. A possible explanation for these obseiwations, however, could be 
the presence o f active Cdk complexes in the EC extracts, able to phosphorylate and 
inactivate pRb (and p l07 /p l30) from PE extracts.
The reduction in the protein levels o f Brfl and Bdpl, observed between days 4 and 5 
do not appear to be directly involved in the down-regulation of pol III transcription, 
but may instead be a consequence o f reduced growth and proliferation rates. A 
summary o f the model proposed here can be seen in Figure 7.1.
This study has focused on the Brfl-containing TFIIIB complex, necessary for 
transcription from type 1 and 2 promoters. That is not to say, however, that class III 
genes with type 3 promoters are not down-regulated during differentiation. Meissner 
et a l (1995) showed that U6 snRNA transcription is dramatically reduced following 
differentiation. The authors attributed this decrease to reduced levels o f PBP (also 
called SNAPc), as well as one or more activities in the TFIIIC-containing fraction. In 
a later report, this was nairowed down to the poorly-characterised TFIIICI activity, 
whereas TFIIIC2 activity (see introduction) was unaffected (Meissner et n;/., 2002). 
The latest report from the same group suggests that an essential component o f this
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TFIIICI activity is Bdpl (Weser et a l ,  2004), which is, in fact, a component of the 
TFIIIB complex, essential for transcription from all three promoter types. 
Furthermore, some regulators o f pol III transcription, for example pRb and CK2, can 
affect genes with type 3 promoters in the same manner as genes with type 1 and 2 
promoters.
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Figure 7.1 Proposed model for the down-regulation of pol III
transcription during differentiation o f F9 cells
In undifferentiated F9 EC cells (day 0), TFIIIB is free to bind to TFIIIC on target 
genes and initiate their transcription. c-Myc has been shown to up-regulate pol III 
transcription, while pRb, a known repressor is hyperphosphorylated and therefore 
inactive. Within 24 hours of induction o f differentiation (day 1), the levels o f c-Myc 
fall dramatically, whereas pRb becomes underphosphorylated, allowing binding o f 
TFIIIB. These changes result in a significant down-regulation of pol III activity, 
which may be compounded by other factors, like the ERK MAPK pathway 
(represented by the question mark). By day 4, pRb levels increase, enhancing the 
repressive effect on pol III transcription. Finally, TFIIIB levels decline (day 7). 
TFIIIC levels appear to stay the same throughout the differentiation.
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It would be interesting to investigate further the regulation o f Brfl and Bdpl at the 
mRNA level. The pattern o f the abundance o f the two mRNA species appears to be 
quite similar, with an overall down-regulation at the end o f the analysed time period. 
It would be interesting to see if  the loss o f tumourigenicity exhibited by the F9 EC 
cells differentiating to PE-like cells correlates with reduced expression o f the two 
genes. The mechanism by which this occurs, although maybe not as important for the 
F9 cell system, might provide some insight into the overexpression o f Brfl seen in 
some cancers (Daly et a l , 2005).
Overall, it appears that the reduction in pol III transcription during the differentiation 
o f F9 cells is not as simple as was previously thought. Rather than one protein 
complex (TFIIIB) being responsible, it seems that various different pathways, most 
o f which target TFIIIB, work together to accomplish this. It is also important to 
consider these mechanisms as a whole, rather than independently, as there is 
considerable cross-talk between them. For example, ERK, which activates pol III 
transcription by phosphorylating TFIIIB, can also stabilise c-Myc and induce cyclin 
D production, thus inactivating pRb (Cheng el a l ,  1998; Sears ei a l,  1999), while 
pRb can stabilise p53 by blocking the activity o f Mdm2 (Hsieh et a l ,  1999a). The 
result o f this is that small perturbations in one pathway can lead to significant 
changes in other regulatory pathways, and thus, amongst other things, to repression 
o f pol III transcription.
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